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Summary 
Premature cardiovascular (CV) death is the commonest cause of death in patients 
with end stage renal disease (ESRD), which includes those receiving or close to 
requiring  renal  replacement  therapy.      In  ESRD  patients,  CV  deaths  are  most 
commonly caused by cardiac arrhythmia and sudden cardiac death compared to the 
general population where myocardial ischaemia and infarction predominate.  Higher 
CV  disease  burden  is  due  to  accumulation  of  “conventional”  risk  factors  (e.g. 
hypertension, diabetes  mellitus, smoking) and “novel” risk factors (e.g. oxidative 
stress,  proteinuria,  anaemia,  inflammation)  in  ESRD  patients.    In  addition,  risk 
factors  specific  to  patients  with  renal  disease  have  been  identified  including 
alteration in left ventricular (LV) structure, called uraemic cardiomyopathy.  These 
structural abnormalities are common in patients with ESRD (between 60-80% of 
subjects upon initiation of dialysis) and include left ventricular hypertrophy (LVH), 
systolic dysfunction (LVSD) and dilatation. These changes in LV structure confer 
adverse CV outcome in ESRD patients and have proven difficult to reverse. 
 
Detection  of  these  abnormalities  is  usually  performed  using  echocardiography, 
however this technique is inaccurate in ESRD patients due to significant alterations 
in  LV  shape  and  geometric  assumptions  made  during  calculation  of  myocardial 
mass.    Cardiovascular  MRI  (CMR)  negates  these  assumptions  and  is  the  most 
accurate, reproducible and reliable method of assessing LV dimensions independent 
of intravascular volume, particularly in patients with altered myocardial architecture.  
Furthermore,  maximal  left  atrial  volume  can  be  measured  using  CMR.        The 
principle aims of the studies presented in this thesis were to elucidate prognostic and 
pathophysiological features of uraemic cardiomyopathy using CMR. 24 
 
In a large study (n=246) of haemodialysis patients, the determinants of each LV 
abnormality of uraemic cardiomyopathy were identified from past clinical history, 
haemodialysis and blood parameters and other LV measurements.   For  LV  changes, 
major determinants were clinical features associated with advanced renal disease, 
namely expansion of intravascular/ extracellular fluid compartment, abnormal bone 
mineral  biochemistry  and  hypertension.    Furthermore,  presence  of  one  LV 
abnormality  was  one  of  the  strongest  predictors  of  presence  of  another,  perhaps 
indicating differing stages of uraemic cardiomyopathy development.  In a subsequent 
prognostic  study  including  these  patients  (n=446),  presence  of  LVSD  and  LV 
dilatation  on  CMR  were  significantly  associated  with  poorer  all  cause  and  CV 
mortality.   Presence of LVH, which is by far the most common structural change, 
was associated with poorer cardiovascular survival only.  In addition, presence of 
two  or  three  abnormalities  (commonly  LVH  with  another  abnormality)  had  a 
significantly  poorer  prognosis  and  independently  predicted  CV  and  all  cause 
mortality.  This has implications for therapeutic strategies which should aim to slow 
or  reverse  cardiac  changes  of  ESRD  and  prevent  progression  from  one  cardiac 
abnormality  to  2  or  more.    In  a  further  study  (n=201)  investigating  additional 
prognostic features of ESRD patients with LVH, maximal left atrial volume (LAV) 
was measured using the bi-plane area length method at end LV systole.  Elevated 
LAV  and  presence  of  LVSD  were  significantly  associated  with  poorer  all  cause 
survival  and  were  independent  predictors  of  death.    The  most  likely  causes  of 
elevated  LAV  in  ESRD  patients  are  LV  diastolic  dysfunction  and  expanded 
extracellular compartment and may provide a target for therapeutic intervention. 
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The electrophysiological features of uraemic cardiomyopathy were assessed using 
microvolt  T  wave  alternans  (MTWA)  which  is  a  novel,  non-invasive  method  of 
measuring small variations in surface electrocardiogram (ECG) T wave morphology 
and thus ventricular repolarisation.  This technique has been used to stratify other 
cohorts  at  elevated  risk  of  sudden  cardiac  death  (such  as  ischaemic  and  non 
ischaemic cardiomyopathy, hypertensive LVH).  A study presented in this thesis, 
compared MTWA results between ESRD (n=200) and hypertensive patients with 
LVH on echocardiography (n=30).  Abnormal MTWA result was significantly more 
common  in  ESRD  patients  compared  to  hypertensive  patients  with  LVH.  
Furthermore, abnormal MTWA result was significantly associated with myocardial 
abnormalities  of  uraemic  cardiomyopathy  and  a  history  of  macrovascular 
atheromatous disease in ESRD patients.  Despite preservation of LV function on 
CMR, the frequency of abnormal MTWA result in ESRD patients was similar to 
previous studies in subjects with heart failure.  
31Phosphorus magnetic resonance 
spectroscopy  is  a  novel,  non-invasive  technique  of  estimating  cardiac  energetic 
status and high energy phosphate (HEP) metabolism in a myocardial area of interest 
and  has  previously  been  used  to  assess  patients  with  global  myocardial  disease 
(dilated cardiomyopathy, hypertensive LVH).  High energy phosphate metabolism 
was compared between patients with ESRD (n=53) and hypertensive LVH (n=30) 
and despite similar LV mass between both groups, PCr: ATP (an indicator of HEP 
metabolism) was significantly reduced in ESRD patients.  These findings are most 
likely  due  to  cardiac  interstitial  fibrosis  and  the  alteration  of  tissue  composition 
within the area of interest, and changes in metabolic function within cardiomyocytes 
of uraemic hearts. Finally, a small study (n=50) investigated the effect of successful 
renal transplantation on LV mass measured by CMR.  On comparison of patients 26 
 
who remained on the renal transplant waiting list, there was no significant difference 
in LV mass in patients who received a renal transplant.  It is likely that previous 
echocardiography studies that demonstrated significant regression of LVH, measured 
improvement in fluid control rather that actual reduction in myocardial mass. 
 
Future  studies  investigating  benefit  of  therapeutic  intervention  may  require 
identification of individuals at higher CV risk and the results of studies presented in 
this thesis aim to provide information for selecting such ESRD patients.    With these 
results in mind, further prospective studies will be able to carefully select groups of 
ESRD  patients  with  differing  left  ventricular,  left  atrial,  electrophysiological  and 
biochemical properties to demonstrate survival benefit with interventional agents.  In 
this  way,  future  therapies  for  ESRD  patients  can  be  tailored  to  improve 
cardiovascular survival. 27 
 
 
Chapter 1 
 
Introduction 28 
 
During  the  latter  part  of  the  20
th  century,  better  understanding  of  renal  disease, 
dialysis techniques and renal transplantation have significantly improved prognosis 
of  patients  with  end  stage  renal  disease  (ESRD).    However,  as  survival  has 
improved,  other  conditions  have  contributed  significantly  to  the  morbidity  and 
mortality  of  ESRD  patients.  Cardiovascular  (CV)  disease,  including  cardiac 
arrest/arrhythmia, acute myocardial infarction (AMI), congestive heart failure and 
stroke,  is  the  commonest  cause  of  premature  death  in  patients  with  ESRD.    In 
addition, early stages of chronic kidney disease (CKD) have also been associated 
with poorer cardiovascular prognosis compared to the general population (1;2).   
 
1.1  Progression and classification of chronic kidney disease 
The natural history of patients with renal disease is shown in Figure 1.1.  After a 
period of deteriorating renal function (which can last many years), some patients 
develop ESRD.  These patients can receive dialysis in the form of haemodialysis 
(which is commonly in-hospital and thrice weekly) or peritoneal dialysis.   Patients 
can  receive  a  renal  transplant  just  before  requiring  or,  more  commonly,  whilst 
receiving dialysis.  Patients with transplants which fail can return to dialysis until 
they are re-transplanted.  Cardiovascular risk is higher than the general population at 
each stage of this disease process (Figure 1.1). 29 
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Figure 1.1  Natural history of patients with CKD and estimated increase in 
CV risk compared to the general population.  Modified from (3). 30 
 
To allow better evaluation and stratification of patients with renal dysfunction, the 
Kidney  Disease  Outcome  Quality  Initiative  (K/DOQI)  guidelines  have  classified 
CKD into 5 stages based on glomerular filtration rate (GFR) and evidence of kidney 
damage  (by  imaging,  histology,  or  urinalysis).    These  have  more  recently  been 
modified to include kidney transplant recipients and dialysis patients (Table 1.1).  
The main aim of implementing this system is to allow early recognition of kidney 
dysfunction  and  commence  preventative  measures  to  slow  CKD  and  CV  disease 
progression (2). 
 
 
Table 1.1 Classification of CKD 2004 (2).  GFR= glomerular filtration rate 
 
Stage  Description  GFR 
(ml/min/1.73m2) 
Related Terms  Treatment 
1  Damage with 
normal or ↑GFR 
≥90  Albuminuria 
Haematuria 
Proteinuria 
 
 
2  Damage with 
Mild ↓ GFR 
60-89  Albuminuria 
Haematuria 
Proteinuria 
 
3  Moderate↓ GFR  30-59  Chronic renal 
insufficiency 
 
4  Severe ↓ GFR  15-29  Chronic renal 
insufficiency 
 
5  Kidney Failure  <15 or dialysis  Renal Failure,ESRD  D if receiving 
dialysis 
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1.2  Epidemiology of cardiovascular disease in ESRD patients 
 
1.2.1  Prevalence of cardiovascular deaths in ESRD 
According to data from the United States Renal Data System (USRDS), in 2008 
annual mortality rates for ESRD patients and prevalent dialysis patients were 165.6 
and 220.7 per 1000 patient-years respectively.  Cardiac disease accounted for 41% of 
deaths in dialysis patients and 40% of deaths in ESRD patients (comprising all CKD 
5 subjects: predialysis and dialysis).  In dialysis patients 65.9% of  cardiac deaths 
(26.9%  of  all  deaths)  were  due  to  cardiac  arrhythmia  or  sudden  cardiac  death 
representing the major cause of CV death (Figure 1.2).  This pattern is also present in 
all ESRD patients (including peritoneal and pre-dialysis) and, to a lesser extent, in 
successfully transplanted patients (4). 
 
Figure 1.2  Mortality rate by primary cause of mortality.  (per 1000 patient 
years at risk, 2008).  32 
 
 
Throughout  all  age  groups  CV  risk  is  higher  than  the  general  population.  
Furthermore, increased relative risk of CV death is greatest in younger patients, who 
have a CV risk similar to elderly (70-80 years) non renal patients (5).  
 
A significant problem of epidemiological studies from renal registries (both US and 
European) is defining the primary cause of death.  In many cases autopsies are not 
performed, death certificates are not accurately completed, definitions used to define 
CV death tend to underestimate true cardiovascular deaths and it is often difficult to 
isolate a single cause of death in many patients.  Nonetheless, these data demonstrate 
significant  pathophysiological  differences  in  CV  death  between  the  general 
population  (where  atherosclerosis  and  subsequent  myocardial  ischaemia  and 
infarction  are  most  common)  and  ESRD  patients  (where  sudden,  presumed 
arrhythmic death predominates CV mortality) (6). 
 
1.2.2  Risk factors for CVD in ESRD patients 
Large population based studies have identified a number of risk factors for CVD in 
the general population (Table 1.2).  Furthermore large interventional studies have 
shown that modification of some of these risk factors improves CV survival.  For 
example, lipid lowering using HMG Co-A reductase inhibitors has been shown to 
provide significant survival benefit for both primary and secondary prevention of CV 
events (7;8) and have been included in current clinical practice for many years. 
 
In ESRD patients, premature cardiovascular death has been associated with higher 
prevalence of these “conventional” risk factors; but the relationship between these 33 
 
risk factors and CVD is much less clear than in the general population.  In addition, 
novel risk factors, which are often associated with the presence of uraemia, appear to 
have a more influential role on subsequent CV events than in the general population 
(Table 1.2).   The majority of studies investigating CV risk factors in ESRD patients, 
have been performed in patients receiving regular haemodialysis, however many of 
these risk factors are also relevant to peritoneal dialysis or predialysis patients.   
 
Table 1.2  Risk Factors for CVD in general population and ESRD patients 
(1;5) 
Traditional CV Risk Factors-  
General Population 
Novel/ Uraemia Specific Risk Factors 
Advancing age  Haemodynamic/metabolic factors ESRD 
Hypertension  Proteinuria 
Dyslipidaemia  ↑ Extracellular fluid volume 
Diabetes Mellitus  Electrolyte imbalance/fluctuation 
Sedentary Lifestyle  Vascular calcification 
Previous IHD/CVA/PVD  Bone mineral disorders 
Smoking  Homocysteine 
Oxidative stress  Anaemia 
LVH/LVSD  Inflammation 
  Uraemic cardiomyopathy 
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1.2.2a  Advancing age and gender 
The mean age of patients commencing RRT has gradually increased over the last 
decade.    Furthermore  increasing  age  is  commonly  an  independent  predictor  of 
mortality  in  most  studies  investigating  associations  with  (CV)  death.    In  all  age 
groups male CKD patients have a significantly higher risk (x2.5) of acute myocardial 
infarction compared to female patients.  However, female CKD patients have a 3-5x 
higher risk of acute myocardial infarction  when compared to age and sex matched 
patients with no renal disease (5).   
 
1.2.2b Hypertension 
In the general population without co-existing CV disease, prospective observational 
studies have demonstrated that increments of 5-6mmHg in diastolic blood pressure 
(DBP) or 10mmHg systolic blood  pressure (SBP) are associated with a 20-25% 
increased risk of ischaemic heart disease, 35-40% greater risk of stroke and 50% 
increased risk of heart failure (9).  Furthermore, reduction of blood pressure reduces 
cardiovascular risk significantly (10).   A number of large prospective trials have 
demonstrated that treatment with calcium channel blockers, diuretics, beta blockers 
and drugs affecting the renin- angiotensin system improve cardiovascular outcome in 
hypertensive patients (11-13).   
 
Hypertension is very common in patients with CKD and is caused by a combination 
of  reduced  arterial  compliance  related  to  vascular  calcification,  endothelial 
dysfunction,  fluid  overload,  and  autonomic  dysfunction  (14).  Furthermore, 
controlling blood pressure in patients with early stages of CKD has also been shown 
to  slow  progression  of  renal  dysfunction  and  improve  cardiovascular  outcome 35 
 
(15;16).  However, similar prospective studies performed in dialysis patients have 
not consistently demonstrated a beneficial role for reducing blood pressure.  Some 
studies  have  demonstrated  that  low  and  high  blood  pressure  are  associated  with 
higher mortality. 
   
· In  a  cohort  study  of  40933  haemodialysis  patients  followed  for  15  months,  pre 
dialysis systolic BP<110mm Hg and diastolic BP <50mmHg were associated with a 
hazard ratio for all cause mortality of 1.60 and 2.00 respectively (17).   
· Similarly, an observational study in 16959 haemodialysis patients demonstrated that 
systolic BP< 120mmHg was associated with higher mortality after 1 and 2 years.  
However, after surviving 3 years on dialysis, higher systolic BP (>150mmHg)  was 
associated  with adverse prognosis suggesting that the  relationship between blood 
pressure and survival may alter with time (18). 
 
This “U” or “J” shaped relationship between blood pressure and mortality is most 
likely due to the association between hypotension and co-morbid conditions such as 
cardiac failure, diabetes mellitus, malnutrition and sepsis in dialysis patients,.  As has 
been  demonstrated  in  other  studies  involving  chronic  conditions  (heart  failure, 
advanced  age),  low  blood  pressure  is  associated  with  adverse  outcome.    This 
phenomenon is known as “reverse epidemiology” and has been demonstrated with 
other risk factors in ESRD patients (see below) (19). 
 
There  are  few  trials  that  have  identified  optimal  targets  and  treatment  for 
hypertension  in  ESRD  patients.    Promising  studies  have  demonstrated  that 
longer/more  frequent  dialysis  may  provide  tight  blood  pressure  control  in 36 
 
haemodialysis patients (20), however more studies are required to determine optimal 
targets and measures to control BP in patients receiving renal replacement therapy. 
 
1.2.2c  Dyslipidaemia  
As  renal  dysfunction  deteriorates  there  are  complex  disturbances  in  lipoprotein 
metabolism  which  are  influenced  by  patient  nutritional  status,  degree  of  renal 
dysfunction, presence of proteinuria, and diabetes mellitus. In patients with ESRD, 
plasma triglyceride levels are elevated and cholesterol levels may be high, normal or 
low dependent on nutritional status and modality of renal replacement.  For example, 
patients  on  haemodialysis  commonly  have  low  total  and  low  density  lipoprotein 
(LDL)  cholesterol.    Peritoneal  dialysis  patients  have  elevated  total  and  LDL 
cholesterol.  In general, ESRD is associated with high levels of atherogenic particles 
(eg small dense LDL) independent of total or LDL cholesterol and reduced levels of 
atheroprotective high density lipoprotein (HDL) cholesterol. 
 
As stated before, in the general population reduction of cholesterol using statins has 
been  associated  with  primary  and  secondary  prevention  of  CV  events  (7;8).  In 
addition, the anti-inflammatory role of statins may contribute to their reduction in 
CV  events.    The  JUPITER  trial  demonstrated  that  rosuvastatin  reduced  LDL-
cholesterol and high sensitivity C reactive protein (CRP) levels. Whilst CV events 
and all cause mortality were significantly reduced in individual groups, the greatest 
reduction in events was found in the patients group that achieved both (21).  In vitro 
studies  have  demonstrated  that  statins  reduce  inflammatory  cell  endothelium 
adhesion,  alter  smooth  muscle  cell  behaviour  in  developing  atheromas  and  aid 
stabilisation of atherogenic plaques (21;22). 37 
 
The relationship between dyslipidemia and CV events/mortality in ESRD patients 
remains less clear.  Data from renal registries suggest that, similar to hypertension, a 
“J”  or  “U”  shaped  relationship  exists  between  serum  cholesterol  and  survival  in 
haemodialysis patients.  As with blood pressure, this “reverse epidemiology” relates 
to high prevalence of malnutrition or other co-morbid conditions (inflammation) in 
patients with low levels of cholesterol. These data have contributed to the under 
usage  of  statins  in  dialysis  patients,  despite  the  high  proportion  of  patients  with 
diabetes and coronary heart disease (23;24).    
 
Two  randomised  placebo  controlled  trials  have  failed  to  demonstrate  significant 
reduction in CV events or death in haemodialysis patients treated with statins. 
 
· The Deutsche Diabetes Dialyse Studie (4D) was a prospective randomised controlled 
trial investigating the effect of atorvastatin therapy on cardiovascular outcome in 
1225 type 2 diabetic haemodialysis patients.  Although LDL cholesterol was reduced 
(42%  reduction),  there  was  no  statistical  significant  reduction  of  the  composite 
primary endpoint (death from all cardiac causes, fatal stroke, non fatal MI, or non 
fatal  stroke).    Interestingly  myocardial  infarction  events  were  reduced  in  the 
treatment arm.   Post hoc analyses, however, revealed that adjudicated deaths due to 
coronary artery disease only accounted for 9% of deaths and sudden death accounted 
for 26% of all cause mortality (25).   
· The AURORA trial was a prospective randomised study investigating therapy with 
rosuvastatin in 2776 haemodialysis patients.  LDL cholesterol was reduced by 43% 
in  the  therapy  arm  but  there  was  no  significant  effect  on  primary  outcome 
(adjudicated death from cardiovascular causes, non fatal MI, non fatal stroke).  In the 38 
 
statin  treated  group,  deaths  from  cardiovascular  cause  occurred  at  a  rate  of  7.2 
events/100 patient-years compared to 7.3 events/100 patient–years in the placebo 
group (p=0.97) and death from definite coronary heart disease was not significantly 
different (26).  
 
In both of these studies, the investigators postulated that lack of benefit in the treated 
cohort  highlighted  the  difference  between  cardiovascular  disease  in  patients  with 
ESRD/diabetes  and  the  general  population.    To  explore  the  difference  in 
cardiovascular disease in ESRD and the non-renal population, the results for placebo 
arms of the AURORA, 4D and 4S studies are shown in Table 1.3.  The 4S study was 
a  randomised  placebo  controlled  study  investigating  the  effect  of  simvastatin  in 
patients who had proven coronary artery disease (8). 
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Table 1.3   Results from placebo arms of AURORA, 4D and 4S studies. 
 
 
 
These data show that patients receiving haemodialysis have a much higher risk of 
cardiac death than non fatal MI.  However in a post MI, non dialysis-dependent 
cohort of patients, non fatal MI is the most prevalent CV event to occur; cardiac 
death is much less common.  When we look at data from USRDS (see Figure 1.2) 
these haemodialysis patients are much more likely to suffer a cardiac arrhythmic 
death. The features that increase risk of sudden cardiac death/cardiac arrhythmia will 
be discussed later in this chapter. 
 
1.2.2d Diabetes mellitus 
According to UK Renal Registry and USRDS data, diabetes is the most common 
primary renal disease in patients receiving RRT and in the developed world diabetic 
nephropathy has become the most common cause of ESRD (between 20-35% of 
patients).  In addition, the prevalence of diabetic patients with ESRD is rising which 
likely  reflects  improved  survival  of  type  2  diabetic  patients  (27).    Interestingly,  
recent  reports  from  Finland  and  US  suggest  that  the  number  of  type  1  diabetic 
 
Study/ 
Cause of Death 
AURORA 
% 
4D 
% 
4S 
% 
Placebo n=1378  Placebo n=636  Placebo n=2223 
Study Population  Haemodialysis  DM+ haemodialysis  Post AMI 
Cardiac Death  5.4  19.5  8.5 
Non Fatal MI  2.5  11.8  16.9 
Non- CV Death  8.1  28.5  3.0 40 
 
patients requiring dialysis is decreasing possibly due to improved glycaemic, blood 
pressure and proteinuria control (28).  
 
Diabetic  patients  who  start  dialysis  have  many  CV  risk  factors  including 
dyslipidaemia,  hypertension,  chronic  inflammation  and  elevated  oxidative  stress 
leading to a poor prognosis on dialysis.  Presence of diabetes at the start of dialysis is 
significantly associated with poorer survival, an independent risk factor for all cause 
and CV death,  and it is estimated that cumulative risk for diabetes (2-3x compared 
to non diabetic ESRD patients) and presence of ESRD increases the overall risk of 
death to 50x that of the general non diabetic population (29).  Accelerated coronary 
artery  disease  (CAD)  is  the  greatest  contributor  to  elevated  CV  morbidity  and 
mortality  in  diabetic  ESRD  patients  (30).    In  one  study  looking  at  155  diabetic 
patients  being  assessed  for  renal  transplantation  (who  are  commonly  positively 
selected due to their fitness to have a transplant), significant occlusion (>50%) in at 
least one vessel was found in 45% of patients despite 28% being asymptomatic of 
angina (31). 
 
1.2.2e  Cigarette smoking 
Initial  studies  suggested  that  smoking  had  little  effect  on  CV  disease  in  ESRD 
patients and clinicians were reluctant to impose further restrictions on chronically 
unwell patients.    However, two studies have demonstrated an association between 
smoking and CV disease similar to the general population.   
 
·  In  an  observational  study  investigating  baseline  CV  risk  factors  and  pre-existing 
disease  in  dialysis  patients,  smoking  was  independently  associated  with  higher 41 
 
relative  risk  of  CV  disease  (32).  In  addition,  a  prospective  study  investigating 
development if CV events in a population of haemodialysis patients over 5 years 
showed that being a smoker at screening significantly increased risk of a subsequent 
CV events (33). 
 
As a result of these and other studies, smoking cessation is encouraged in ESRD 
patients to improve CV survival. 
 
1.2.2f  Ischaemic heart disease 
As stated above, sudden cardiac death and cardiac arrhythmia are the commonest 
cause  of  death  in  the  ESRD  population.    Nonetheless,  accelerated  CAD  and  its 
sequelae account for almost 20% of CV deaths and is a significant feature of CV 
disease in ESRD patients.  Cause of death classification is not always supported by 
post  mortem  evidence  and  it  is  likely  that  a  significant  proportion  of  deaths 
attributed as “arrhythmic” in origin are due to silent, undiagnosed CAD.   
 
The  classical  triad  to  identify  myocardial  infarction:  namely  symptoms,  ECG 
changes  and  myocardial  enzyme  elevation,  can  be  misleading  in  this  patient 
population  making  design  of  trials  very  difficult.  Resting  ECG  abnormalities 
(particularly  T  wave  and  left  ventricular  axis  changes)  are  common  in  ESRD 
patients and  can be mistaken for ischaemia.    In addition, significant myocardial 
ischaemia may be present in dialysis patients despite atypical or absent symptoms.  
Finally, myocardial enzymes such as troponin I and T may be elevated in renal 
impairment despite the absence of significant myocardial damage. 
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Nonetheless, several observational studies have highlighted elevated burden of CAD 
in ESRD patients.  It has been estimated that in patients commencing dialysis, 30% 
of patients will experience AMI in the first year and 52% after the second (34).  
Furthermore, follow up data of these patients (35) has demonstrated poor prognosis 
in patients who suffered an MI with only 40%  alive at 12 months and post-MI 
cardiac arrhythmias contributing to a very high in- hospital mortality (21% vs.  8% 
in the general population)   
 
Poor post-MI prognosis may be due to under- or late diagnosis of MI at the time of 
presentation and delay in appropriate treatment.  Even when patients with AMI are 
identified, a significantly lower number of patients are treated with thrombolytic 
therapy or referred for primary percutaneous intervention (PCI) compared to the non 
dialysis population.  When discharged, these patients are under prescribed standard 
secondary  preventative  therapy:  only  50-75%  of  patients  receive  aspirin,  22% 
receive β- blockers and 26% receive statin therapy (36).  Reluctance to prescribe 
these drugs is presumably due to absence of evidence supporting their use in ESRD 
patients, who were commonly excluded from large studies for secondary prevention 
of CV events.  However, a number of small observational studies have demonstrated 
significant benefit of treatment with aspirin, β- blockers or angiotensin converting 
enzymes in the 30 day post MI period compared to those not treated (37). 
 
At the time of presentation, both thrombolytic therapy and primary PCI have been 
shown  to  significantly  improve  survival  in  ESRD  patients.  From  USRDS  data, 
Herzog et al showed that thrombolysis therapy for ST elevation MI was associated 
with  a  28%  relative  risk  reduction  in  all  cause  mortality  at  48  months  (38).    43 
 
Furthermore, if the centre that patients present has access to primary PCI, ESRD 
patients  should  be  treated  similarly  to  the  general  population.    In  a  large 
observational  study  of  4758  CKD  patients  who  presented  to  hospital  with  acute 
coronary syndrome, Keeley et al demonstrated a significant improvement in long 
term  mortality  in  patients  with  CKD  4-5  treated  with  primary  PCI  compared  to 
medical therapy (39). 
 
In dialysis patients with significant symptomatic CAD there is survival benefit of 
coronary artery bypass grafting (CABG) compared to PCI with angioplasty (± stent). 
Dialysis patients from the USRDS who received their first coronary revascularisation 
procedure between 1995 and 1998 were compared in a large retrospective study.  All 
cause 2  year survival was significantly higher in patients who underwent CABG 
(56.4%) compared to PCI and PCI and stent groups (48.2% and 48.4% respectively; 
p<0.01).  Multivariate survival analyses, demonstrated a 20% reduction in all cause 
mortality in patients treated with CABG and 6% reduction with PCI and stenting 
compared  to  PCI  alone.    However,  the  benefits  of  CABG  over  PCI  need  to  be 
balanced with higher peri-operative complication rate of these procedures (8.6% for 
CABG vs. 6.4% for angioplasty and 4.1% for stenting) (35).   
 
These studies suggest that coronary artery intervention is appropriate in the acute 
setting and/or in patients with critical coronary artery stenoses.  In ESRD patients 
with less severe but flow limiting CAD, the role of coronary intervention is less clear 
due  to  a  lack  of  prospective  randomised  controlled  trials.    In  the  CARP 
(asymptomatic  patients  undergoing  high  risk  vascular  surgery)  and  COURAGE 
studies  (asymptomatic  patients  with  stable  CAD),  PCI  conferred  no  significant 44 
 
survival  benefit  compared  to  patients  treated  with  optimal  medical  therapy 
highlighting  the  need  for  careful  selection  of  patients  who  undergo  coronary 
revascularisation (40;41).  At present, a prospective randomised controlled trial is 
planned in the US to determine the possible benefit of coronary revascularisation in 
ESRD patients. 
 
1.2.2g  Sedentary lifestyle 
ESRD patients are at risk of physical deconditioning due to a number of reasons 
including  large  burden  of  co-morbidity  (diabetes  mellitus,  peripheral  vascular 
disease,  CAD),  recurrent  hospital  admissions,  myopathy  related  to  uraemia, 
hyperparathyroidism and anaemia.  The UK Renal Association recommends regular 
exercise programmes for dialysis patients usually 3-5 times a week despite a lack of 
convincing  evidence  of  benefit  (42).    Results  from  the  Dialysis  Morbidity  and 
Mortality Wave 2 study demonstrated a significantly higher mortality in patients 
with  severe  limitations  in  physical  activity.    When  different  patient  groups  were 
exposed to varying levels of exercise, frequent exercise (4-5/week) was associated 
with improved survival (43). 
 
1.2.2h Oxidative stress 
Essential  steps  in  development  of  atherosclerosis  include  perioxidation  of 
membrane-bound, lipoprotein-associated fatty acids (in particular LDL- cholesterol) 
and oxidation of proteins by reactive oxygen species (ROS).  Furthermore, ROS play 
a part in ischaemia-reperfusion injury during myocardial ischaemia/infarction.  In the 
general population, interventional randomised trials have investigated the effect of 
antioxidants  (e.g.  acetylcysteine),  which  significantly  reduce  oxidation  of  LDL-45 
 
cholesterol and impair cellular response to oxidised LDL-cholesterol.  Unfortunately, 
these studies have shown no significant clinical benefit (44). 
 
A number of studies have demonstrated that patients receiving RRT (particularly 
haemodialysis) have higher levels of oxidative stress which may be amenable to 
intervention  with  antioxidant  therapy.    Although  evidence  is  lacking,  two  small 
studies have demonstrated some benefit: 
 
·  In one study investigating 196 haemodialysis patients with known cardiac disease, 
treatment with oral vitamin E significantly reduced composite CV events during a 
median follow up of 519 days.  However this study was limited by small numbers of 
patients and subsequent events (45).  In a smaller randomised, placebo  controlled 
study (n=134), acetylcysteine therapy was also associated with a lower all cause and 
CV mortality in haemodialysis patients (46). 
 
Unfortunately, the use of these agents in ESRD patients has been limited by the 
absence of larger studies demonstrating a convincing clinical benefit. 
 
1.2.2i  Uraemic cardiomyopathy 
Abnormalities  of  myocardial  structure,  detected  by  echocardiography,  are  very 
common (approximately 85%) in patients starting renal replacement therapy and are 
strongly associated with poorer outcome.  These changes in myocardial architecture 
and function have been termed “uraemic cardiomyopathy”.  Parfrey et al (47) studied 
432  patients  on  initiation  of  dialysis  and  characterised  three  patterns  of 46 
 
cardiomyopathy:    left  ventricular  hypertrophy  (LVH),  left  ventricular  systolic 
dysfunction (LVSD), and left ventricular dilatation (Table 1.4): 
 
Table 1.4 Prevalence and survival of uraemic cardiomyopathy (47). 
 
Abnormality  LV 
Hypertrophy 
LV Dilation  LV Systolic 
Dysfunction 
Normal 
Prevalence (%)  41  28  16  15 
 
Median Survival 
(months) 
48  56  38  66 
 
 
Only 15% of patients in this cohort had normal LV dimensions.  On 2 year follow 
up, each abnormality was significantly associated with poorer survival compared to 
patients  with  normal  echocardiograms  after  adjustment  for  age,  and  presence  of 
diabetes and CAD.   Additional data from USRDS have also demonstrated poorer 
survival in dialysis patients with LVH on echocardiogram (48). 
 
LVH is the commonest abnormality of uraemic cardiomyopathy and a precursor for 
the development of other cardiac abnormalities.  The development of LVH in ESRD 
patients  will  be  discussed  in  detail  in  Chapter  3.    Briefly,  LV  thickening  is  an 
adaptive process to: 
 
· Increased  pressure  load  leading  to  uniformly  increased  LV  wall  thickening  with 
preservation of LV cavity size (concentric hypertrophy). 47 
 
· Increased volume load causing LV dilatation and LV wall thickening to maintain 
wall stress.  This leads to eccentric hypertrophy (49).   
 
A number of factors associated with ESRD (e.g. anaemia, hyperparathyroidism) may 
also promote myocardial fibrosis in addition to sarcomere formation.  Thus, the key 
histological features of uraemic cardiomyopathy which have been demonstrated in 
animal  and  patient  biopsy  studies  are  increased  cardiomyocyte  volume  and 
interstitial myocardial fibrosis (50;51). 
 
1.2.2j  Anaemia 
The  presence  of  anaemia  has  been  associated  with  significant  morbidity  and 
mortality in ESRD patients. Historically, anaemia has been associated with increased 
cardiac workload and subsequent development of LVH and LV dilatation in CKD 
patients.  Despite  observational  studies  demonstrating  improved  cardiovascular 
outcome,  prospective  randomised  studies  have  failed  to  demonstrate  significant 
reduction of LV mass or improved outcome in patients whose anaemia has been 
corrected.    Furthermore,  elevated  haemoglobin  levels  have  been  associated  with 
increased mortality in a number of prospective studies: 
 
·  In  dialysis  patients  with  cardiac  disease  treated  with  erythropoietin,  the  Normal 
Hematocrit Study (NHS) was stopped early due to a trend toward poorer outcome in 
the high haematocrit compared to the low haematocrit group (52).  Furthermore, 
Foley et al demonstrated no difference in LV mass of dialysis patients treated with 
erythropoietin to achieve full or partial correction of haemoglobin levels (53). 48 
 
·  In pre-dialysis patients, two randomised prospective studies (CHOIR and CREATE) 
have demonstrated poorer cardiovascular outcome and/or higher mortality in patient 
groups treated with erythropoietin to achieve higher haemoglobin levels (54;55). 
 
Given that patients with lower haemoglobin include those with more comorbidities, 
including ongoing inflammation and malnutrition, it is not surprising that anaemia is 
associated  with  poorer  survival  in  ESRD  patients.      However,  optimum  level  of 
haemoglobin  and  time  of  commencement  of  erythropoietin  therapy  remain 
controversial.    The  relationship  between  anaemia  and  features  of  uraemic 
cardiomyopathy will be discussed in further detail in Chapter 3. 
 
1.2.2k Proteinuria 
Proteinuria is defined as urinary protein excretion greater than 300mg over 24 hours.  
A  number  of  observational  studies  have  demonstrated  that  proteinuria  is  an 
independent risk factor for all cause and cardiovascular mortality in patients with and 
without diabetes mellitus: 
· Post hoc analyses of the RENAAL (Reduction in Endpoint in Non-insulin dependent 
diabetes mellitus patients with the Angiotensin II Antagonist Losartan) trial showed 
that proteinuria>3g/24 hours was associated with doubling of serum creatinine or 
ESRD in 85% and cardiovascular morbidity or mortality in 44% of patients.  These 
endpoint  rates  were  significantly  higher  compared  to  patients  with  proteinuria 
<1.5g/24hours (28% and 29% respectively) (56).   
·  In a 16 year study of non diabetics of the Framingham cohort, evidence of significant 
proteinuria (>2+ on dipstix) increased mortality threefold (57). 49 
 
·  Tonelli et al (58) demonstrated in patients with ischaemic heart disease, that those 
with reduced eGFR or dipstick urinalysis positive proteinuria (≥1+) were at highest 
risk  of  dying  from  a  CV  event  compared  to  those  without  these  risk  factors.  
Furthermore, those subjects with both had the worse survival and highest CV event 
rate. 
 
These  and  other  studies  support  a  significant  association  between  presence  of 
proteinuria and CV events or death in diabetic and non diabetic patients.  The link 
between  proteinuria  and  CV  risk  in  CKD  patients  is  multi-factorial  and  felt  to 
represent pathophysiological associations rather than a causal relationship.  These 
factors include: 
·  Extracellular volume overload 
·  Hypertension and activation of the renin angiotensin aldosterone system 
·  Vascular calcification 
·  Endothelial dysfunction/oxidative stress 
 
1.2.2l  Bone mineral disorders and vascular calcification 
As  renal  function  deteriorates,  chronic  hyperphosphataemia  and  hypocalcaemia 
cause  secondary  and  occasionally  tertiary  hyperparathyroidism.    Disturbances  of 
calcium and phosphate homeostasis have been reported as early as CKD stage 3 and 
a  number  of  large  observational  studies  have  identified  serum  markers  of  bone 
mineral disorders as risk factors of poor outcome: 
 
·  Data  from  the  USRDS  demonstrated  that  hyperphosphataemia  and  calcium- 
phosphate  product  were  strong  independent  predictors  of  mortality  in  7096 50 
 
haemodialysis  patients  when  corrected  for  age,  sex,  race,  smoking  status,  and 
presence of diabetes mellitus or neoplasm.  Elevated serum PTH was also associated 
with death (59). 
·  Hyperparathyroidism not only increases risk of fractures, but also has adverse effects 
on  all  cause  and  cardiovascular  mortality.    In  a  much  larger  US  dialysis  study, 
moderate  to  severe  hyperparathyroidism  (PTH>600pg/ml)  was  independently 
associated with mortality, CV hospitalisation and fracture when corrected for age, 
sex, race, diabetes and dialysis vintage (60).  PTH has been associated with adverse 
cardiovascular  outcome  due  to  its  effects  demonstrated  in  vitro.    PTH  specific 
receptors  present  on  myocardial  and  vascular  cells  isolated  from  rat  perfusion 
models, have demonstrated positive inotropic and chronotropic effects due to altered 
intracellular  calcium  handling  when  stimulated.    Furthermore  in  vitro  effects  of 
elevated  PTH  (as  in  patients  with  CKD)  demonstrate  stimulation  of  cardiac 
fibroblasts to produce collagen type 1 with subsequent interstitial fibrosis (61). 
 
The development of vascular calcification (VC) has been associated with increased 
cardiovascular morbidity and mortality.  Vascular calcification is associated with 
calcium deposition within the medial and intimal layers of arterial walls.  Medial 
deposition, which is very common in dialysis patients, results in reduced arterial 
compliance, widened pulse pressure, decreased coronary perfusion, and associated 
autonomic and endothelial dysfunction.  Intimal deposition, which can also occur in 
patients  with  normal  renal  function,  is  associated  with  atherosclerotic  plaques, 
subsequent  myocardial  infarction  and  other  thrombotic  events.  Intimal  layers  of 
cardiac  valves  can  also  be  affected  leading to significant aortic and mitral valve 
stenosis.  In patients with CKD, VC is commonly localised to coronary, aortic and 51 
 
ileo-femoral vascular regions and can be detected using plain X rays and computed 
tomography (usually electron beam; EBCT).  Vascular calcification can be observed 
in young dialysis patients and its presence and extent are strong predictors of CV and 
all cause mortality: 
 
· In a prospective study of 110 dialysis patients, Blacher et al measured VC using 
ultrasonography and scored patients according to presence of VC at different sites.  
Each increase in 1 unit score was independently associated with all cause and CV 
mortality (62). 
· Using  EBCT  to  prospectively  assess  101  dialysis  patients,  Matsuoka  et  al 
demonstrated that all cause and CV mortality was higher in patients with evidence of 
coronary artery calcification (63).  
 
Although  bone  mineral  disorders  are  associated  with  development  of  VC,  most 
investigators do not believe that this is merely due to precipitation of calcium and 
phosphate within vessel walls.  In vitro studies have demonstrated transformation of 
vascular  smooth  muscle  cells  to  osteoblasts  mediated  by  phosphate,  calcium  and 
other  osteogenic  protein  such  as  ostecalcin,  ostenectin,  alkaline  phosphatase,  and 
collagen type 1.  This is also associated with reduced serum levels of VC inhibitors 
such  as  Gla-protein,  fetuin-  A  and  ostepontin  in  ESRD  patients  (64).    In  CKD 
patients the reason for alteration in vessel wall activity remains unclear and is an area 
of intense research interest. 
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1.2.2m   Inflammation and C- reactive protein 
In the general population, the presence of a chronic inflammatory process  has  been 
implicated  as  an  important  contributor  to  atherogenesis  and  plaque  rupture.    A 
number of studies have demonstrated C-reactive protein (CRP), which is an acute 
phase reactant produced by hepatocytes in response to interleukin-1 and 6 (IL-1, IL-
6) and tumour necrosis factor alpha (TNFα), as a predictor of adverse cardiovascular 
outcomes.    Whether  CRP  is  a  non-specific  marker  of  an  ongoing  inflammatory 
response  or  directly  involved  in  the  atherogenic  process  remains  unclear.  
Nonetheless, presence of elevated CRP is a marker of poor primary and secondary 
CV outcome in the general population: 
 
· In a Danish study of over 50000 individuals in whom high sensitivity CRP (hs-CRP) 
was measured, CRP>3mg/L was associated increased risk of ischaemic heart disease 
(RR1.6) and stroke (RR 1.3) compared to patients with CRP<1mg/L (65). 
· In patients with ischaemic heart disease, elevated CRP measured 12-24 hours post 
acute coronary syndrome (n=448) was associated with a significantly higher 30-day 
mortality, greater infarct size and higher risk of subsequent heart failure (66). 
· In  a  case  control  study  of  22071  healthy  male  physicians  who  had  a  single 
measurement  of  CRP  and  were  followed  for  17  years,  baseline  CRP  was 
significantly  associated  with  sudden  cardiac  death.    In  addition,  individuals  with 
CRP in the highest quartile had the highest risk of sudden cardiac death (RR 2.78) 
compared to the lowest quartile (67). 
 
Patients with ESRD are in a state of chronic inflammation and various studies have 
demonstrated  inflammatory  biomarkers  such  as  CRP,  IL-6  and  TNF  α  as 53 
 
independent  predictors  of  CV  mortality.    In  addition,  hypoalbuminaemia  often 
accompanies chronic inflammation and is also associated with adverse outcome: 
 
· In 224 maintenance dialysis patients, elevated CRP concentrations measured at study 
recruitment  were  significantly  associated  with  poorer  survival  and  independently 
predicted  death  when  adjusted  for  age,  sex  race,  dialysis  vintage,  smoking  and 
cardiac history, and dialysis adequacy (68). 
· In a prospective study of 176 ESRD patients, lower serum albumin and elevated IL-6 
independently predicted development of CV morbidity and all cause mortality over a 
follow up of 26 months (69).  
 
As in the general population, it is unclear whether these pro-inflammatory proteins 
are directly involved in initiation and progression of atherosclerosis in CKD/ dialysis 
patients or are markers of ongoing atheromatous formation, endothelial dysfunction, 
vascular calcification and insulin resistance.  In vitro evidence suggests IL-6 and 
TNFα  directly  stimulate  endothelial  cells  to  promote  atherogenesis  by  increasing 
monocyte adhesion, smooth muscle proliferation and LDL-oxidation (69).   
 
1.2.2.n   Haemodynamic instability during haemodialysis  
Intermittent haemodialysis (HD), particularly when large volumes of ultrafiltration 
are attempted, exerts significant haemodynamic imbalance and it is estimated that 
approximately 25% of patients develop episodes of intradialytic hypotension (IDH) 
(70).  Patients receiving haemodialysis are also susceptible to myocardial ischaemia, 
as discussed above, due to: 
 54 
 
· Large vessel epicardial CAD 
· Micro-coronary  artery  occlusion  and  myocyte-  capillary  circulatory  mismatch 
associated with LVH 
· Impaired diastolic coronary blood flow due to reduced vascular compliance. 
 
ECG studies have demonstrated the presence of asymptomatic ST segment changes 
during HD  at rates between 15-40%.  More recently, intradialytic  LV functional 
analyses using echocardiography or cardiac positronic emission tomography, have 
demonstrated development of myocardial wall stunning during HD, usually in the 
absence of symptoms.  These abnormalities develop in the absence of significant 
CAD or cardiovascular disease.  In a small study (n=70) of HD patients assessed 
during  dialysis,  intradialytic  hypotension  and  volume  of  ultrafiltration  were 
independent predictors of myocardial stunning.  After 1 year follow up, presence of 
intradialytic myocardial stunning was associated with higher mortality and poorer 
LV function compared to those with no intradialytic LV changes (71). 
 
Promising  measures  to  reduce  myocardial  stunning  during  dialysis  have  been 
pursued  including  reduced  temperature  dialysis  (35°C  instead  of  37°C)  and 
biofeedback dialysis (BFD) which reduces ultrafiltration rates in response to small 
changes in blood pressure (72;73).  Both techniques significantly reduce IDH and are 
associated with reduced RWMA number. The effect that these measures have on 
long term outcomes is awaited. 55 
 
1.3  Sudden cardiac death in ESRD patients 
 
As  previously  discussed,  CV  disease  in  ESRD  patients  differs  from  the  general 
population.  The predominant cause of death in ESRD patients is cardiac arrest or 
cardiac  arrhythmia  (Figure  1.1),  as  opposed  to  complications  of  coronary 
atherosclerotic  disease  which  accounts  for  most  deaths  in  the  non-renal  disease 
population.    Event  rates  for  SCD  in  the  general  non-renal  population  have  been 
estimated at 1.89/ 1000 patient  years, in contrast to ESRD rates of 48 per 1000 
patient years and dialysis rates of 60 per 1000 patient years (74).  Treatment of risk 
factors  (e.g.  dyslipidaemia,  hypertension)  which  have  been  shown  to  reduce  CV 
morbidity and mortality in the general population, has little, if any effect on ESRD 
patients suggesting that pathogenesis is inherently different. 
 
1.3.1  Definition 
Various criteria have been employed to define SCD.  For the purposes of this thesis 
sudden cardiac death is defined as an unexpected death of cardiac aetiology, which 
occurs within one hour from the start of any cardiac-related symptoms due to cardiac 
arrest or arrhythmia.  These deaths are commonly due to ventricular arrhythmias, 
namely ventricular tachycardia (VT) or fibrillation (VF).  Although SCD can occur 
in  patients  with  structurally  normal  hearts,  it  is  more  common  in  patients  with 
underlying  myocardial  structural  abnormalities  such  as  hypertrophic 
cardiomyopathy, or less commonly LVH.    
 
In  general  terms,  development  of  a  fatal  cardiac  arrhythmia  requires  abnormal 
“substrate” (e.g. LVH, cardiomyopathy) interacting with a “triggering mechanism” 56 
 
(e.g. ischaemia, hyperkalaemia).  Both substrate and triggers are common in ESRD 
patients. 
Sustained VT has been studied extensively in post MI patients and occurs due to 
slowed  cardiac  action  potential  (AP)  propagation  between  areas  of  ventricular 
scarring, followed by re-entry into excitable, viable myocardium.  As a result a rapid 
ventricular  circuit  is  established.    In  patients  with  reduced  LV  function,  rapid 
ventricular rate results in significant haemodynamic compromise (75).  Whether VT 
directly  leads  to  SCD  or  more  life  threatening  cardiac  arrhythmias  remains 
debatable,  however  the  presence  of  sustained  VT  on  24  hour  ECG  (from  ICD 
monitoring) has been significantly associated with SCD (76).  The development of 
VF is not as well understood and usually requires more diffuse underlying cardiac 
disease.  Currently, VF is thought to be due to multiple small regions of disorganised 
re-entry  resulting  in  abnormal  depolarisation  fronts  and  dispersion  of  ventricular 
repolarisation.  Since there is no ordered ventricular depolarisation, there is no co-
ordinated contraction resulting in failure to generate adequate cardiac output (77).  
 
1.3.2  Epidemiology of sudden cardiac death in ESRD patients 
Data  from  the  US  demonstrate  the  huge  impact  on  mortality  of  SCD  in  ESRD 
patients.  Sudden cardiac death is the commonest cause of death in all ESRD patients 
accounting for 20-30% of all deaths.  Similar rates are seen for dialysis (haemo- and 
peritoneal) patients.  These figures are similar to rates of sudden cardiac deaths (25-
30%) reported in the HEMO and 4D trials (25;78). 
 
The risk of SCD after initiation of dialysis increases with dialysis vintage.   In a 
retrospective study of incident dialysis patients from the US who had survived at 57 
 
least 1 year after dialysis initiation, event rate rose from 93 per 1000 patient years at 
2  years  to  164  per  1000  patient  years  after  5  years  from  dialysis  initiation.   
Comparison  of  dialysis  modality  reveals  that  in  the  first  3  months  of  dialysis, 
patients  receiving  haemodialysis  have  a  50%  higher  risk  of  SCD  compared  to 
peritoneal dialysis patients.  However after 18 months, event rates are similar and by 
36 months peritoneal dialysis are higher by less than 10% (79;80). 
 
1.3.3  Aetiology of sudden cardiac death in ESRD patients 
Section 1.2 has described many of the risk factors commonly associated with CV 
disease in ESRD patients.  However, high prevalence of these risk factors in ESRD 
patients only partially accounts for elevated risk of SCD.  Figure 1.3 highlights some 
of the features associated with SCD in ESRD patients.  In particular, factors which 
promote  changes  in  myocardial  structure  (substrate)  or  cardiac  environment 
(triggers) have been implicated (81). 
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Figure 1.3  Factors associated with SCD in ESRD patients.  CAD= coronary 
artery disease.  Modified from (81). 
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1.3.3a Uraemic cardiomyopathy and sudden cardiac death 
Myocardial structural changes associated with uraemic cardiomyopathy (described in 
section  1.2.2i)  have  been  associated  with  sudden  cardiac  death.    In  post  MI 
populations, LV systolic dysfunction is the greatest predictor of sudden cardiac death 
and has been used as the most important factor to determine primary prevention of 
cardiac arrest in this patient population:   
 
·  The Multicenter Automatic Defibrillator  Implantation Trial (MADIT  II) recruited 
1232  post  MI  patients  with  reduced  LV  ejection  fraction  (LVEF<30%)  on 
echocardiography.    Patients  were  assigned  to  receive  implantable  cardioverter 
defibrillator  (ICD)  or  conventional  therapy.    Patients  in  the  ICD  arm  had  a 
significantly  lower  mortality  rate  (14.2%  ICD  vs  19.8%  conventional  medical 
therapy, p=0.016) (82)  
·  The  Sudden  Cardiac  Death  in  Heart  Failure  Trial  (SCD-HeFT)  assigned  2521 
patients with symptomatic heart failure (from ischaemic and non-ischaemic causes) 
and  LVEF  less  than  35%  to  conventional  therapy,  conventional  therapy  and 
amiodarone or conventional therapy and ICD.  Mortality rate was significantly lower 
in the ICD group (22% ICD, 28% medical therapy with amiodarone, 29% medical 
therapy  without  amiodarone).    ICD  therapy  was  associated  with  a  23%  relative 
reduction in risk of death and absolute reduction in mortality of 7.2% after 5 years 
compared to the medical therapy without amiodarone group (83). 
 
Both  of  these  studies  have  been  instrumental  in  American  College  of 
Cardiology/American  Heart  Association  (ACC/AHA)  guidelines  stating  that  ICD  
insertion should be considered in patients with “LVEF less than or equal to 35% and 60 
 
mild  to  moderate  symptoms
  of  heart  failure  and  in  whom  survival  with  good 
functional capacity is
 otherwise anticipated to extend beyond 1 year” (84).    
 
Unfortunately,  patients  with  ESRD  were  excluded  from  these  trials.    Severe  LV 
systolic dysfunction has been reported to be present in 15-20% of ESRD patients, and 
has not been demonstrated as a significant predictor of SCD.   
 
·  A retrospective analysis of dialysis patients in the US who died of sudden cardiac 
death,  showed  that  71%  had  normal  or  only  mild-moderate  LV  dysfunction  on 
echocardiogram (85).  Furthermore, Genovesi et al demonstrated that LVEF <40% 
was not a significant predictor of SCD in ESRD patients (86). 
 
Left  ventricular  hypertrophy  has  been  associated  with  SCD  in  patients  with 
hypertension and ischaemic heart disease.  The Framingham Study demonstrated a 5 
fold increase risk in men and 3 fold increase risk in woman of SCD in patients with 
LVH on ECG compared to those with normal resting ECG (87).  LVH is believed to 
increase risk of ventricular arrhythmias and SCD due to a number of factors: 
 
·  Microvascular  ischaemia-  reduced  subendocardial  blood  flow  due  to  elevated 
diastolic  blood  pressure,  inadequate  capillary  angiogenesis  (causing  myocyte-
capillary mismatch) and increased oxygen requirement due to elevated wall tension 
result in ventricular ischaemia. 
·  Electrophysiological  changes-  irregular  myofibril  architecture  and  fibrosis  may 
partially  impede  AP  propagation  leading  to  non  uniform  ventricular  de-  and 
repolarisation. 61 
 
·  Abnormalities  of  hypertrophied  myocyte-  cellular  changes  tend  to  increase 
arrhythmogenic properties including alteration in intercalated disc spaces involved in 
cell  to  cell  AP  propagation  and  changes  in  transverse  tubule  system  which 
communicate between surface cell membrane and the sarcomere.  It remains unclear 
if these changes in structure are related to specific structural changes. 
·  External pressure- cardiac myocytes respond to external pressure (eg increased wall 
tension) via stretch activated channels which stimulate cytoplasmic ionic changes 
and lower AP excitation threshold. 
 
As stated before, LVH is very common (60-80%) in ESRD patients and is associated 
with sudden cardiac death in dialysis patients, independent of blood pressure: 
 
·  Post hoc analyses of the 4D study demonstrated that in 1253 patients, those with 
ECG evidence of LVH had a 60% increased risk of SCD after 4 years (88). 
·  Poaletti et al demonstrated that worsening of LVH on echocardiogram (per 1g/m
2) 
independently predicted SCD in haemodialysis patients followed for 10 years (89). 
 
It  should  be  noted  that  in  these  and  other  studies,  presence  of  LVH  has  been 
demonstrated  using  ECG  criteria  or  M-mode  echocardiography.  As  will  be 
discussed, these techniques are inaccurate when estimating LV mass, particularly in 
ESRD patients. 
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1.3.3b Coronary artery disease and sudden cardiac death 
As previously discussed, accelerated CAD is common in patients with ESRD and 
accounts for a significant proportion of CV morbidity.  As in the general population, 
it is likely that CAD also contributes, albeit not as significantly, to SCD.  This has 
been highlighted in a study in patients with ESRD and significant occlusive coronary 
disease.  Despite revascularisation, subsequent annual mortality due to arrhythmic 
deaths was considerably higher than non-renal populations (8.5% and 7% after PCI 
and stenting and CABG respectively) suggesting that improving coronary blood flow 
may not reduce risk of SCD and alternative factors may play an important role (90).  
Furthermore,  agents  that  modify  established  risk  factors  for  CAD  in  non  renal 
patients (e.g. dyslipidaemia) have not altered CV outcome of ESRD patients. 
 
1.3.3c Electrolyte fluctuation and hyperkalaemia 
Due  to  the  non-physiological  and  intermittent  nature  of  maintenance  HD,  rapid 
electrolyte shifts and hyperkalaemia (due to accumulation of potassium) increase risk 
of  cardiac  arrhythmias.    This  elevated  risk  is  unsurprising  given  the  significant 
electrolyte imbalance present immediately before HD and the haemodynamic stress 
produced  during  an  HD  session.    These  changes  are  reflected  in  many  studies 
investigating  the  temporal  risk  of  SCD  in  maintenance  HD  patients  which  have 
shown that risk is highest immediately before and after the first weekly HD session.  
One study reported a 3-fold increase in risk of sudden death in the immediate 12 
hours before the end of the long weekend and a 1.7-fold increased risk of SCD in the 
12  hours  from  the  start  of  dialysis  after  the  long  weekend  (85;91).  As  expected 
elevation of serum potassium, which is highest just before the start of dialysis, was 63 
 
shown to be an independent risk factor for SCD in HD patients (K+>6mmol/l; RR 
2.74). 
 
1.3.3d Autonomic dysfunction 
Autonomic  dysfunction,  resulting  in  enhanced  sympathetic  activity,  has  been 
associated with SCD in post MI and heart failure patients.  Furthermore, autonomic 
function in ESRD patients is characterised by sympathetic over activity: 
 
· In one study, sympathetic nerve discharge was higher in HD patient compared to 
normal  controls.    Interestingly  sympathetic  activity  in  HD  patients  with  bilateral 
nephrectomies  was  similar  to  controls,  leading  the  investigators  to  believe  that 
autonomic imbalance arose from the failing kidneys (92). 
· In  a  prospective  study  of  228  HD  patients,  plasma  norephinephrine  level  was 
elevated compared to previously published levels and significantly associated with 
adverse outcome and CV events (93). 
 
Thus it is likely that autonomic dysfunction may play a role in promoting cardiac 
arrhythmias in ESRD patients. 
 
1.3.3e  Factors promoting myocardial fibrosis 
As  stated  above,  the  creation  of  a  non-uniform  wavefront  of  myocyte  de-  and 
repolarisation  promotes  the  development  of  VTA.    Due  to  differences  in  action 
potential  conductivity  between  myocyte  plasma  membrane  and  collagen  fibres, 
myocardial fibrosis promotes VTA formation (94).  Post mortem endomyocardial 
biopsies  of  ESRD  and  renal  transplant  patients  have  demonstrated  significantly 64 
 
elevated levels of interstitial fibrosis compared to non diabetic, non hypertensive 
controls.  In these studies, severity of fibrosis was correlated with dialysis vintage 
and was demonstrable years after renal transplantation (51). 
 
A number of animal models have isolated humoral and mechanical factors, some of 
which have previously been discussed, that may promote cardiac fibrosis in uraemic 
patients  including  fluid  overload,  oxidative  stress,  inflammation  with  excess  of 
cytokines  such  as  cardiotrophin-1  and  transforming  growth  factor  β  (TGFβ), 
hyperphosphataemia, hyperparathyroidism, anaemia, vitamin D deficiency and other 
uraemic “toxins” yet to be identified (95;96). 
 
1.3.4  Identification of the ESRD patient at risk of SCD 
Identification of patients at high risk is desirable in order to implement prophylactic 
measures to reduce the rate of SCD in ESRD patients.  However, this remains very 
difficult due to the multifactorial nature of SCD within this patient group.  If criteria 
from the heart failure population are applied to ESRD patient (i.e. reduced LVEF) 
we will not only expose patients to an invasive procedure (ICD insertion) without 
adequate evidence from prospective trials, but also potentially omit patients that may 
be at risk (as mentioned above LVSD has been noted to be present in only 15% of 
patients). 
 
In heart failure/post MI patients, reduced LVEF alone has been shown to have low 
sensitivity and specificity for predicting SCD.  As an adjunct, electrophysiological 
(EP) tests have been evaluated to identify heart failure patients at higher risk of SCD 
and reduce the number of unused ICDs. It is estimated, based on reduced LVEF 65 
 
alone,  almost  18  ICDs  need  to  be  implanted  to  save  one  life  in  the  post  MI 
population    Furthermore,  in  early  primary  prevention  trials,  EP  tests  involved 
invasive  direct  cardiac  stimulation  to  induce  VT,  however  more  recently  non 
invasive techniques have been evaluated (97;98).  Evidence is  absent for the use of 
EP tests (both invasive and non-invasive) for prospectively assessing risk of cardiac 
arrhythmia  in  ESRD  patients  since  these  patients  were  excluded  from  initial 
prospective  studies  using  SCD  as  the  primary  endpoint.    Some  studies  have 
attempted to identify high risk ESRD patients. 
   
1.3.4a Ambulatory electrocardiography 
Presence of non sustained VT (defined as 3 or more consecutive beats of ventricular 
origin with a rate >120bpm and lasting greater than 30s) with structural heart disease 
or complex ventricular premature beats (R on T, runs of 2 or more, multiform or 
bigeminal beats) in patients post MI has been demonstrated to increase risk of SCD 2 
to 5- fold compared to patients without such arrhythmias (99;100). 
 
In  patients  with  ESRD,  ventricular  arrhythmias  are  commonly  observed  on 
ambulatory ECG especially during and immediately after HD sessions when there 
are  significant  changes  in  patient  electrolyte  and  haemodynamic  status  (101).  
However the role of ventricular arrhythmias detected by ambulatory monitoring for 
predicting future arrhythmic events is not well established in ESRD patients. 
 
1.3.4b Microvolt T wave alternans 
Beat to beat variation in ECG wave amplitude and shape has been observed for over 
a century.  Specifically, T wave alternans (TWA) is defined as fluctuations in T 66 
 
wave shape or amplitude and macroscopic TWA has anecdotally associated with 
onset  of  VTA,  especially  VF,  in  a  variety  of  clinical  situations  including  MI, 
electrolyte derangements, and long QT syndrome (102). 
 
At both cellular and tissue level, TWA has been shown to be closely associated with 
repolarisation alternans (RA) which describes regular variation between two patterns 
of ventricular repolarisation on an every-other- beat basis, each with a constant cycle 
length.    Repolarisation  alternans  is  thought  to  underlie  development  of  TWA.  
Pastore et al used optical mapping of the guinea pig heart to demonstrate that with 
increasing atrial pacing, TWA developed on surface ECG with the development of 
RA at the level of the cardiomyocyte (103). Magnitude of RA is much larger than 
corresponding 12-lead ECG TWA and development of ECG digital processing  has 
allowed  very  small  (at  the  microvolt  level)  changes  in  T  wave  amplitude  and 
morphology (called Microvolt T Wave alternans: MTWA) to be quantified.  It is 
important  to  appreciate  that  RA  is  a  physiological  rate  dependent  property  of 
cardiomyocytes that develops during tachycardia in structurally normal heart, but 
develops at much lower heart rates in diseased hearts.  
 
The cellular basis of RA is the focus of intense experimental study and remains 
controversial, but aims to provide insight into the arrhythmogenic state of different 
cardiac  conditions.    Briefly,  generation  of  RA  is  believed  to  be  due  to  action 
potential duration alternans (whereby premature stimulation of myocytes that have 
altered  properties  greatly  affect  their  diastolic/refractory  interval  and  thus  affects 
subsequent action potential duration) and abnormal handling of intracellular Ca
2+ 
(termed calcium transient alternans) (104). Presence of RA is thought to produce 67 
 
arrhythmogenicity  due  to  development  of  discordant  RA  between  neighbouring 
cardiomyocytes.    Normally,  RA  develops  in  a  uniform  (concordant)  fashion  that 
ensures  all  myocytes  alternate  in  phase  (long-short-long).    However,  at  elevated 
heart rates or after ventricular ectopy, some myocytes move out of phase, resulting in 
discordant  alternans  between  adjacent  cardiomyocytes  (long-short  vs  short-long) 
thus increasing the chance that a cardiomyocyte will attempt to conduct AP to a 
neighbouring  cell  in  a  refractory  state.    This  amplifies  any  non-uniformity  in 
ventricular repolarisation and increases risk of VF in structurally normal heart and 
VT or torsades de pointes in abnormal hearts. 
 
Initial  clinical  studies  of  MTWA  during  invasive  atrial  pacing  demonstrated  an 
increase  risk  of  VTA.    MTWA  is  currently  performed  during  exercise  using 
commercially  available  systems  (CH2000  or  HearTwave  II,  Cambridge  Heart, 
Bedford, MA).  Exercise ECGs are digitally acquired at stable heart rate and aligned 
according  to  the  start  of  the  QRS  complex,  allowing  measurement  of  T  wave 
amplitude.  Spectral analyses are performed to quantify fluctuations in alternate beat 
T  wave  size.    Fast  Fourier  transformation,  a  computer  mathematical  modelling 
system to quantify variations in frequency for continuous variables, is performed and 
T wave alternans is said to be present and result classified according to established 
electrophysiological  criteria.    Tests  are  classified  as  positive,  negative  or 
indeterminate by the commercial system and for clinical purposes as negative or 
non-negative/abnormal  (positive  or  indeterminate  result)  depending  on  the  study.  
More details for classification of tests are provided in Section 2.6.  Presence of atrial 
fibrillation does not allow MTWA testing as unequal R-R wave intervals interfere 
with frequency analysis.   68 
 
 Initial studies showing a significant association between MTWA result and SCD 
were  performed  in  high  risk  post-MI  patients  with  reduced  LVEF.    More  recent 
studies assessing the use of MTWA for primary prophylactic ICD insertion have 
shown improved efficiency for intervention: 
 
·  In a prospective US study of 549 patients with reduced LVEF, 49% of patients had 
documented CAD and an abnormal MTWA result was an independent predictor (HR 
6.5) of the primary end point of all cause mortality and non sustained VT after 2 
years (105). 
·  Similarly, Chow et al demonstrated in 768 patients with ischaemic cardiomyopathy 
and LVEF<35%, that an abnormal MTWA result was a significant predictor of all 
cause and arrhythmic mortality (HR 2.24 and 2.29 respectively) (106). 
·  The Alternans Before Cardioverter Defibrillator (ABCD) trial was the first study to 
use  MTWA  to  guide  prophylactic  insertion  ICD  insertion.    566  patients  were 
recruited  with  ischaemic  cardiomyopathy  and  documented  non  sustained  VT.  
Patients underwent EP studies or MTWA testing and ICDs were inserted if tests 
were positive.  One year survival showed that positive and negative predictive values 
for  MTWA  results  were  comparable  to  more  invasive  EP  studies.    Furthermore 
primary end point (ICD discharge or SCD) event rates were similar after 1 year.  
Interestingly,  predictive  values  were  much  better  if  patients  had  positive  EP  and 
MTWA tests suggesting that these tests were complementary (107). 
 
These studies have suggested that MTWA may improve the inefficient practice of 
ICD insertion based on reduced LVEF alone.  Most studies estimate that MTWA 69 
 
testing may improve efficiency of number needs to treat to save one life from 18 to 9 
103:104). 
 
Two more recent studies have suggested that the predictive value of MTWA may not 
be as encouraging as initial studies suggested: 
 
·  The MASTER I (Microvolt T Wave Alternans Testing for Risk Stratification of Post 
MI Patients) failed to demonstrate an increase in ICD detected VTAs in patients with 
abnormal  MTWA  result.    However  in  this  study,  abnormal  MTWA  test 
independently predicted death (108;109). 
·  A  MTWA  sub  study  (n=490)  of  the  SCD-HeFT  demonstrated  no  significant 
predictive  value  of  an  abnormal  MTWA  result  for  VTA’s  or  mortality  after  14 
months.  However in the original study the survival curves did not begin to separate 
until 14 months in favour of ICD group suggesting that the MTWA sub study may 
have been stopped too early (110). 
 
Nonetheless, these two large trials have cast doubt on the usefulness of MTWA in 
heart failure patients.  Some investigators believe that MTWA should only be part of 
risk stratification process which also includes assessment of LV function and possible 
EP testing.   
 
There have been very few studies investigating other groups at risk of SCD.  In type 2 
diabetics without evidence of CV disease, abnormal result was found in 25.4% of 
patients  compared  to  only  5.7%  in  healthy  age  and  sex  matched  controls  (111).  
Similarly, in athletes with previous evidence of VTA (ventricular ectopics or NSVT) 70 
 
referred for EP studies, abnormal MTWA was detected in 32% of subjects and there 
was significant correlation between EP studies and MTWA results (112).   
 
Only one small (n=9) study has been performed in HD patients immediately before 
and after an HD session.  This study demonstrated that the number of patients with an 
abnormal MTWA result increased immediately after an HD session (113).  
 
1.3.4c  QT dispersion 
QT  dispersion  has  emerged  in  recent  years  as  another  non-invasive  method  of 
predicting development of ventricular arrhythmias.  QT dispersion is defined as the 
difference between the shortest and the longest heart rate corrected QT interval on a 
standard  12  lead  ECG;  it  represents  variation  in  ventricular  repolarisation  (like 
MTWA)  and  predisposition  to  ventricular  tachyarrhythmias.    As  with  MTWA,  a 
wide QT dispersion (above 65-74ms) has been shown to be a risk factor for cardiac 
arrhythmia  in  patients  starting  dialysis,  with  biventricular  cardiac  failure  after 
myocardial infarction and drug induced VTAs (114;115).   
 
A  study  in  haemodialysis  patients  measured  QT  dispersion  over  a  single 
haemodialysis  session.    Compared  to  healthy  individuals,  QT  dispersion  was 
significantly higher in haemodialysis patients (63.1 +/- 20.6ms before haemodialysis 
vs 36.0 +/- 13.7ms in controls).  After haemodialysis, QT dispersion rose to levels 
measured in post MI patients suggesting that haemodialysis patients are at greater 
risk of arrhythmias and sudden death in the post dialysis period (101). There has 
been  ambivalence  among  cardiac  electrophysiologists  regarding  the  relevance  of 
QTD  predicting  risk  of  arrhythmia  in  high  risk  groups  (eg.post  myocardial 71 
 
infarction). However a considerable amount of literature supports its use and this 
technique has not been completely evaluated within the ESRD group. 
 
1.3.4d Heart rate variability 
As  mentioned  above,  autonomic  dysfunction  is  associated  with  SCD  in  ESRD 
patients.  Heart rate variability (HRV) measures autonomic influence on the heart by 
quantifying R-R intervals or heart rate changes over a specified number of cardiac 
cycles. The commonest way to assess HRV uses ambulatory ECG to determine time 
and  frequency  domain  measurements.    Time  domains  provide  continuous 
measurements of R-R intervals, whilst frequency domains estimates changes in heart 
rate as a frequency function using fast Fourier transformation. 
 
In healthy individuals HRV is high due to respiration (parasympathetic control) and 
higher values are associated with a functionally efficient autonomic nervous system. 
However, reduced HRV independently predicts mortality and SCD in patients with 
underlying  CV  disease  and  healthy  controls  (116).    Studies  measuring  HRV  in 
dialysis  populations  have  demonstrated  reduced  heart  rate  variation  as  an 
independent predictor of all cause or CV mortality.  
  
·  Oikawa et al assessed 383 HD patients and demonstrated that decreased HRV on 
ambulatory ECG monitoring was an independent predictor of CV death adjusting for 
the presence of diabetes mellitus.  A similar study (n=196) has also shown decreased 
HRV as a predictor of SCD in dialysis patients(117;118). 
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In these studies the ratio of low frequency (indicating sympathetic activity) to high 
frequency (parasympathetic/vagal activity) HRV provides an estimate of autonomic 
control of the sino-atrial node and has been shown to predict SCD in the dialysis 
population. 
 
Other  tests  to  assess  autonomic  dysfunction  (baroreceptor  reflex,  heart  rate 
turbulence) and myocardial impulse conduction (signal averaged ECG) have been 
attempted in small studies of dialysis patients.  Unfortunately, outcome data does not 
convincingly demonstrate a discriminatory role for these tests in ESRD patients.  
 
1.3.5   Prevention of sudden cardiac death in ESRD patients 
Primary and secondary prevention of SCD had been extensively investigated in high 
risk groups such as post MI and heart failure patients.  However, data are absent for 
ESRD patients due to their exclusion from interventional studies and absence of post 
hoc sub group analyses.  Nonetheless, some interventions have been evaluated. 
 
1.3.5a  β adrenergic blockers 
The use of β blockers to prevent SCD has been established by many interventional 
trials  for  high  risk  cohorts  (post  MI,  congestive  cardiac  failure).    In  a  large 
retrospective study from the USRDS, β blocker therapy was associated with reduced 
all cause mortality in haemodialysis patients followed for 7 years (119).  Cice et al 
demonstrated reduced CV deaths (68% reduction over 24 months) in haemodialysis 
patients  with  dilated  cardiomyopathy  (n=114)  randomised  to  receive  carvedilol 
instead of placebo (120).  In this study there was a trend towards reduced rates of 
SCD,  but  this  did  not  reach  statistical  significance.    In  a  further  study  of 73 
 
haemodialysis patients who had survived cardiac arrest (n=729), β blocker therapy 
was significantly associated with improved survival after 6 months and the effect 
was greater at higher doses of treatment (121). 
 
1.3.5b ACE inhibitors/Angiotensin II receptor blockers 
ACE inhibitors and ARBs have been shown to reduce mortality in patients with 
significant myocardial diseases and normal renal function (122). Unfortunately, there 
have been few adequately powered, randomised trials in ESRD patients, and thus a 
significant effect in reducing sudden death has not been convincingly demonstrated.  
In dialysis patients, use of ACE inhibitors has not been significantly associated with 
improved survival of ESRD in the absence of heart failure. 
 
·  In a randomised control trial of fosinopril in ESRD patients with normal LV function 
on echocardiography (n=397), there was no significant difference in rates of CV 
events between treatment and placebo groups, although there was a trend towards 
lower CV events in the fosinopril treated arm (123). 
 
AIIRBs  have  been  shown  in  two  prospective  trials  to  improve  CV  prognosis  in 
ESRD patients.  However numbers of patients recruited were small: 
 
·  Takahashi  et  al  showed  in  80  haemodialysis,  that  treatment  with  candersartan 
significantly reduced CV events compared to placebo (7/43 candersartan vs. 17/37 
placebo; p<0.01) (124). 
·  In a larger prospective study (n=366), Suzuki et al demonstrated treatment with ARB 
reduced  fatal  and  nonfatal  CV  events  (HR  0.51),  when  adjusted  for  sex,  age, 74 
 
presence  of  diabetes,  and  systolic  blood  pressure  compared  to  placebo  treated 
patients.    There  was  a  lower  mortality  rate  in  the  treatment  group  compared  to 
placebo, however this did not achieve statistical significance (125). 
 
For ACE inhibitors and ARBs, larger prospective studies are needed to establish 
their role in reducing SCD in ESRD patients. 
 
1.3.5c  Statins 
As mentioned in section 1.2.2b, statin therapy in patients with no renal disease has 
been shown to be effective in preventing CV events including sudden cardiac death 
(126). However, as demonstrated by the 4D and AURORA studies (24; 25), although 
therapy  with  statins  significantly  reduces  total  and  LDL-cholesterol  serum 
concentrations, it does not significantly reduce SCD rates in haemodialysis patients, 
highlighting  the  differing  mechanisms  of  SCD  between  uraemic  and  other 
cardiomyopathies. 
 
1.3.6d Implantable defibrillators 
No prospective trials have demonstrated benefit of ICD insertion in ESRD patients 
for primary prevention of SCD.  These patients were excluded from original ICD 
trials or sub group analyses have not been published.  In addition, it is not clear 
whether criteria used in the non renal populations to identify high risk groups (e.g. 
low ejection fraction) are relevant to ESRD patients.  
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In  contrast  to  results  from  observational  in  heart  failure  populations,  it  has  been 
difficult to demonstrate a statistically significant benefit of ICD insertion in ESRD 
patients due to co-morbid conditions: 
 
·  In a study of 585 ICD recipients, 19 were previously receiving haemodialysis and 
although dialysis was a significant predictor of VTA or ICD discharge (HR 2.30), 
median survival was significantly lower in the dialysis patients compared to the non-
dialysis  cohort.    The  authors  concluded  that  other  co-morbidities  contributed  to 
reduced survival in the dialysis cohort (127). 
·  In retrospective analyses from the USRDS of ESRD patients that survived a VTA, 
ICD insertion was shown to improve survival.  Although rates of insertion were low 
in patients where ICD was indicated according to AHA/ACC guidelines (8%), ICD 
implantation was significantly associated with reduced mortality (HR 0.58) when 
adjusted for other co-morbid conditions (128). 
·  In a smaller, single centre study (n=78) comparing stage 3 CKD to dialysis patients, 
ICD insertion was significantly associated with improved survival in the non dialysis 
population.  There was no survival benefit conferred by ICD insertion in the dialysis 
cohort (n=45) (129). 
 
Although, life table estimates for survival probability after ICD insertion published 
by the USRDS have demonstrated a theoretical benefit for primary and secondary 
prevention  of  death,  sufficient  prospective  data  are  lacking.    The  AHA/ACC 
guidelines do not exclude ESRD patients from ICD insertion for primary prevention 
of SCD.  Nonetheless, only 15% of ICDs inserted in ESRD patients were for primary 76 
 
prevention between 1996 and 2003 suggesting underutilisation in patients in whom 
ICD would be indicated (128).   
 
Overall, there is a reluctance of cardiologists to insert these devices because of a lack 
of  prospective  data  and  high  complication  rates  (bleeding,  infection)  in  ESRD 
patients (130).  ICD insertions may have a role in primary and secondary prevention 
of SCD in ESRD patients and appropriate prospective studies (e.g. ICD2 study) are 
currently  underway.    In  addition,  appropriate  selection  of  patients  based  on  LV 
function +/- EP characteristics may be needed to demonstrate a significant effect of 
ICD insertion on patient survival. 
 
1.4  Assessment of uraemic cardiomyopathy 
 
In  this  section  clinical  methods  of  assessing  abnormalities  of  uraemic 
cardiomyopathy will be discussed. 
 
1.4.1  Echocardiography 
Echocardiography  remains  the  most  convenient,  inexpensive  and  best  tolerated 
imaging  method  to  assess  myocardial  function.    It  uses  ultrasound  at  wave 
frequencies between 2-20 MHz to penetrate through non-homogenous tissue.  These 
waves  are  reflected  at  different  acoustic  impedance  which  are  recorded  and 
displayed as monochromic dots.  The position of dots is determined by location of 
the  reflecting  tissue  and  intensity  of  image  dependent  on  acoustic  impedance.  
Ultrasound  energy  is  generated  by  a  transducer  that  not  only  emits  but  detects 
reflected waves to produce an image. 77 
 
Since  its  introduction  in  1954,  most  studies  employ  M-  mode  echocardiography 
since  it  is  the  easiest  form  of  image  to  produce  and  analyse.    M-mode 
echocardiography involves the use of a single beam of ultrasound to produce a one 
dimensional image of the moving heart along the plane of interest.  Scrolling images 
over the time period of acquisition are generated, and thus allows measurements of 
cardiac  dimensions  and  detailed  information  of  motion  patterns  depending  on 
transducer angulation.  Time relationship analyses are also performed when ECGs 
and heart sounds are collected at image acquisition.  Although resolution of images 
in M-mode echocardiography is good, it does not allow structural visualisation of the 
heart  or  spatial  relationships  of  the  structures  during  the  cardiac  cycle.    Two 
dimensional echocardiography (2DE) scans are obtained from the transducer in 2 
perpendicular planes to give detailed information on cardiac anatomy including LV 
geometry.   
 
In both the clinical setting and research studies, M-mode images are still used to 
calculate LV mass (usually reported as LV mass index which is corrected for body 
surface area and recorded as g/m
2).  Measurements of posterior wall, internal LV 
dimensions at end diastole, and interventricular septal thickness are recorded and 
conventional “cube” calculations (see Formula 1 below) performed to estimate LV 
mass (131).  These calculations have been validated in normal shaped hearts from 
human autopsies, however are not as accurate in distorted ventricles (such as specific 
cardiomyopathies)  (132).    In  this  situation,  it  has  been  recommended  that  more 
complex calculations using 2DE images be utilised. 
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Penn Formulae LV mass = 1.04 ([LVIDD + PWTD + IVSTD] 
3- [LVIDD] 
3) -13.6 g 
LVIDD= LV internal diameter diastole,  
PWTD= posterior wall thickness diastole 
IVSTD= interventricular septum thickness diastole 
 
Formula 1   Example of “cube” calculation for estimating LV mass from M 
mode measurements (131) 
 
LV  function  can  be  estimated  from  M-mode  LV  end  diastolic  and  end  systolic 
internal  diameters  to  calculate  LV  ejection  fraction.    Previously  used  parameters 
such  as  fractional  shortening  have  been  discarded  since  this  overestimates 
contractility  in  patients  with  abnormal  myocardial  due  to  differential  transmural 
contractility.  Two-dimensional echocardiography also allows accurate estimation of 
LV  function  using  the  biplane  method  of  disc  (Simpson’s  rule)  to  calculate  end 
systolic and diastolic volumes after tracing of LV epi- and endocardial borders from 
2  and  4-chamber  views.  Furthermore,  left  atrial  volume  (LAV)  can  reliably  be 
determined using similar techniques from 2DE and has been validated in coronary 
angiography and contrast enhanced CT studies (133).  This will be discussed in more 
detail in Chapters 2 and 5. 
 
Original studies demonstrating significant cardiac structural changes in patients with 
CKD and ESRD used echocardiography.  These abnormalities included detection of 
uraemic pericardial effusions, valvular calcification and ventricular wall thickening.   
As mentioned before, studies from  Newfoundland, Canada by Parfrey  and Foley 
published in the 1980s and 90s were the first to demonstrate a convincing association   
with  echocardiographic  abnormalities  and  poor  outcome  in  dialysis  patients 
(47;134).   79 
 
However  echocardiographic  assessment  of  LV  mass  depends  on  LV  internal 
dimensions, which in turn depend on cardiac preload.  In dialysis patients there are 
great  variations  in  volume  status  during  the  inter-dialytic  period  resulting  in 
significant  changes  in  LV  chamber  dimensions.    Furthermore,  due  to  the  cubed 
calculations  used  to  estimate  LV  mass,  any  potential  errors  may  be  magnified 
(Formula 1).  As stated above, calculations based on M-mode measurements have 
been validated in healthy hearts.  Geometric assumptions of these calculations (such 
as cubic shaped LVs) make LV mass estimation inaccurate in patients with LVH and 
thus  do  not  apply  to  ESRD  patients  who  often  have  features  of  uraemic 
cardiomyopathy  (132;135).    The  inaccuracies  of  echocardiography  to  assess  LV 
mass in ESRD patients will be discussed below.  
 
Newer  techniques  to  assess  LV  mass  in  distorted  ventricles  are  currently  being 
assessed  including  3D  echocardiography  (usually  real  time)  which  requires  no 
geometric assumption to assess LV size and has been shown to have reduced inter-
observer variation and improved reproducibility (136).  There have been few studies 
using this technique in patients with CKD or ESRD.   
 
1.4.2 Cardiovascular magnetic resonance imaging 
Cardiovascular MRI (CMR) is the “gold standard” method for measuring cardiac 
dimensions and function.  Due to rapid development in hardware and software, CMR 
has  been  established  as  a  reliable  and  clinically  relevant  imaging  modality  in 
cardiology. 
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1.4.2a  Principles of magnetic resonance imaging 
MRI is based on the principle of nuclear magnetic resonance.  Protons and neutrons 
spin  on  their  own  axis within  atomic  nuclei.   When  a  nucleus  has  an  odd  mass 
number, the nucleus is left with a net spin and as a result of the (positive) charge and 
spin,  develops  a  magnet  field  (the  direction  and  size  can  be  represented  by  a 
magnetic moment).  The human body has very high water content.  When protons 
(hydrogen nuclei derived from water) are placed in an external magnetic field, their 
magnetic moments align themselves (either parallel or anti-parallel) in line with the 
direction of the external magnet.  The net magnetisation vector (NMV) is dependent 
on which directions of magnetic moment are in excess within the field.  Each nuclei 
begins to precess (or wobble) on its own axis and the speed of rotation is dependent 
on the size of the external magnetic field.  
 
When a radiofrequency (RF) pulse is applied at the same frequency of the specific 
precessional frequency of the hydrogen nuclei and at 90° to the external magnetic 
field, the nuclei begin to resonate (absorb energy from the RF) which causes the 
NMV to rotate to a position towards the plane of the external RF.  Other nuclei are 
not affected because they require RFs pulses of a different frequency to cause their 
nuclei to resonate.  Once the RF pulse stops, the NMV recovers to its former position 
releasing  an  MR  signal  that  is  recorded  by  a  receiver  coil.    Image  acquisition, 
contrast, and signal intensity are dependent on the relaxation of the NMV producing 
T1  (longitudinal)  recovery  and  T2  (transverse)  decay  at  the  same  time  and  the 
density of protons in the tissue.  In broad terms, the properties of air, fat and fluid 
allow for sufficient image contrast to provide high resolution images.    
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Images are obtained using pulsed sequences which consists of a series of RF pulses 
applied  at  different  duration,  strength  and  intervening  time  periods  with  external 
magnetic field gradients adjusted for the tissue of interest.  In CMR, spin-echo and 
gradient-echo  pulsed  sequences  are  used  and  image  acquisition  is  gated  to  the 
patient’s  ECG  at  different  stages  of  the  cardiac  cycle  to  obtain  cinematic  (cine) 
images of the full cardiac cycle.  ECG gating can be prospective, where the scans are 
acquired and triggered by the R wave at the time of scanning or retrospective, where 
ECG and images are acquired at the same time and digitally reconstructed after data 
collection.    These  gating  techniques  are  required  to  reduce  movement  artefacts 
caused by cardiac and respiratory movement.  These can also partially be removed 
by breath holding during image acquisition which usually last 10-15seconds. 
 
1.4.2b CMR and uraemic cardiomyopathy 
CMR remains the most accurate, reliable and reproducible method of assessing LV 
function and chamber size available to cardiologist and radiologists (137).  Long and 
short  axis  views  (Chapter  2)  of  the  LV  are  obtained,  epicardial  and  endocardial 
borders  are  delineated  on  thin  slices  of  the  short  axis  LV  images,    and  using  a 
Simpson’s rule based algorithm, calculation of LV ejection fraction, chamber size 
and mass are obtained without the need for geometric assumptions.  Importantly, 
these  measurements  are  not  dependent  on  the  patient’s  extracellular/intravascular 
volume status.  In a similar way CMR can reliable assess maximal left atrial volume 
by measuring LA area and maximal length at end ventricular systole.     The CMR 
protocol is described in detail in Chapter 2.   
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Cardiovascular magnetic resonance imaging can also reliably detect the presence of 
myocardial fibrosis using gadolinium for contrast enhanced CMR.  Late gadolinium- 
diethylenetriamine-  pentaacetic  acid  (Gd-DTPA)  enhancement  (LGE)  has  been 
shown to correlate well with endomyocardial biopsy findings of interstial myocardial 
fibrosis with a sensitivity of 74% and specificity of 81% (138).  In ESRD patients, 
Mark et al demonstrated that presence of LVSD was significantly associated with 
presence  of  a  subendocardial  pattern  of  LGE  on  contrast  CMR  (139).  
Subendocardial  LGE  represents  areas  of  previous  (commonly  silent)  myocardial 
infarction.    Based  on  these  results  it  was  postulated  that  LVSD  of  uraemic 
cardiomyopathy  is  mostly  due  to  atherosclerotic  coronary  artery  disease  and  its 
sequelae.  Unfortunately, the use of gadolinium based contrast agents in advanced 
CKD patients has been halted due to the association of their use with development of 
nephrogenic systemic fibrosis; however newer agents are currently in development.  
Unfortunately, CMR is not as readily available as echocardiography in many centres 
due to high cost.  In addition, many patients are unable to undergo scanning due to 
claustrophobia,  inability  to  breathe  hold,  or  presence  of  ferromagnetic  implants 
(cardiac pacemakers or ICD, intracerebral clips).  Given these reasons, the transition 
from research tool to widely available clinical test has been slow. 
 
1.4.3  Echocardiography vs. CMR for assessing uraemic cardiomyopathy 
As stated above, echocardiography derived measurements of LV function and mass 
are  inherently  flawed  in  ESRD  patients  and  other  patient  groups  who  have 
significant alterations in cardiac shape.    M-mode echocardiography, which is the 
most commonly used means of assessing LV mass, overestimates LVMI compared 
to CMR: 83 
 
·  In ESRD patients, Stewart et al showed in 35 HD patients assessed within 24 hours 
of  their  last  HD  session,  that  as  LV  mass  and  chamber  size  increased 
echocardiographic measurements overestimated mass (Figure 1.4) (135). 
·  Similar studies performed in hypertensive patients and patients with aortic stenosis 
and LVH without CKD have also shown that M-mode echocardiography derived 
measurements of LV mass overestimate LV mass compared to CMR values (132). 
 
In HD patients, pre and post dialysis measurement of LV mass show small changes 
(up  to  10g)  on  CMR  (140).    Echocardiogram  changes  of  up  to  45g  have  been 
recorded and it is likely that, whilst some change may be due to removal of fluid from 
cardiac interstitial tissues, the large disparities between echocardiography and CMR 
are due to changes in chamber dimensions during HD and ultrafiltration (141). These 
changes are amplified due to further cubed computations performed to calculate LV 
mass. 
 
Figure 1.4  Comparison of LVMI measurement techniques (142) 
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Greater precision and reproducibility of CMR to detect small, non artefactual changes 
in LV mass allows studies to recruit much smaller cohorts.  For example, Keenan et 
al have estimated that to detect a 10g drop in LVMI after a therapeutic intervention at 
a power of 80% and p value of 0.05, the sample size would have to be 505 patients 
with  2D  echo  and  only  14  using  CMR,(137).    Although  these  theoretical  power 
calculations provide significantly exaggerated results, they adequately highlight the 
benefit that CMR would provide over echocardiography.  
 
1.5  Cardiac magnetic resonance spectroscopy 
Magnetic resonance spectroscopy (MRS) uses the spin property of nuclei to allow 
non-invasive assessment of the biochemical composition and metabolic activity of 
tissues of interest without the need of external contrast media/tracers.  MRS provides 
this information for nuclei that contain atoms with nuclear spin. As stated before, the 
nuclear spin of atoms with odd mass numbers results in development of magnetic 
fields/moment  and  thus  susceptibility  to  nuclei  specific  (dependent  on  the 
gyromagnetic frequency of the nucleus) radiofrequency waves to cause wobble of 
these  nuclei  on  their  axis.    In  cardiac  MRS,
  31P  is  the  most  extensively  studied 
nucleus.  Other nuclei of interest include 
1H, 
13C and 
23Na.  
  
MRS has been used experimentally for over 30 years, however its use in clinical 
practice has been limited due to the very low concentration of nuclei and subsequent 
low resolution of metabolic/biochemical images acquired.  Nonetheless, 
31P MRS of 
the human heart has been obtained to study cardiac high energy phosphate (HEP) 
metabolism. 
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1.5.1  Principles of 
31P MRS 
Hydrolysis  of  adenosine  triphosphate  (ATP)  provides  free  energy  for  energy 
consuming reactions in cells:  
ATP  ↔  ADP   + Pi 
ADP= adenosine diphosphate 
Pi= inorganic phosphate. 
 
Phosphocreatine  (PCr)  is  a  high  energy  phosphate  compound  which  acts  as  an 
energy  transfer  molecule  in  the  “creatine  kinase  (CK)/PCr  energy  shuttle”  (see 
Figure  1.5).  The  high  energy  phosphate  bond  is  transferred  from  areas  of  ATP 
production (mitochondria) to the myofilaments or other sites of ATP utilisation by 
PCr where the back reaction is performed.  Newly formed ATP is then used for 
cardiomyocyte contraction. 
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Figure 1.5  Schematic  representation  of  creatine  kinase  (CK)/PCr  energy 
shuttle.   
 
 
 
This shuttle is required because free intra- cytoplasmic ADP concentrations are too 
low to allow adequate diffusion into mitochondria for ATP production. Elevated free 
ADP  also  inhibits  intracellular  enzyme  function,  thus  when  [PCr]  is  normal  the 
shuttle strives to keep [ADP] to as low as possible since the chemical equilibrium 
favours ATP production.  [ADP] will rise only when [PCr] are depleted. During 
myocardial  activity  when [ATP] is low, the equilibrium shifts to ATP synthesis.  
Thus PCr acts as a buffer to resist changes of intracellular ATP concentration (143).  
31P-MRS allows examination of relative concentrations of PCr, ATP and inorganic 
phosphate (Pi).   
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1.5.2  Methodology of 
31P MRS 
MR  scanners  that  allow  spectra  acquisition  use  the  same  magnets  used  for 
conventional CMR imaging (usually 1.5T or 3T), however nucleus specific coils and 
software to process specific sequences are needed.  Prior to spectra collection, the 
magnetic  field  must  be  homogenised  as  much  as  possible  using  shim  coils.  
Furthermore, to account for cardiac movement during scanning, scans are performed 
with  cardiac  gating.     
1H  images  are  obtained  of  the  myocardium  to  allow 
localisation of specific voxels over areas of interest (Figure 1.6). 
 
 After a 
31P specific radiofrequency pulse causes spin excitation, the resulting MR 
signal (free induction decay) is recorded.  Subsequent fast Fourier transformation 
splits the time varying decaying MR signal into it frequency components generating 
an MR spectrum.  Small differences in the MR signal for different 
31P containing 
molecules are caused by shielding of the nuclei of interest by surrounding nuclei 
(hydrogen, carbon) -so called “chemical shift”.  The area under each resonance peak 
in the spectrum is directly proportional to the concentration of each 
31P containing 
molecule in the area of interest allowing measurement of relative concentrations. 
(Figure 1.6)  Absolute concentrations are much more difficult to obtain and involve 
calibration against a 
31P containing molecule of known concentration at the time of 
scanning.  More information regarding acquisition of 
31P-MRS is provided in section 
2.5. 88 
 
RF impulse
RF response
Fourier transformation
Figure 1.6  Acquisition on
 31P spectra in a healthy volunteer 
 
 
 
 
 
A typical 
31P spectrum is shown in Figure 1.6 depicting the resonances of interest: 
three 
31P atoms of ATP (α, β and γ), phosphocreatine (PCr), inorganic phosphate (Pi) 
and phosphodiesters (PDE)/ membrane phospholipids (PME).  Although not shown 
due  to  its  proximity  to  the  Pi  resonance,  2,  3-diphosphoglycerate  (2,3-DPG) 
resonances can be detected due to the presence of red blood cells in the voxel of 
interest. 
 
The  most  common  way  of  quantifying 
31P  spectra  from  the  human  heart  is  by 
calculating PCr: ATP ratios which are considered a measure of the cardiac energetic 
state.  The CK/PCr chemical equilibrium favours ATP over PCr synthesis by a factor 
of almost 100.  Thus ATP concentrations will only decrease when PCr concentration 
is substantially depleted i.e. the buffer is exhausted. However, PCr: ATP ratio is 89 
 
limited since it may underestimate changes in PCr if ATP levels are reduced and 
does not provide information of changes in relative ATP concentrations.  A further 
limitation of 
31P MRS is that the entire heart cannot be investigated due to limitation 
in acquisition voxel size.  Most studies in patients with homogenous  myocardial 
changes (eg valve disease, dilated cardiomyopathy) have investigated the LV antero-
apical  wall  (144;145).    Another  measurement  which  has  been  evaluated  is 
phosphodiester/ATP ratio which is believed to measure cell membrane integrity in 
animal models; however its use in clinical studies is limited.   
 
1.5.3  Clinical studies on 
31P-MRS 
In healthy volunteers, PCr:ATP ratios have been measured with values of 1.0-2.6 
(mean 1.8) and this wide range is most likely due to differing spectra acquisition 
systems and analyses software.  Nonetheless, PCR: ATP levels have a reciprocal 
relationship with age and have been demonstrated to fall in healthy individuals after 
atropine-dobutamine stress to 85% maximal heart rate (146).   
 
Patients with stable symptomatic heart failure, reduced LVEF, and valvular heart 
disease have been shown to have reduced PCr: ATP ratios (145).  Furthermore,   in 
patients with dilated cardiomyopathy, PCr: ATP ratio <1.6 has been significantly 
associated  with  poorer  survival  (144).    Heart  failure  is  associated  with  impaired 
energy  metabolism  due  to  alteration  in  substrate  consumption  (fatty  acid, 
carbohydrate),  impaired  oxidative  phosphorylation,  and  reduced  HEP  metabolism 
(147). Furthermore, treatments with β blockers and ACE inhibitors/ARBs have been 
associated  with  elevation  of  PCr:  ATP  ratios  and  symptomatic  improvement  in 90 
 
patients  with  dilated  cardiomyopathy,  suggesting  that  improved  cardiac  HEP 
metabolism may provide one of the pharmacological benefits of these drugs.   
 
As one would expect, patients with current or past history of coronary artery disease 
have reduced resting and stress PCr:ATP ratios in areas of myocardial scarring or 
regional wall motion abnormalities.  Similarly, in symptomatic women with normal 
coronary  arteries  and  echocardiograms  exercise  PCr:ATP  ratios  are  reduced 
compared to resting levels and presumed a consequence of microvascular ischaemia 
(148). 
 
Athletes with  physiological LV hypertrophy do not have reduced PCr: ATP ratios.  
However,  studies  in  patients  with  hypertension  related  LVH  have  demonstrated 
reduced PCr: ATP ratios at rest and during exercise.  Patients with type 1 and 2 
diabetes mellitus and normal LVEF have reduced PCr: ATP ratios suggesting that 
altered cardiac phosphate metabolism (presumably due to small vessel myocardial 
ischaemia and handling of free fatty acids) may partially account for higher levels of 
heart failure within this population(143).   
 
Two observational studies has investigated resting PCr: ATP levels in patients with 
kidney disease.   
 
·  In type 1 diabetic uraemic patients.  Perseghin et al (149) studied 43 patients (11 
diabetic  uraemic  patients,  5  non  diabetic  uraemic  patients,  11  diabetic  kidney 
transplant recipients, and 16 diabetic kidney pancreas recipients) and 24 non diabetic 
controls  (11  non  diabetic  kidney  transplant  recipients  and  13  healthy  controls).  91 
 
Patients  with  uraemia  (diabetic  and  non  diabetic)  had  reduced  PCr:  ATP  ratios 
compared  to  healthy  controls  and  kidney  transplant  recipients.  Diabetic  uraemic 
patients had the lowest PCr: ATP ratios leading the authors to conclude that altered 
myocardial  HEP  metabolism  may  contribute  to  accelerated  LV  dysfunction  in 
diabetic uraemic patients.  The authors also suggested that impaired HEP metabolism 
may be partially reversed by successful transplantation.   
·  A small study in haemodialysis patients (n=14) demonstrated a significant reduction 
in PCr: ATP in haemodialysis patients compared to control patients with (n=7) and 
without LVH (n=7).  In this study no association was found between PCr:ATP and 
features of uraemic cardiomyopathy (150). 
 
The clinical use of MRS has been limited due to the availability of CMR and noisy 
signals obtained at lower magnetic field strengths (<1.5T).  As stronger MR systems 
become readily available to clinicians and better resolutions of spectra acquisition 
are achieved, MRS may develop into a useful tool to evaluate biochemical/metabolic 
function in addition to myocardial abnormalities detected by CMR.   
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1.6 Aims of this thesis 
 
The aims of this thesis are to: 
·  Identify the determinants of LV abnormalities, measured by CMR, in haemodialysis 
patients from clinical, dialysis and blood characteristics. 
·  Assess the effect of these CMR detected  LV abnormalities on all cause and CV 
survival. 
·  Establish the effect of left atrial volume, measured by CMR, on survival in ESRD 
patients with LVH. 
·  Estimate  the  prevalence  of  abnormal  MTWA  in  a  cohort  of  ESRD  patients  and 
identify associations with features of uraemic cardiomyopathy. 
·  Establish  the  effect  of  LV  abnormalities  on  high  energy  phosphate  metabolism 
measured by 
31Phosphorus MR spectroscopy in ESRD patients.. 
·  Determine  whether  renal  transplantation  has  an  effect  on  LV  mass  measured  by 
CMR. 
 
1.6.1  Hypotheses 
These studies are designed to test the hypothesis that uraemic cardiomyopathy is 
associated  with  specific  electrophysiological,  biochemical,  and  other  cardiac 
abnormalities which may have an influence on the outcome of ESRD patients.  
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1.7  Outline of this thesis 
Data from six studies are presented in chapters 3 to 8 of this thesis.  These studies 
investigate prognostic and pathophysiological features of uraemic cardiomyopathy: 
 
Chapter 3  :  A  study  of  independent  predictors  of  uraemic 
cardiomyopathy in haemodialysis patients 
 
Chapter 4  :  A  study  identifying  predictors  of  cardiovascular  death  in 
ESRD  patients  undergoing  screening  for  renal 
transplantation. 
 
Chapter 5  :  A study of determinants of mortality in ESRD patients with 
LVH: the role of left atrial volume. 
 
Chapter 6  :  A study of Microvolt T Wave Alternans in ESRD patients. 
 
Chapter 7  :  A study of 
31P magnetic resonance spectroscopy in uraemic 
and hypertensive cardiomyopathy. 
 
Chapter 8  :  A  study  of  changes  in  left  ventricular  mass  after  renal 
transplantation. 
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Chapter 2 
 
Material and Methods 95 
 
2.0   Introduction 
The  major  techniques  utilised  for  this  thesis  provided  information  regarding 
myocardial structure and electrophysiology of ESRD patients.  Detailed evaluation 
of cardiac structure was obtained using cardiovascular magnetic resonance imaging 
(CMR).  
31Phosphorus magnetic resonance spectroscopy (
31P-MRS) was performed 
to evaluate myocardial metabolic activity.  Cardiac electrophysiology was evaluated 
using  electrocardiography  (ECG)  and  Microvolt  T  wave  alternans  measurement 
during exercise.  In this chapter, the background, apparatus, and protocols for these 
techniques will be described. 
 
2.1  Ethical approval 
Ethical approval was obtained from the West Glasgow Ethics Committee for these 
studies to be performed at the Western Infirmary, Glasgow.  All subjects provided 
written informed consent with forms approved by the Ethics Committee. 
 
2.2  Study subjects 
 
2.2.1  Inclusion criteria 
Patients with ESRD were recruited from the renal unit at the Western Infirmary.   
Patients  receiving  regular  haemodialysis  and  peritoneal  dialysis  were  assessed. 
Haemodialysis  patients  were  studied  on  a  non-dialysis  day.    Since  the  risk  of 
cardiovascular death is similar between those patients who receive and those near to 
requiring renal replacement therapy, patients who would require renal replacement 
therapy within 6 months were also assessed.  According to K/DOQI classification 
(151), these patients would be classified as chronic kidney disease stage 5 (CKD 5).   96 
 
Eligible  patients  were  identified  by  the  renal  transplant  assessment  team  for 
cardiovascular  screening  as  part  of  their  preparation  for  inclusion  on  the  renal 
transplant  waiting  list.    Death  in  renal  transplant  recipients  is  most  commonly  a 
result of cardiovascular disease.  In keeping with Renal Association guidelines (42), 
pre- transplant cardiac assessment is necessary to ensure recipient survival is not 
compromised  immediately  after  transplantation.    Furthermore,  screening  is 
recommended  to  reduce  peri-  and  post  operative  cardiac  complications.    Factors 
prompting referral for cardiac assessment in our centre are: 
 
·  Age≥ 50 years of age 
·  Presence of diabetes mellitus 
·  Prior history of ischaemic heart, cerebrovascular or peripheral vascular disease 
·  Family history of cardiovascular disease in a first degree relative 
·  Previous abnormal ECG or cardiac stress test indicating ischaemic heart disease 
·  Previous evidence of left ventricular (LV) abnormalities on echocardiography 
·  The clinical opinion of the transplant assessment team (which includes a consultant 
transplant surgeon and nephrologist) 
 
The  assessment  included  clinical  history,  examination,  standard  12-lead  ECG, 
Standard Bruce Protocol exercise test, assessment of LV structure and function by 
CMR and blood sampling. Clinical history of ischaemic heart disease was defined as 
past  or  current  history  of  angina  pectoris,  myocardial  ischemia/infarction  and/or 
coronary  revascularisation  procedure.  After  review  of  these  results  by  an 
independent  cardiologist,  myocardial  perfusion  and/or  coronary  angiography 
scanning were performed.  The decision regarding addition onto the renal transplant 97 
 
waiting list was made at a separate, independent clinic involving a transplant surgeon 
and  physician.  The  results  of  non  invasive  (and  invasive,  if  performed) 
cardiovascular  assessment  tests  were  available  to  the  assessing  surgeon  and 
nephrologists  before  a  final  decision  was  reached.  However,  no  specific 
recommendation was provided regarding the suitability of an individual patient for 
renal transplantation based on cardiovascular assessment results.   
 
2.2.2  Exclusion criteria 
Patients  were  excluded  from  these  studies  if  magnetic  resonance  imaging  was 
contraindicated  (presence  of  ferromagnetic  implants  or  permanent  cardiac 
pacemaker,  claustrophobia  and  pregnancy).    Patients  were  also  excluded  from 
MTWA  testing  if  their  underlying  cardiac  rhythm  was  atrial  fibrillation  as  this 
precludes testing using HearTwave  II system (Cambridge Heart, Bedford, Mass.) 
(152).   
 
2.3   Cardiovascular magnetic resonance scanning 
Patients underwent CMR scanning using a 1.5 Tesla MRI scanner (Sonata, Siemens, 
Erlangan, Germany).  As stated before, this technique provides a detailed, reliable, 
reproducible  and  volume  independent  measurement  of  cardiac  structure  and  is 
considered  the  most  accurate  method  for  assessing  ventricular  dimensions  in 
patients.  Scans  were  performed  and  analysed  by  myself  or  a  trained  CMR 
radiographer  (Tracey  Steedman,  Glasgow  Clinical  Research  Initiative,  Western 
Infirmary, Glasgow). 
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2.3.1  Timing of CMR scan 
To reduce the effect of interdialytic fluid accumulation on ventricular wall thickness, 
haemodialysis  patients  underwent  scanning  the  day  after  a  dialysis  session.  
Peritoneal dialysis patients were scanned at their “dry weight” according to their 
dialysis clinical records.   
 
2.3.2  CMR image acquisition 
 
2.3.2a  Patient position 
Patients were placed head first into the scanner in the supine position.  A handheld 
alarm provided patients with the means of contacting the investigator.  Headphones 
were also used to provide noise protection and convey breathing instructions.   An 
anterior chest 6 channel phase array coil was used to acquire images.  
 
2.3.2b Assessment of left ventricular mass, chamber size and function 
An ECG gated fast imaging with steady-state precession (true FISP) sequence during 
end expiratory breath holding was used to acquire cine images in long axis planes 
(vertical long axis, horizontal long axis, left ventricular outflow tract) followed by 
sequential short axis LV cine loops (8 mm slice thickness, 2 mm gap between slices) 
from the atrioventricular ring to the apex.  The formal protocol was (Figures 2.1- 
2.4): 
1. An  initial  multi-slice  localiser  was  performed  at  end  tidal  expiration  and  the 
optimal  transverse  section  of  the  LV  and  inter-ventricular  septum  was  selected 
(Figure 2.1). 99 
 
2. A vertical long axis (VLA) localiser of the LV was obtained from the centre of the 
mitral valve annulus to the apex. From this localiser a subsequent horizontal long 
axis (HLA) localiser was taken from the mitral valve annulus to the apex (Figure 
2.2). 
3. Three short axis (SA) localisers were generated from the HLA localiser.  Images 
were obtained at the level of the atrio-ventricular groove parallel to the mitral and 
tricuspid valve annuli (Figure 2.2). 
4. These SA localisers were used to plan cine images. Four and two-chamber, and left 
ventricular outflow tract (LVOT) cine scans were generated (Figure 2.3). 
5. From the 4 chamber scans, a short axis stack was obtained.  Two mm scans were 
obtained at 8 mm intervals from the atrio-ventricular groove to the LV apex.  
 
Imaging parameters, which were standardized for all subjects, included repetition 
time  (TR)/echo  time  (TE)/flip  angle/voxel  size/field  of  view 
(FoV)=3.14 ms/1.6 ms/60°/2.2 x 1.3 x 8.0 mm/340 mm. 
 
2.4 Analysis of CMR scans 
2.4.1 Measurement of left ventricular mass, function and chamber size  
Short axis cinema loops of the LV were used to assess LV function (Figures 2.4 and 
2.5).    LV mass was measured from short axis cine loops using manual tracing of 
epicardial  and  endocardial  end-systolic  and  end-diastolic  borders.    From  these 
images,  analysis  software  (Argus,  Siemens,  Erlangen,  Germany)  was  used  to 
calculate left ventricular ejection fraction (LVEF) using the equation: 
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LVEF (%)= End Diastolic Volume (ml)
End Diastolic Volume (ml) –End Systolic Volume (ml)
X  100
 
 
Similarly LV mass (LVM), end diastolic volume (EDV) and end systolic volume 
(ESV) were calculated from these images and indexed according to body surface 
area (LVMI, EDV/BSA, ESV/BSA respectively).  Body surface area was calculated 
using the Dubois formula (153): 
 
Body Surface Area= 0.20247 x Height (m)
0.725 x Weight (kg)
0.425 
 
2.4.2 Values used to define left ventricular abnormalities 
LV abnormalities were defined by normal published mean (± 2 standard deviations) 
LV measurements in healthy volunteers (154). Left ventricular hypertrophy (LVH) 
was defined as LVMI >84.1 g/m
2 (male) or >76.4 g/m
2 (female). Left ventricular 
systolic  dysfunction  (LVSD)  was  defined  as  LVEF<55%  and  LV  dilatation  was 
defined as end diastolic volume/body surface area  (EDV/BSA)>111.7 ml/m
2 (male) 
or  99.3 ml/m
2  (female)  or  end  systolic  volume  /body  surface  area  (ESV/BSA) 
>92.8 ml/m
2 (male) or 70.3 ml/m
2 (female).   101 
 
Figure  2.1 Multi slice breath hold localiser in end expiration 
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Figure 2.2  Generation  of  3  short  axis  localisers  from  transverse  slice 
multilocaliser, vertical long axis and horizontal long axis 
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Figure 2.3  Generation of long axis cine images from short axis localiser  
 (arrows correspond to planes highlighted in short axis pilots). Coloured lines (blue, 
green, red) correspond to plane of image acquisition 
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Figure 2.4  Generation of short axis stack images from 4 chamber cine 
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Figure 2.6  Short axis view of left ventricle  
(upper  panel=  basal,  lower  panel=  mid  ventricular)  with  epicardial  (green)  and 
endocardial (red) borders traced using image analysis software  106 
 
2.4.3  Measurement of left atrial volume 
The bi-plane area length method for ellipsoid bodies was used (155;156) to measure 
left atrial volume (LAV). Horizontal and vertical long axis cine images were used to 
obtain images of the left atrium at maximal filling (Figure 2.7). The atrial lengths 
and areas were measured from both views using image measurement tools (Siemens, 
Erlangen, Germany), and LAV calculated using the equation: 
 
0.85 x LA Area 2 chamber (cm2) x LA Area 4 chamber(cm2) 
Mean LA Length (cm)
LA Volume (ml) =
 
  
LAV was corrected for body surface area (LAV/BSA). Left atrial appendages were 
not included in these measurements. 107 
 
Figure 2.7  Measurement of maximal left atrial volume. 
Panel A measurement of LA length (white) and LA area (red) from 2 chamber view. 
Panel B, measurement of LA length (white) and LA area (red) from 4 chamber view. 
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2.5  
31Phosphorus MR spectroscopy 
 
2.5.1 
31Phosphorus MR spectroscopy acquisition 
31Phosphorus MR Spectroscopy (
31P-MRS) was performed using a 1.5 Tesla MRI 
scanner (Sonata, Siemens, Erlangan, Germany).  A dedicated spectroscopy surface 
coil (dual resonant heart/liver 
31P/
1H coil) was used. As before, patients were placed 
in the supine position and the coil placed over the left ventricle on the anterior chest 
wall.  
 
After localisation, pilot scans were performed in the cardiac vertical long axis plane 
(fast low angle shot (FLASH) images, slice thickness 10mm, TR/TE 7/7.37ms, FoV 
350mm), 
31P-MRS data were obtained with a 2-D chemical shift imaging sequence 
(CSI).  The acquisition matrix size was 25mm x 25mm and TE = 2.3ms, flip angle 
=90º, no signal averaging NSA=60.    The chemical shift imaging (CSI) grid was 
positioned over the left ventricle to ensure one voxel covered the LV apex and the 
remaining voxels provided coverage for the LV superior and inferior walls (Figure 
2.7a).  Prospective ECG gating was used with an acquisition trigger delay of 100ms 
and data was acquired during diastole.  An optimised radiofrequency pulse (length 
2.4ms)  centered  between  γ-  and  α-  adenosine  triphosphate  (ATP)  resonance 
frequencies was used to ensure uniform excitation of all spectral peaks (Figure 2.7b).   
 
2.5.2   Data acquisition 
Spectra were obtained and areas under the curves of interest were measured using 
spectroscopic  fitting  software  (Siemens,  Erlangen,  Germany).    The  spectral 
resonances for β-ATP, 2,3- DPG and phosphocreatine (PCr) were fitted using prior 109 
 
knowledge relating to peak frequencies and J- coupling patterns.  PCr: β-ATP ratios 
(PCr: ATP) were calculated accordingly.  
 
2.5.3  Correction for blood contamination 
A correction for intraventricular blood was performed.  In addition to causing scatter, 
intracorpuscular  ATP  prevents  accurate  estimation  of  true  myocardial  PCr:  ATP.  
Blood contains 2,3 diphosphoglycerate (DPG) which exhibits resonances at roughly 
5.4 and 6.3ppm relative to PCr.   The effect of blood ATP was corrected using 
Equation 2.5, which has been validated in patients with dilated cardiomyopathy and 
healthy volunteers (157). 
 
Equation 2.5:   b b b b-ATPCorrected = b b b b-ATPHEART – (0.15 ´ ´ ´ ´ 2,3-DPGBLOOD) 110 
 
Figure 2.7   31Phosphorus MR spectroscopy 
(a)  CSI grid positioned over the left ventricle superior and inferior walls  
 
 
 
 
 
 
 
 
 
 
(b) Example of 
31P MRS obtained from voxel (blue) above 111 
 
2.6  Microvolt T wave alternans 
 
2.6.1  Exercise testing- microvolt T wave alternans (MTWA) 
All tests were performed by the investigator on the day of CMR scanning.  Skin was 
prepared by shaving and cleansing with abrasive electrode gel to ensure close contact 
with  electrodes.  Seven  standard  and  seven  high  resolution  electrodes  (Microvolt 
Sensors,  Cambridge  Heart  Inc,  Bedford,  Mass.)  were  attached  to  patients  in  the 
standard 12-lead and Frank orthogonal position (158) and connected to a HearTwave 
II System (Cambridge Heart, Bedford, Mass) for MTWA testing. 
 
An initial check was performed by the device to ensure adequate electrode contact 
and testing began with acquisition of ECG data at rest for 20 seconds.  Patients were 
then asked to undergo gentle treadmill exercise to allow sufficient elevation in heart 
rate (HR).  Increase in speed and incline was performed to ensure HR elevation to 
between 100-110bpm for 150 seconds.  If patients could tolerate more exercise, a 
further 90 seconds of walking was performed in order to achieve heart rate between 
110 and 120bpm. At the end of the exercise period, patients were allowed to sit at 
rest until HR was below 90bpm, after which the test was terminated.   ECG data was 
collected digitally by the HearTwave system (108; 159). 
 
2.6.2  Spectral analyses of ECG data 
Collected ECG data were interpreted according to standard criteria using spectral 
analyses  and  reported  using  standard  automated  classification  (HearTwave  II 
System, Cambridge Heart, Bedford, Mass). This technique measured amplitude of 
corresponding points of 128 consecutive T waves where each T wave was measured 112 
 
precisely at the same time point relative to the QRS complex start.  Beat- to- beat 
amplitude fluctuations were plotted and a fast Fourier transformation was performed 
to provide quantification of the frequency variation (Figure 2.8).  As measurements 
were taken every beat, the frequencies were in units of cycles per beat.  The point on 
the spectrum corresponding to exactly 0.5 cycles per beat represents the power of T-
wave front alternation.  Significant alternans was calculated from comparison with 
the background noise frequency band (0.44 and 0.49 cycles per beat) (160). 
 
After MTWA testing, a positive MTWA result was defined as presence of sustained 
alternans (sufficient alternans present for at least 1 minute) at heart rates <110bpm 
on exercise or at rest (even if higher than 110 bpm). A negative MTWA test result 
was defined as the absence of positive test criteria with a maximum heart rate≥105 
beats/min.  A test that did not satisfy positive or negative criteria was classified as 
indeterminate (Figure 2.9).  Based on previously published studies (161) results were 
further  classified  as  “abnormal”  (for  positive  and  indeterminate  test  results)  or 
“negative”  (reported  as  a  negative  test).    If  initially  an  indeterminate  result  was 
obtained,  immediate  retesting  was  attempted.  Reasons  for  indeterminate  test 
provided by the analysis software were: 
·  failure to achieve sufficient heart rate rise 
·  excessive ventricular ectopy during exercise 
·  a noisy recording due to ECG artefact 
·  rapid rise through target heart rate of 105-110bpm 
·  unsustained MTWA (≤1 min) 113 
 
Figure 2.8  Spectral analyses of ECG and generation of frequency spectrum 
(162)  114 
 
Figure 2.9  Classification  of  MTWA  result  based  on  duration  of  sufficient 
alternans and heart rate achieved during exercise.   
Modified from (152). 
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2.7  Blood sampling 
Thirty millilitres of blood was drawn for biochemical and haematological hospital 
laboratory analyses.  Blood electrolytes, urea, creatinine, glucose, and haemoglobin 
were measured.  Plasma brain natriuretic peptide (BNP) was measured using a one 
step radio immunoassay (ShionoRIA, Shinogi, Japan) after centrifugation of 6 mls of 
blood (this was frozen within 20 minutes of collection and stored at -70°C until 
measurement).  Plasma total cholesterol, triglyceride, low density lipoprotein, high 
density  lipoprotein  and  high  sensitivity  C-reactive  protein  (CRP)  were  measured 
using standard biochemical methods. 
 
2.8  Patient follow up 
Follow- up data, including patient clinical events and deaths, were recorded from 
date of CMR scan until 30
th September 2009 using the Western Infirmary, Glasgow 
and Glasgow Royal Infirmary electronic patient records. 116 
 
 
Chapter 3 
 
A study of independent predictors of uraemic cardiomyopathy in haemodialysis 
patients. 117 
 
3.1  INTRODUCTION 
   
As  discussed  in  the  introduction,  patients  with  end  stage  renal  disease  (ESRD), 
particularly those receiving dialysis have an increased risk of premature CV disease 
(1).    The  features  of  uraemic  cardiomyopathy,  namely  LVH,  LVSD,  and  LV 
dilatation independently predict poorer survival in ESRD patients (47).   
 
Studies to date assessing independent predictors of uraemic cardiomyopathy have 
used echocardiography. Such studies implicate factors such as hypertension, reduced 
blood vessel compliance, anaemia, phosphate control and dose of dialysis (134;163-
165).    In  addition,  gadolinium  enhanced  CMR  findings  indicating  previous 
myocardial ischaemia have been associated with LVSD (139). 
 
However, as discussed before, echocardiography provides an inaccurate assessment 
of LVMI and chamber size particularly in fluid overloaded patients where image 
acquisition  and  measurements  of  LV  wall  thickness  (e.g.  posterior  and 
interventricular  septum)  can  be  difficult.    Measurements  obtained  by 
echocardiography tend to overestimate LV mass particularly at higher values when 
compared to CMR (135).  Few studies have used accurate, volume independent, 
measurements  obtained  from  CMR  to  assess  individual  predictors  of  uraemic 
cardiomyopathy.   
 
Thus the aims of the following study were to demonstrate the predictors of LVH, 
LVSD and LV dilatation, measured by CMR, in a cohort of haemodialysis (HD) 118 
 
patients.  In particular past dialysis and blood data, in addition to CMR features, 
were included in the analyses. 
 
3.2  METHODS 
 
3.2.1  CMR acquisition 
Only ESRD patients receiving thrice weekly haemodialysis therapy were recruited 
into the study.  Scans were consistently performed on the day after an HD session.  
CMR scans were acquired and analysed as previously described.  Definitions for 
LVH, LVSD and LV dilatation have been presented in Chapter 2. 
 
3.2.2  Demographic, dialysis and blood data acquisition 
Demographic information and clinical (including drug) history were recorded at the 
time of CMR.  Retrospective review of the electronic patient record was performed 
to retrieve biochemical and haematological blood results. Haemodialysis information 
including immediate pre (preHD) and post (postHD) dialysis systolic and diastolic 
blood pressure (SBP and DBP respectively); dose of ultrafiltration (UF) and dialysis 
adequacy using urea reduction ratio (URR) were also collected.  Information was 
collected at 30 day intervals up to 180 days before CMR and mean results were 
calculated.    Calcium  phosphate  product  (Ca  x  PO4)  was  calculated  from  blood 
results collected. URR ratio was calculated using established protocol (166). 
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3.2.3  Statistical analyses 
Statistical  analyses  were  performed  using  SPSS  version  15.0  (SPSS  Inc.  Illinois, 
USA). Correlations between LV measurements and other factors were evaluated by 
Pearson’s  and  Spearman’s  correlation  coefficient  as  appropriate.      Variables 
identified  by  univariate  linear  regression  analyses  as  significant  predictors  were 
entered into a backward stepwise linear regression model to identify independent 
predictors  of  LVMI,  ejection  fraction  or  end  diastolic  volume/BSA  (EDV/BSA).  
Similarly, simple followed by multiple logistic regression analyses were performed 
to  identify  predictors  of  LVH,  LVSD  or  LV  dilatation.    Due  to  significant 
interdependence, systolic or diastolic blood pressures and only one cardiac parameter 
(EDV/BSA, ESV/BSA, or ejection fraction) were entered into the model. The most 
predictive regression model was thus generated. 
 
3.3  RESULTS 
 
3.3.1    Patient demographics 
Table 3.1 shows demographic, clinical, drug and blood result data for 246 patients 
who were studied and also highlights the accumulation of traditional cardiovascular 
risk  factors  within  such  a  patient  group.  Data  regarding  dialysis  and  cardiac 
dimensions are also presented in Table 3.1. 
 
The frequencies of isolated and combined cardiac abnormalities are shown in Figure 
3.1.  One hundred and fifty seven (63.8%) had LVH, 45 (18.3%) had LVSD and 39 
(15.9%) had LV dilatation. Eighty two patients (33.3%) had normal LV structure. 120 
 
Variable  Total  N=246 
Age (years)  51.4  (±12.1) 
Male (%)  157  (63.8) 
BMI (kg/m
2)  25.6  (±4.6) 
Primary Renal Disease  Diabetic Nephropathy  57  (23.2) 
  APCKD  25  (10.2) 
  Glomerulonephritis  52  (21.1) 
  Renovascular Disease  19  (7.7) 
  Chronic Pyelonephritis  26  (10.6) 
  Other  38  (15.4) 
  Unknown  29  (11.8) 
Diabetes mellitus  156  (63.4) 
Ischaemic Heart Disease  51  (20.7) 
Hypertension  223   (90.7) 
Chronic heart failure  15  (6.1) 
Cerebrovascular disease  20   (8.1) 
Peripheral vascular disease  18  (7.3) 
Hypercholesterolemia  113  (46.3) 
Smoking  Never  124  (50.4) 
  Current  70  (28.5) 
  Ex  52  (21.1) 
Aspirin  97  (39.4) 
ACEI/ARB  61  (24.8) 
Diuretic  50  (20.3) 
Calcium Channel Antagonist  73  (29.7) 
β Adrenoceptor Blocker  106  (43.1) 
Epo receptor stimulating agent (ESA)  196  (79.7) 
Vitamin D Analogue  99  (40.2) 
Statin  93  (62.2) 
Haemoglobin (g/dL)  11.3  (±1.3) 
Adjusted Calcium (mmol/L)  2.31  (±0.2) 
Phosphate (mmol/L)  1.27  (±0.4) 
Albumin (g/dL)  37.3  (±5.9) 
CaxPO4 Product  2.93  (±1.0) 
Parathyroid Hormone (pmol/L)  28.8  (20.3,34.0) 
Duration on HD (y)   3.0  (±3.0) 
Mean Ultrafiltration Volume (L/session)  2.2  (±1.1) 
Mean PreHD SBP (mmHg)   142.3  (±21.8) 
Mean PostHD SBP (mmHg)   132.3  (±23.1) 
Mean PreHD DBP(mmHg)   79.8  (±14.0) 
Mean PostHD DBP(mmHg)   73.3  (±13.8) 
Mean PreHD PP (mmHg)   62.5  (±17.1) 
Mean PostHD PP (mmHg)   58.9  (±17.6) 
Urea Reduction Ratio (%)  70.8  (±7.5) 
Ejection Fraction %  64.7  (±13.3) 
LVMI (g/m
2)  99.4  (±30.0) 
EDV/BSA (ml/ m
2)  77.8  (±31.1) 
ESV/BSA (ml/ m
2)  29.6  (±21.9) 
LVH  157  (63.8) 
LVSD  45  (18.3) 
LV dilatation  39  (15.8) 
 
Table 3.1   Demographic, clinical, drug, blood and cardiac data for patients.  
Data are number with percentage in parentheses or mean ± standard deviation except 
parathyroid  hormone  where  median  and  interquartile  range  are  shown.121 
 
Figure 3.1  Frequency of cardiac abnormalities of uraemic cardiomyopathy 
in cohort studied.  
Note the high prevalence of LVH alone and in combination with other abnormalities 
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3.3.2  Left ventricular mass index and hypertrophy 
3.3.2(a)  Correlates of LVMI 
There were strong positive correlations between LVMI and EDV/BSA (Pearson’s 
R=0.60, p<0.01), ESV/BSA (Pearson’s R =0.54, p<0.01) and negative correlation 
with LV ejection fraction (Pearson’s R = - 0.37, p<0.01).  In addition, there were 
weaker but significant correlations with mean dose of ultrafiltration (Pearson’s R 
=0.18,  p<0.01)  and  Ca  x  PO4  (Pearson’s  R  =0.13,  p=0.05).    Factors  close  to 
statistical significance were postHD DBP (Pearson’s R =0.13, p=0.06), and mean 
preHD SBP (Pearson’s R =0.11, p=0.08). 
   
3.3.2(b)  Associations of left ventricular mass index and hypertrophy 
Multivariable  linear  regression  analysis  was  performed  to  create  the  most  robust 
predictive model for LVMI (Table 3.2).  Factors considered in the model were those 
identified as significant (or close) correlates with LVMI or factors identified from 
previous studies as predictors of LVMI.  Using a backward stepwise model, the most 
significant  model  (highest  R
2=0.49)  generated  included  EDV/BSA,  mean  pre 
dialysis systolic blood pressure and Ca x PO4 product as significant predictors of 
LVMI.  
 
Patients  with  or  without  LVH  were  compared.    Higher  preHD  systolic  blood 
pressure, preHD pulse pressure (PP) and Ca x PO4 were significantly  associated 
with LVH (Table 3.3).   Serum phosphate and mean UF dose were higher in the 
LVH group of patients, but were not statistically significant.  When comparing both 
groups there were no significant differences in age, sex, body mass index (BMI), 
past cardiovascular history, duration on haemodialysis, mean post HD systolic and 
diastolic  BP,  mean  pre  HD  diastolic  BP  and  URR.    Furthermore,  LVH  was  not 123 
 
significantly associated with a difference in mean haemoglobin, albumin, adjusted 
serum calcium, or parathyroid hormone (PTH) measured over the 180 days before 
CMR.  There was no significant difference in drug usage between both groups. Table 
3.3  also  shows  measured  left  ventricular  cardiac  parameters–  ejection  fraction, 
EDV/BSA and ESV/BSA.  LVH was significantly associated with lower ejection 
fraction, higher end diastolic and systolic LV volumes, LVSD and LV dilatation.  
 
Univariate followed by multivariate logistic regression analyses were performed to 
determine predictors of LVH (Table 3.4). Univariate analyses identified EDV/BSA, 
mean Ca x PO4 product and mean pre dialysis systolic BP as factors significantly 
associated with presence of LVH.  Multivariate logistic regression modelling (only 
entering  one  BP  variable  and  cardiac  parameter  due  to  their  significant 
interdependence)  similarly  identified  EDV/BSA,  pre  dialysis  systolic  BP,  and 
CaxPO4 as the most robust (R
2=0.50) independent predictors of LVH. 124 
 
 
  Standardised 
coefficient 
p  95% CI  
for β 
  β     
R
2=0.49, p<0.01         
Constant  - 13.5  0.40  -45.33, 18.3 
EDV/BSA(ml/m2)  0.66  <0.01  0.36, 0.91 
Mean PreHD  SBP (per mmHg)   0.13  0.01  0.09, 0.42 
Ca x PO4 product(mmol
2/l
2)  0.16  <0.01  0.11,  0.24 
 
Table  3.2  Backward  stepwise  multivariate  linear  regression  analyses  model 
demonstrating independent associations of LVMI (R
2= 0.49).   
Variables entered into the model were, age, cardiac parameters (individually), mean 
calcium phosphate product, mean haemoglobin, mean albumin, mean parathyroid 
hormone,  mean  dose  of  UF  per  dialysis  session,  duration  on  renal  replacement 
therapy and pre or post HD systolic or diastolic BP (individually) 125 
 
 
 
 
   No LVH 
n=89 
LVH 
n=157 
p 
Age (years)  51.8(12.2)   51.2(12.1)   0.20  
Male (%)  55(61.8)   102(65.0)   0.62 
BMI (kg/m
2)   25.2(4.2)   25.8(4.8)  0.45  
Ischaemic Heart Disease  21(23.6)  30(19.1)  0.40 
Diabetes Mellitus  58 (65.2)  98(62.4)  0.67 
Chronic Heart Failure  5(5.6)  10(6.4)  0.81 
Cerebrovascular Disease  10 (11.2)  10(6.4)  0.18 
Peripheral Vascular Disease  7(7.9)  11(7.0)  0.80 
Hypertension  79(88.8)  144(91.4)  0.44 
Duration on HD (y)   2.9(3.1)   3.0(2.9)  0.89 
Mean UF Volume (L)  2.1(0.9)   2.3(1.2)   0.08 
Mean PreHD SBP (mmHg)   138.1(24.3)   144.6(20.0)   0.02 
Mean PostHD SBP (mmHg)   129.2(24.8)   133.8(21.9)   0.14  
Mean PreHD DBP(mmHg)   79.1(16.4)   80.3(12.4)   0.52  
Mean PostHD DBP(mmHg)   72.3(15.9)   73.9(12.5)   0.36 
Mean PreHD PP (mmHg)   59.1(17.6)  64.4(16.5)  0.02 
MAP PostHD PP (mmHg)   57.1(18.9)  60.0(16.8)  0.22 
Urea Reduction Ratio (%)  67.6 (11.9)  70.7 (6.4)   0.64 
Haemoglobin (g/dL)   11.3(1.5)   11.3(1.3)   0.95 
Adjusted Ca (mmol/l)   2.29(0.2)   2.31(0.2)   0.61 
Phosphate (mmol/l)   1.20(0.40)   1.32(0.5)   0.06 
Ca x PO4 product   2.72(0.9)   3.05(1.0)  0.03 
Albumin   37.9(6.1)   36.9(5.8)   0.24 
PTH   34.3(13.4,48.3)   31.4(15.2,45.7)   0.54  
Aspirin  38(42.7)  59(37.6)  0.43 
ACEI/ARB  23(25.8)  38(24.2)  0.78 
Diuretic  23(25.8)  27(17.2)  0.11 
CCA  25(28.1)  48(30.6)  0.68 
α Adrenoceptor blocker  9(10.1)  8(5.1)  0.14 
β Adrenoceptor blocker  36 (40.4)  70(44.6)  0.53 
ESA  74(83.1)  122(77.7)  0.46 
Vitamin D analogue  35 (39.3)  64 (40.8)  0.83 
Statin  42 (47.2)  51 (32.2)  0.09 
Ejection Fraction (%)  68.5(7.9)  62.6 (15.1)  <0.01 
LVMI (g/m
2)  67.2(10.8)  116.9 (31.3)  <0.01 
EDV/BSA (ml/ m
2)  58.2(18.3)  88.7(34.7)  <0.01 
ESV/BSA (ml/ m
2)  19.7(10.8)  36.5 (27.5)  <0.01 
LVSD  6(6.7)  39 (24.8)  <0.01 
LV dilatation  2 (2.2)  37 (23.6)  <0.01 
Table 3.3  Comparisons  between  patients  with  and  without  LVH  are 
shown.  
Data are number with percentage in parentheses, mean ± standard deviation or 
median  interquartile  range  for  PTH.  Tests  of  significance  are  t-test  and  Chi-
square  (parametric data) or Mann Whitney  (non parametric data). Significant 
results are highlighted. 
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  Univariate Analyses  Multivariate analyses 
 
Variable  OR   95% CI  p  OR   95% CI  P 
EDV/BSA (per ml/m
2)  1.08  1.04,1.13  <0.01  1.06  1.04,1.08  <0.01 
Mean Ca x PO4 (per mmol
2/l
2)  1.37  1.01,1.87  0.04  1.74  1.17,2.57  <0.01 
Mean PreSBP (per mmHg)  1.02  1.01,1.05  0.04  1.02  1.01,1.04  0.01 
Age (per year)  0.99  0.99,1.02  0.70       
Sex (Male vs. Female)  1.55  0.91,2.65  0.11       
BMI (per kg/m
2)  0.96  0.89,1.03  0.27       
HD duration (per year)  1.01  0.85,1.20  0.88       
Ischaemic Heart Disease  1.34  0.67,2.60  0.38       
Diabetes Mellitus  1.20  0.69,2.60  0.52       
Chronic Heart Failure  0.88  0.28,2.72  0.82       
Cerebrovascular Disease  2.76  0.96,6.93  0.09       
Peripheral Vascular Disease  0.83  0.29,2.42  0.74       
UF volume (per litre)  1.26  0.95,1.66  0.11       
Urea Reduction Ratio (per %)  1.06  0.91,1.23  0.45       
Mean Post SBP (per mmHg)  0.99  0.97,1.02  0.55       
Mean PreDBP (per mmHg)  0.98  0.95,1.01  0.21       
Mean PostDBP (per mmHg)  1.01  0.98,1.04  0.49       
Mean Pre PP (per mmHg)  1.02  1.01,1.05  0.05       
Mean Post PP (per mmHg)  0.99  0.97,1.01  0.47       
Ejection fraction (per %)  0.95  0.88,1.03  0.21       
ESV/BSA (per ml/m
2)  0.93  0.85,1.02  0.12       
Mean Haemoglobin (per g/dL)  0.86  0.60,1.23  0.41       
Mean Adjusted Ca (per mmol/l)  1.61  0.35,7.48  0.54       
Mean Serum PO4 (per mmol/l)  2.10  1.00,4.29  0.06       
Mean Albumin (per g/dL)  1.00  0.96,1.05  0.91       
Mean PTH (per pmol/l)  0.99  0.99,1.01  0.54       
 
Table 3.4  Simple  (left)  followed  by  backward  stepwise  (conditional) 
multiple  logistic  regression  analyses  (R
2=0.50)  demonstrating  independent 
predictors of presence of LVH.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate  model.    Cardiac  and  blood  pressure  parameters  were  entered 
individually to generate the most predictive model. 127 
 
3.3.3    LV ejection fraction and systolic dysfunction 
 
3.3.3(a)  Correlates with LV ejection fraction 
LV ejection fraction was used as an indicator of left ventricular function.  In addition 
to the correlates demonstrated above, there were strong negative correlations with 
ESV/BSA  (Pearson’s  R=  -0.84;  p<0.01)  and  EDV/BSA  (Pearson’s  R=  -0.53; 
p<0.01)  as  expected.      There  was  a  weak  negative  correlation  with  dose  of 
ultrafiltration during dialysis (Pearson’s R= -0.18; p<0.01). 
 
3.3.3(b)  Associations of LV ejection fraction and LV systolic dysfunction 
As  before,  backward  stepwise  multivariate  linear  regression  analyses  were 
performed (Table 3.5).  Factors considered influential based on initial evaluation of 
correlation data or identified from previous studies as predictors of LV function were 
entered into the model. End systolic volume corrected for BSA and pre HD systolic 
BP were the significant independent predictors of LV ejection fraction (R
2=0.76). 
 
In patients with LVSD, there was a significantly higher proportion of patients with a 
past medical history of ischaemic heart disease and symptomatic heart failure (Table 
3.6) compared to those with normal LV function. In addition, mean dose of UF, pre 
HD diastolic blood pressure and therapy with aspirin were significantly higher in 
LVSD patients.  As expected from correlations with ejection fraction, LVSD was 
significantly associated with higher LVMI, EDV/BSA, and ESV/BSA. 
 
Logistic  regression  analyses  were  performed  to  determine  predictors  of  LVSD 
(Table  3.7).  Univariate  analyses  identified  ESV/BSA,  EDV/BSA,  LVMI,  past 128 
 
history  of  ischaemic  heart  disease,  symptomatic  chronic  heart  failure,  duration 
receiving  haemodialysis  therapy,  and  mean  dose  of  ultrafiltration  as  significant 
predictors  of  LVSD  on  CMR.          Multivariate  logistic  regression  analyses  was 
performed  entering  significant  factors  from  univariate  analyses  and  the  most 
predictive  model  (R
2=0.43)  included  ESV/BSA,  past  history  of  ischaemic  heart 
disease and mean dose of UF.   129 
 
 
  Standardised 
coefficient 
p  95% CI 
for β 
  β     
R
2=0.76, p<0.001         
Constant  89.6  <0.01  75.5, 103.6 
ESV/BSA(ml/m2)  -0.80  <0.01  -1.46, -0.29 
Mean PreHD  SBP (per mmHg)   -0.17  0.05  -0.29, -0.06 
 
Table 3.5   Backward  stepwise  multivariate  linear  regression  analyses  to 
identify independent predictors of LV ejection fraction (R
2= 0.76).   
Variables entered into the model were age, cardiac parameters (individually), mean 
calcium,  mean  phosphate,  mean  haemoglobin,  mean  albumin,  mean  parathyroid 
hormone,  mean  dose  of  UF  per  dialysis  session,  duration  on  renal  replacement 
therapy, pre or post HD systolic or diastolic BP (individually). 130 
 
Table 3.6  Comparisons between patients with and without LVSD  
Data are number with percentage in parentheses or mean ± standard deviation 
or  median  and  interquartile  range.  Tests  of  significance  are  t-test  and  Chi-
square.   
 
 
   No LVSD 
n=201 
LVSD 
n=45 
p 
Age (years)  51.1 (11.8)  52.3(13.5)  0.37 
Male (%)  124(61.7)  33 (73.3)  0.62 
BMI (kg/m
2)   25.8 (4.6)  24.8(4.1)  0.14 
Ischaemic Heart Disease  37 (18.4)  17 (37.8)  <0.01 
Diabetes Mellitus  130 (64.7)  26 (57.8)  0.35 
Chronic Heart Failure  8 (4.0)  5 (11.1)  0.05 
Cerebrovascular Disease  17 (8.5)  3 (6.7)  0.69 
Peripheral Vascular Disease  12 (6.0)  6 (13.3)  0.09 
Hypertension  181 (90.0)  42 (93.3)  0.49 
Duration on HD (y)   2.88(3.7)  4.30 (7.2)  0.06 
Mean UF Volume (L)  2.1(1.1)  2.7 (0.7)  <0.01 
Mean PreHD SBP (mmHg)   141.4(21.8)  146.0 (21.5)  0.20 
Mean PostHD SBP (mmHg)   131.6(23.5)  135.6(21.0)  0.29 
Mean PreHD DBP(mmHg)   78.8(13.9)  83.6(13.8)  0.04 
Mean PostHD DBP(mmHg)   72.6 (13.9)  83.3(13.8)  0.20 
Mean PreHD PP (mmHg)   62.5(17.5)  62.4(15.2)  0.96 
MAP PostHD PP (mmHg)   58.9(17.9)  59.1(15.3)  0.94 
Urea Reduction Ratio (%)  70.7(7.1)  68.0(9.3)  0.49 
Haemoglobin (g/dL)   11.4(1.4)  11.0(1.3)  0.12 
Adjusted Ca (mmol/l)   2.31(0.2)  2.32(0.3)  0.77 
Phosphate (mmol/l)   1.25 (0.4)  1.35(0.5)  0.21 
Ca x PO4 product   2.95 (1.0)  2.88(0.9)  0.72 
Albumin   37.1(6.2)  38.2(4.7)  0.31 
PTH   32.7(11.6,45.3)  31.7(14.2,53.7)  0.87 
Aspirin  17 (35.3)  26 (57.8)  <0.01 
Warfarin  8 (4.0)  3 (6.7)  0.43 
ACEI/ARB  47 (23.4)  14 (31.1)  0.27 
Diuretic  42 (20.9)  8 (17.8)  0.64 
CCA  58 (28.9)  15 (33.3)  0.55 
α Adrenoceptor blocker  14 (7.0)  3 (6.7)  0.14 
β Adrenoceptor blocker  85 (42.3)  21 (46.7)  0.59 
ESA  157 (78.1)  39 (86.7)  0.19 
Vitamin D analogue  80(39.8)  19(45.2)  0.28 
Statin  73 (36.3)  20 (44.4)  0.31 
Ejection Fraction %  67.1(10.9)  52.0(17.3)  <0.01 
LVMI (g/m
2)  94.3(31.1)  122.8(50.5)  <0.01 
EDV/BSA (ml/ m
2)  72.7(26.8)  100.9(38.6)  <0.01 
ESV/BSA (ml/ m
2)  25.1(16.7)  49.6(30.4)  <0.01 
LVH  118 (58.7)  39 (86.7)  <0.01 
LV dilatation  18 (9.0)  21 (46.7)  <0.01 131 
 
 
  Univariate Analyses  Multivariate analyses 
Variable  OR   95% CI  p  OR   95% CI  P 
ESV/BSA (per ml/m
2)  1.05  1.03,1.06  <0.01  1.07  1.04,1.10  <0.01 
Ischaemic Heart Disease  2.62  1.33,5.42  <0.01  4.68  1.60,13.7  <0.01 
UF volume (per litre)  1.47  1.05,2.08  0.03  2.06  1.02,1.06  0.03 
EDV/BSA (per ml/m
2)  1.03  1.02,1.04  <0.01       
LVMI (per g/m
2)  1.01  1.01,1.03  <0.01       
HD duration (per year)  1.03  1.01,1.06  0.04       
Chronic Heart Failure  4.44  1.52,12.9  <0.01       
Mean Albumin (per g/dL)  1.14  1.01,1.28  0.10       
Age (per year)  1.02  0.98,1.04  0.38       
Sex (ref Female)  1.78  0.83,3.51  0.15       
Diabetes Mellitus  0.74  0.38,1.44  0.39       
BMI (per kg/m
2)  0.95  0.85,1.05  0.31       
Cerebrovascular Disease  0.78  0.22,2.76  0.69       
Peripheral Vascular Disease  2.42  0.85,6.84  0.09       
Urea Reduction Ratio (per %)  1.06  0.95,2.07  0.76       
Mean PreSBP (per mmHg)  1.00  0.97,1.03  0.82       
Mean Post SBP (per mmHg)  1.01  0.98,1.04  0.63       
Mean PreDBP (per mmHg)  1.02  0.98,1.06  0.37       
Mean PostDBP (per mmHg)  1.00  0.96,1.05  0.86       
Mean Pre PP (per mmHg)  1.00  0.97,1.03  0.89       
Mean Post PP (per mmHg)  1.00  0.97,1.03  0.88       
Mean Haemoglobin (per g/dL)  0.79  0.51,1.21  0.79       
Mean Adjusted Ca (per mmol/l)  0.18  0.01,6.14  0.34       
Mean Serum PO4 (per mmol/l)  0.93  0.26,3.25  0.92       
Mean Ca x PO4 (per mmol
2/l
2)  1.30  0.44,3.81  0.63       
Mean PTH (per pmol/l)  1.00  0.98,1.02  0.94       
 
Table 3.7  Simple  (left)  followed  by  backward  stepwise  (conditional) 
multiple  logistic  regression  analyses  (R
2=0.43)  demonstrating  independent 
predictors of presence of LVSD.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate model.  Cardiac parameters were entered individually to generate the 
most predictive model. 132 
 
3.3.4  End diastolic volume/BSA and left ventricular dilatation 
 
3.3.4(a)   Correlates with EDV/BSA 
EDV/BSA was used to define LV chamber volume and LV dilatation.  EDV/BSA 
was  positively  correlated  with  LVMI  (Pearson’s  R=0.63;  p<0.01)  and  ESV/BSA 
(Pearson’s R=0.84; p<0.01) and negatively correlated with LV ejection fraction as 
mentioned before.  There was a weaker correlation with mean dose of UF (Pearson’s 
R=0.22; p<0.01). 
 
3.3.4(b)  Associations of EDV/BSA and LV dilatation 
Multiple  backward  stepwise  linear  regression  analyses  were  also  performed  to 
provide the most predictive (R
2=0.47) model of EDV/BSA.  Independent predictors 
of EDV/BSA were LV ejection fraction and mean dose of UF during dialysis (Table 
3.8). 
 
Patients with and without LV dilatation were compared (Table 3.9).  Presence of LV 
dilatation was significantly associated with higher dose of UF during haemodialysis 
therapy.  As demonstrated before, LV dilatation was significantly associated with 
higher LVMI (and presence of LVH), end diastolic and systolic LV volumes and 
lower ejection fraction (and presence LVSD).  Independent predictors of presence of 
LV dilatation were left ventricular ejection fraction and mean dose of ultrafiltration 
during haemodialysis (Table 3.9). 
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  Standardised 
coefficient 
p  95% CI 
for β 
  β     
R
2=0.47, p<0.001         
Constant  143.6  <0.01  111.8, 175.4 
LV ejection fraction (per %)  -0.49  <0.01  -0.64, ,-0.22 
Mean Ultrafiltration (per L)  0.16  0.05  0.10, 0.78 
       
 
Table  3.8  Backward  stepwise  multivariate  linear  regression  analyses  model 
demonstrating independent associations of EDV/BSA (R
2= 0.47).   
Variables entered into the model were, age, cardiac parameters (individually), mean 
calcium,  mean  phosphate,  mean  haemoglobin,  mean  albumin,  mean  parathyroid 
hormone,  mean  dose  of  UF  per  dialysis  session,  duration  on  renal  replacement 
therapy, pre or post HD systolic or diastolic BP (individually). 134 
 
 
  No LV 
Dilatation 
N=207 
LV Dilatation 
N=39 
P 
Age (years)  51.5(12.1)  50.9(12.2)  0.77 
Male (%)  130 (62.8)  27 (69.2)  0.44 
BMI (kg/m
2)   25.7(4.7)  25.2(3.6)  0.65 
Ischaemic Heart Disease  43 (20.8)  8 (20.5)  0.97 
Diabetes Mellitus  133 (64.3)  23 (59.0)  0.53 
Chronic Heart Failure  11 (5.3)  4 (10.3)  - 
Cerebrovascular Disease  17 (8.2)  3 (7.7)  - 
Peripheral Vascular Disease  16 (7.7)  2 (5.1)  - 
Hypertension  186 (89.9)  37 (94.9)  0.32 
Duration on HD (y)   4.98 (6.8)  5.96 (6.7)  0.45 
Mean UF Volume (L)  2.1(1.1)  2.8(0.7)  <0.01 
Mean PreHD SBP (mmHg)   142.7(22.2)  139.7(18.3)  0.43 
Mean PostHD SBP (mmHg)   132.4(24.0)  139.7(18.3)  0.81 
Mean PreHD DBP(mmHg)   79.5(14.1)  131.2(17.3)  0.59 
Mean PostHD DBP(mmHg)   73.5(13.9)  72.2(13.9)  0.74 
Mean PreHD PP (mmHg)   63.1(17.6)  58.9(13.3)  0.15 
MAP PostHD PP (mmHg)   58.9(18.2)  58.8(14.0)  0.96 
Urea Reduction Ratio (%)  71.8(34.5)  76.9(33.3)  0.76 
Haemoglobin (g/dL)   11.3 (1.4)  11.1(1.2)  0.33 
Adjusted Ca (mmol/l)   2.31(0.2)  2.31(0.3)  0.99 
Phosphate (mmol/l)   1.28 (0.4)  1.22(0.4)  0.48 
Ca x PO4 product   2.94(0.9)  2.90(1.1)  0.83 
Albumin   37.3(5.9)  37.3(6.2)  0.94 
PTH   32.5(12.6,45.3)  31.5 (12.0,43.7)  0.98 
Aspirin  84 (40.6)  13 (33.3)  0.40 
Warfarin  8 (3.9)  3 (7.7)  - 
ACEI/ARB  52 (25.1)  9 (23.1)  0.79 
Diuretic  45 (21.7)  5 (12.8)  0.20 
CCA  61 (29.5)  12 (30.8)  0.87 
α Adrenoceptor blocker  16 (7.7)  1 (2.6)  - 
β Adrenoceptor blocker  89 (43.0)  17 (43.6)  0.95 
ESA  162(78.3)  34 (87.2)  0.20 
Vitamin D analogue  85 (41.1)  14 (35.9)  0.55 
Statin  80 (38.6)  13 (33.3)  0.53 
Ejection Fraction %  68.3(0.7)  45.6(13.3)  <0.01 
LVMI (g/m
2)  93.4(31.8)  131.6(45.4)  <0.01 
EDV/BSA (ml/ m
2)  70.1(23.2)  118.5(36.3)  <0.01 
ESV/BSA (ml/ m
2)  22.5(12.0)  67.1(25.0)  <0.01 
LVH  120 (58.0)  37( 94.9)  <0.01 
LVSD  24 (11.6)  21 (53.8)  <0.01 
 
Table 3.9  Comparisons between patients with and without LV dilatation. 
Data  are  number  with  percentage  in  parentheses,  mean  ±  standard  deviation  or  median 
interquartile range for PTH. Tests of significance are t-test and Chi- square (parametric data) 
or Mann Whitney (non parametric data). 135 
 
  Univariate Analyses  Multivariate analyses 
 
Variable  OR   95% CI  p  OR   95% CI  P 
Ejection fraction (per %)  0.86  0.83,0.90  <0.01  0.87  0.83, 0.91  <0. 01 
UF volume (per litre)  1.73  1.18,2.54  <0.01  1.53  1.09, 2.17  0.01 
LVMI (per g/m
2)  1.03  1.02,1.04  <0.01       
Mean PreSBP (per mmHg)  0.97  0.95,1.00  0.08       
Age (per year)  0.99  0.97, 1.02  0.77       
Sex (Male vs. Female)  0.75  0.36,1.57  0.44       
BMI (per kg/m
2)  0.98  0.86,1.08  0.65       
HD duration (per year)  1.02  0.97, 1.08  0.45       
Ischaemic Heart Disease  0.98  0.41, 2.37  0.97       
Diabetes Mellitus  0.81  0.40,1.65  0.81       
Chronic Heart Failure  2.15  0.63, 7.36  0.22       
Cerebrovascular Disease  1.00  0.27, 3.74  0.99       
Peripheral Vascular Disease  0.57  0.12, 3.74  0.49       
Urea Reduction Ratio (per %)  1.56  0.76, 7.89  0.57       
Mean Post SBP (per mmHg)  1.02  0.99, 1.05  0.23       
Mean PreDBP (per mmHg)  1.04  1.00, 1.08  0.06       
Mean PostDBP (per mmHg)  0.97  0.93,1.01  0.19       
Mean Pre PP (per mmHg)  0.97  0.95,1.00  0.05       
Mean Post PP (per mmHg)  1.02  0.99-1.05  0.20       
Mean Haemoglobin (per g/dL)  0.86  0.65, 1.12  0.33       
Mean Adjusted Ca (per mmol/l)  3.48  0.48, 26.5  0.23       
Mean Serum PO4 (per mmol/l)  0.62  0.22, 1.75  0.36       
Mean Ca x PO4 (per mmol
2/l
2)  0.96  0.66, 1.40  0.83       
Mean Albumin (per g/dL)  1.00  0.94, 1.07  0.99       
Mean PTH (per pmol/l)  1.00  0.99, 1.02  0.98       
 
Table 3.10  Simple  (left)  followed  by  backward  stepwise  (conditional) 
multiple  logistic  regression  analyses  (R
2=0.55)  demonstrating  independent 
predictors of presence of LV dilatation.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate model.  Cardiac parameters were entered individually to generate the 
most predictive model. 136 
 
3.4  DISCUSSION 
 
Uraemic cardiomyopathy describes a heterogeneous group of cardiac abnormalities 
that are very common in patients close to or receiving RRT (167;168). However, our 
understanding of its aetiology and thus identification of therapies to prevent, slow or 
reverse its development have proven difficult.  Our current understanding is derived 
from echocardiography which is inaccurate when estimating LV chamber size and 
wall thickness in ESRD patients. 
 
3.4.1 Development of uraemic cardiomyopathy 
The  development  of  uraemic  cardiomyopathy  is  believed  to  be  initiated  and 
perpetuated by elevated cardiac preload and afterload (see Table 3.11) (169;170). 
LVH  develops  as  an  adaptive  response  to  maintain  stroke  volume  and  minimise 
ventricular  wall  stress  in  the  face  of  volume  and  pressure  overload  which  are 
common in advancing stages of CKD.   Both of these  changes increase  LV wall 
tension due to Laplace’s Law (170; 171): 
 
T = LV wall tension, P= intraventricular pressure, D= LV internal diameter  
 
Volume overload causes myocardial stretch, stimulating sarcomere proliferation in 
series and elongating pre-existing fibres to maintain stroke volume.  This manifests 
as eccentric ventricular remodelling and LV dilatation.  Wall tension rises increasing 
oxygen requirements of cardiomyocytes and subsequent risk of ischaemia (170;171).   
T  =   PD
4137 
 
 
Table  3.11  Causes  of  increased  preload  and  afterload  in  ESRD  patients  -
modified from (170) 
 
Systemic hypertension, on the other hand, increases cardiac afterload and stimulates 
sarcomere production in parallel resulting in LV wall thickening with preservation or 
reduction of chamber size.  The ventricle is remodelled in a uniform and concentric 
pattern.  
     
Thus,  wall  tension  increases  as  intraventricular  pressure  (systemic  hypertension, 
aortic  stenosis)  and  intraventricular  diameter  (fluid  overload)  rise.    Adaptive 
responses are implemented to reduce wall stress (defined as T: cross sectional area of 
LV) redistributing work over a larger area and reducing energy consumption per 
muscle fibre. 
   
However,  as  the  LV  wall  thickens,  inadequate  angiogenesis  reduces  capillary 
density, myocardial reserve and subsequently leads to myocyte ischaemia, death and 
reparative myocardial fibrosis.  This reduces contractile function per unit volume of 
myocardium and eventually causes symptomatic left ventricular failure.  Myocyte 
death is also facilitated by poor dialysis, poor nutrition and hyperparathyroidism, 
which are common in ESRD (134;171). 
Preload  Afterload 
Intravascular volume expansion  Systemic Hypertension 
Arteriovenous fistula  Calcific Aortic Stenosis 
Anaemia  Vascular calcification 138 
 
Not all structural abnormalities have been attributed to these haemodynamic factors.  
Higher levels of interstitial myocardial fibrosis have been demonstrated in autopsy 
sections from dialysis patients when compared to hypertensive and diabetic patients 
(50).  Furthermore, in vivo studies have demonstrated a potential role of angiotensin 
II, aldosterone, PTH, catecholamines, and endothelin stimulating cardiac interstitial 
fibroblasts (61;172).   
 
3.4.2  Predictors of uraemic cardiomyopathy on CMR 
This study is the first to use CMR to define individual abnormalities of uraemic 
cardiomyopathy in a cohort of haemodialysis patient and use past clinical, blood and 
dialysis data, collected over 180 days prior to scanning, to assess the trends that 
predict presence of LVH, LVSD and LV dilatation. 
 
In ESRD patients, the presence of one myocardial abnormality is predictive of other 
features of uraemic  cardiomyopathy.   Figure 3.1 demonstrated that  abnormalities 
often  occur  in  combination  and  correlation  analyses  for  cardiac  parameters 
demonstrated  significant  relationships  between  all  LV  measurements.  In  our 
regression analyses, only the most predictive models were presented after adding one 
cardiac abnormality.  However, when other cardiac abnormalities were included (e.g. 
ejection  fraction  for  LVMI)  similarly  significant  but  less  robust  models  were 
generated.   Given the close association of cardiac abnormalities in patients with 
uraemic cardiomyopathy and the processes described above, it is likely that different 
combinations  of  structural  changes  represent  varying  stages  of  the  same 
adaptive/disease process. 
 139 
 
In  addition,  this  study  demonstrates  that  clinical,  blood  and  dialysis  features 
previously  proposed  as  predictors  of  uraemic  cardiomyopathy  detected  by 
echocardiography, are not associated with LV abnormalities detected by CMR. 
 
3.4.2  Predictors of LVH 
LVH is the most common abnormality of uraemic cardiomyopathy and is estimated 
to be present in approx 67% of haemodialysis patients assessed by CMR.  A cross 
sectional study of patients with varying degrees of CKD demonstrated a progressive 
increase in the prevalence of LVH with deteriorating renal function (173).  LVH has 
been  demonstrated  as  an  independent  predictor  of  heart  failure,  ventricular 
tachyarrhythmia and sudden cardiac death (47).   These data show that LVH assessed 
by CMR is common (63.8%) but is lower than previous echocardiography studies 
highlighting the tendency for echocardiography to overestimate LV mass in ESRD 
patients (132; 139).  These data also show that both LVMI and presence of LVH are 
associated with, and independently predicted by elevated end diastolic LV volume, 
pre-dialysis systolic blood pressure and Ca x PO4 product. 
 
3.4.2(a) Hypertension and LVH 
A  number  of  different  studies,  using  echocardiography,  have  demonstrated  a 
significant association between LVH and hypertension: 
·  Harnett  at  al  studied  haemodialysis  patients  with  progressive  LVH.    They 
demonstrated that age and pre-dialysis systolic blood pressure were associated with 
increased LV mass (174).   140 
 
·  Parfrey  et al showed in 432 patients with a median of 3.3 months from starting 
haemodialysis,  that  presence  of  concentric  LV  hypertrophy  was  independently 
predicted by systolic blood pressure and female gender (47).   
 
Data from this thesis using CMR assessment support earlier studies suggesting that 
systolic  hypertension  acts  as  a  major  determinant  of  cardiac  afterload  and  thus 
significantly predicts LVMI and presence of LVH. 
 
Previous studies have demonstrated that LVMI and dialysis BP measurements (pre- 
and  post-  HD)  are  usually  only  weakly  (r=0,15-0.20)  correlated  (175).  This  is 
unsurprising  given  inaccuracies  of  blood  pressure  measurement  at  the  time  of 
dialysis. A number of studies have demonstrated that pre and post dialysis blood 
pressures  provide  misleading  estimates  and  less  reproducible  measurements  in 
haemodialysis patients. 
 
·  In a comparative study between dialysis and 48 hour ambulatory BP measurements 
(ABPM),    Coomer  et  al  demonstrated  that  predialysis  BP  overestimated  mean 
intradialytic systolic BP by 10mmHg and post dialysis BP underestimated systolic 
measurements by 7mmg (176). 
·  Peixoto  et  al  investigated  21  haemodialysis  patients  who  had  pre-  and  post-HD 
measurements  compared  with  2  separate  48  hours  ABPM  monitoring  readings.  
Their  results  showed  that  ABPM  provided  less  variable  and  more  reproducible 
results (177). 
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Despite  these  studies,  ABPM  monitoring  remains  unpopular  because  the 
methodology  is  not  universally  available,  time  consuming  and  uncomfortable  for 
dialysis patients. In this study, ABPM was offered to patients, but many refused as 
they did not wish to wear the monitor overnight. 
 
The cause of hypertension in haemodialysis patients is multifactorial but is mostly 
due  to  volume  overload  (178).    Elevated  intravascular  volume  stimulates  higher 
cardiac output  (due to  Starling’s  Law of the heart) and inappropriately  increases 
systemic  vascular  resistance  (believed  to  be  caused  by  secretion  of  oubain  like 
ATPase  inhibitors  which  increase  vascular  smooth  muscle  intracellular  Ca
2+ 
concentration).    In  addition,  inappropriate  activation  of  the  sympathetic  nervous 
system  by  uraemic  metabolites,  vascular  stiffness  due  to  calcification, 
vasoconstriction  caused  by  abnormal  endothelial  function  and  erythropoietin 
administration may contribute to elevated BP in ESRD patients (175). 
 
3.4.2(b) Ca x PO4 product and LVH 
Elevated Ca x PO4 product is a risk factor for arterial calcification and consequently 
contributes to elevated blood pressure and the development of LVH (60;179).  It has 
been shown to be an independent predictor of cardiovascular and sudden death in 
patients with ESRD: 
·  In  the  Dialysis  Outcomes  and  Practice  Patterns  Study  (DOPPS),  all  cause  and 
cardiovascular mortality was directly and independently predicted by serum calcium, 
phosphate, PTH and Ca x PO4 product(180). 142 
 
·  In a study of 134 patients (only 80 of these were receiving haemodialysis) assessed 
twice by multi slice spiral CT, independent predictors of mortality included elevation 
of vascular calcification score (181). 
 
Other  measurements  and  markers  of  vascular  calcification,  such  as  pulse  wave 
velocity  and  electron  beam  CT,  have  demonstrated  an  association  with  LVH  in 
ESRD patients. 
 
·  Nitta et al investigated 49 haemodialysis patients using applanation tonometry to 
assess pulse wave velocity and abdominal CT to quantify aortic calcification index.  
LVMI  was  significantly  correlated  and  independently  predicted  by  both 
measurements (182). 
 
3.4.2(c)   End diastolic volume and LVH 
In  our  study,  EDV/BSA  was  the  strongest  predictor  of  LVMI  and  LVH  after 
multivariate analyses supporting an association between elevated LV mass and long-
term volume overload and ventricular stretch.  In addition, brain natriuretic peptide, 
whose  production  is  stimulated  by  myocardial  stretch,  has  been  used  to  predict 
presence of LVH in ESRD patients with sensitivities ≥ 87% (183).  Unfortunately, 
we did not have samples available for measurement of BNP in this cohort.  
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3.4.2(d)   Anaemia and LVH 
Our study did not demonstrate a predictive role of haemoglobin concentration for 
LVMI.  The potential aetiological role of anaemia in development of LVH remains 
uncertain in ESRD patients.  In theory, haemodilution increases myocardial work to 
ensure  adequate  oxygenation  of  tissues  resulting  in  hypervolaemia  (±worsening 
hypertension) and increased cardiac preload.  Studies using echocardiography have 
demonstrated a strong predictive role of anaemia in LVH: 
 
·  In  a  study  of  51  dialysis  patients  studied  by  serial  echocardiography,  lower 
haemoglobin independently predicted LVMI.  However only 8 of these patients were 
receiving erythropoietin therapy (184). 
·  Levin  et  al  showed  that  left  ventricular  growth  was  independently  predicted  by 
haemoglobin concentration and systolic blood pressure in 246 dialysis patients (185). 
 
These  earlier  studies,  however,  were  performed  before  the  routine  use  of 
erythropoietin to correct anaemia in patients receiving renal replacement therapy.   
Erythropoietin receptors are present in myocardial tissues and in vivo studies have 
demonstrated that stimulation alters cellular turnover (186).  Studies demonstrating 
correction  of  moderate  anaemia  using  erythropoietin  stimulating  agents  have  not 
shown significant reversal of LVH. 
 
·  In  a  2009  meta-analysis  pooling  data  from  15  studies  with  1731  erythropoietin 
treated patients, regression of LVH was observed only in patients treated with severe 
anaemia (Hb<10g/dL)  Patients with moderate anaemia (mean Hb≥10g/dL but <12 144 
 
g/dL) had insignificant changes in LVMI.  These findings were consistent in dialysis 
and predialysis patients (187). 
 
The absence of significant association in our study is likely due to higher values and 
narrower  range  of  haemoglobin  in  this  cohort  (mean  haemoglobin  =  11.3g/dl, 
standard deviation= 1.3) compared to other studies.  In addition, echocardiography 
overestimates LVMI at lower haematocrit and higher intravascular volumes (135).  
Thus  any  therapy  that  reduces  haemodilution  (e.g.  correction  of  anaemia)  could 
provide artefactual reduction in LVMI measured by echocardiography.  The use of 
CMR  to  assess  change  in  LVMI  after  correction  of  anaemia  in  ESRD  patients 
remains to be studied. 
 
3.4.3  Predictors of LVSD 
As in the general population, symptomatic heart failure predicts early mortality in 
ESRD patients and increasing severity, defined by the New York Heart Association 
(NYHA) classification, is associated with increased mortality: 
 
·  In  a  study  from  the  United  Stated  Renal  Database  System  comparing  310456 
haemodialysis patients admitted to hospital for the first time with symptomatic heart 
failure, fluid overload or pulmonary oedema,  5- year survival rates were 12.5%, 
20.2% and 21.3% respectively (188). 
·  Postorino  et  al  demonstrated  that  NYHA  classifications  1-4  were  independently 
associated with increasingly poorer survival in ESRD patients (189).   
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Previous echocardiography studies have demonstrated differing prevalence of LVSD 
in ESRD patients (between 18-62%) (167;190).  This variability is presumably due, 
in part, to the difficulty obtaining accurate and reproducible images in patients with 
varying  intraventricular  cavity  diameters.      However,  data  presented  here  are 
consistent with previous CMR studies in this patient cohort from our research group: 
 
·  In a pilot study using CMR to assess myocardial structure in 134 ESRD patients, 
Mark  et  al  demonstrated  LVSD  prevalence  of  8.2%,  although  this  included 
peritoneal dialysis and predialysis patients (139). 
·  In  a  cross  sectional  study,  LVSD  was  present  in  15.6%  of  patients  undergoing 
cardiovascular assessment for renal transplantation who underwent CMR (135; 191). 
 
LVSD is more common in ESRD patients compared to the general population and 
has historically been attributed to the accumulation of traditional cardiovascular risk 
factors  (192)  including  ischaemic  heart  disease,  hypertension,  older  age,  and 
anaemia.   In addition, factors  found only in  ESRD patients have been  shown to 
reduce  LV  function  including  chronic  fluid  overload,  uraemia  and  calcific  aortic 
stenosis (190).  
 
3.4.3(a)  LVSD and fluid retention  
Our  data  show  that  lower  LV  ejection  fraction  and  presence  of  LVSD  are 
independently associated with higher ESV/BSA.  As suggested previously, this is 
most  likely  due  to  intravascular  volume  expansion,  elevated  diastolic  LV  filling, 
inadequate  LV  systolic  emptying  and  subsequent  decompensated  heart  failure.  
Independent predictors of LVSD also included mean dose of ultrafiltration consistent 146 
 
with a recent study that demonstrated an association between elevated interdialytic 
weight gain and adverse outcome: 
 
· Data  from  a  large  (n=34107),  retrospective  study  of  haemodialysis  patients 
investigated  weight  gain  between  dialysis  sessions  and  outcome.  Mortality  was 
highest in patients with 3 month averaged interdialytic weight gain greater than 4kg 
and lowest in patients with gains less than 1kg.  The investigators concluded that 
higher fluid retention (especially >4kg) was associated with greater all-cause and 
cardiovascular mortality independent of other co-morbid conditions (193).   
 
It is impossible to determine whether elevated dose of ultrafiltration may be a cause 
or sequela of  LVSD from the results presented  above.  Dose of ultrafiltration is 
calculated from a patients “dry weight” and determined by the nephrologist on the 
basis of his/her clinical assessment.  However, this may not represent an accurate 
measure  of  patient’s  ideal  oedema  free,  normotensive  weight.    More  objective 
methods of assessing patients’ fluid status and thus dose of ultrafiltration, such as 
bioelectrical  impendance  analysis  and  radionuclide  tagging  are  currently  being 
investigated to determine their effect on myocardial function and patient outcome 
(194). 
 
3.4.3(b)  LVSD and hypertension  
These data demonstrate a close relationship between blood pressure and LV systolic 
function: higher pre-HD SBP was significantly associated with lower LV ejection 
fraction.  This finding is in keeping with previous studies in the general population 
and ESRD patients: 147 
 
·  In  the  NHANES  I  follow  up  study  in  patients  with  congestive  cardiac  failure, 
hypertension  was  identified  as  an  independent  predictor  of  reduced  LV  ejection 
fraction and symptomatic chronic heart failure (195). 
·  Harnett et al demonstrated hypertension as an independent predictor of congestive 
cardiac disease in patients with ESRD. Diastolic blood pressure predicted presence 
of de novo and recurrent congestive heart failure (192). 
 
3.4.3(c)   LVSD and ischaemic heart disease 
Consistent with other studies in the general population and ESRD patients, these data 
show  that  past  history  of  symptomatic  occlusive  coronary  disease  independently 
predicted presence of LVSD.  The definition of ischaemic heart disease included 
patients with history of myocardial infarction, coronary artery intervention (surgical 
or percutaneous) or current symptoms of angina pectoris.  Mark et al previously 
showed  that  presence  of  LVSD  is  significantly  associated  with  presence  of 
subendocardial  pattern  of  myocardial  fibrosis  highlighted  by  late  gadolinium- 
diethylenetriamine-  pentaacetic  acid  (Gd-DTPA)  enhancement  (LGE)  on  contrast 
CMR (139).  Subendocardial LGE represents areas of previous (commonly silent) 
myocardial infarction and based on these results it was postulated that LVSD in 
uraemic cardiomyopathy is mostly due to CAD and myocardial ischaemia/infarction.  
These data support the association of ischaemic heart disease and LVSD in ESRD 
patients. 
 
3.4.4  Predictors of LV dilatation 
LV  dilatation,  when  assessed  by  echocardiography,  is  common  in  haemodialysis 
patients  with  a  prevalence  reported  between  28-36%  in  most  cohorts  (134).    As 148 
 
discussed  previously,  echocardiography  provides  inaccurate  measurements  of  LV 
chamber  size  in  fluid  overloaded  patients.    In  contrast,  CMR  assessment  of  our 
cohort  demonstrated  prevalence  of  LV  dilatation  at  15.9%  of  patients  and  is 
consistent with other CMR studies within this patient group (135). LV dilatation has 
previously been shown to be an independent predictor of death in ESRD patients: 
   
·  Parfrey et al demonstrated that presence of LV dilatation in patients assessed by 
echocardiography within a year of starting haemodialysis had a higher mortality after 
2 years on ESRD therapy (HR=1.86; p=0.02).  LV dilatation independently predicted 
death  of patients in this cohort (47). 
·  Further  analysis of these patients investigated  LV  geometry and outcome after 2 
years  on  ESRD.    The  results  separated  the  effect  of  LVH  and  LV  dilatation  on 
outcome.  In patients with normal cavity size and preserved systolic function, high 
LV mass and mass: volume ratios were independently associated with late mortality. 
Cavity volume did not have any effect on mortality.   In patients with elevated cavity 
size and preserved systolic function, high cavity size and low mass: volume ratios 
independently  predicted  death  with  LVMI  having  no  effect  on  prognosis.    The 
authors concluded that the effect of mass: volume ratio on patients survival was 
dependent on LV cavity size (134). 
 
These data demonstrate that independent predictors of EDV/BSA and presence of 
LV dilatation were lower LV ejection fraction and higher mean doses of UF.  As 
demonstrated before, fluid retention and its subsequent effect on LV function plays a 
pivotal role in determining myocardial abnormalities and it is most likely that poor 
LV ejection fraction and higher mean UF doses are aetiological and perpetuating 149 
 
agents  of  LV  dilatation.    Thus,  potential  reversal  of  LV  dilatation  may  involve 
attempts to improve LV function and more stringent adherence to fluid restriction in 
an attempt to break this cycle. 
 
Other  factors  have  been  identified  as  predictors  of  LV  dilatation  assessed  by 
echocardiography: 
 
·  In the two studies mentioned above, Foley et al demonstrated advancing age, male 
sex,  low  haemoglobin,  serum  calcium  and  albumin  and  high  phosphate  as 
independent risk factors for presence of LV dilatation (47;134).  
 
This CMR study did not demonstrate such associations presumably highlighting the 
inaccurate estimation of LV chamber size in ESRD patients by echocardiography.  In 
particular, the inclusion of haemoglobin and albumin are most likely the artefactual 
result of haemodilution, elevated intravascular volume, and imprecise measurement 
of chamber dimensions.   
 
3.4.5  Modifying uraemic cardiomyopathy 
Previous  studies  have  identified  potentially  modifiable  factors  to  reverse  the 
abnormalities of uraemic cardiomyopathy and improve cardiovascular prognosis in 
ESRD patients.  Unfortunately, these studies have had limited success due in part to 
the  many  facets  of  cardiovascular  disease  in  ESRD  patients  and  inaccuracy  of 
echocardiography when measuring cardiac chamber dimensions. 150 
 
Based on the data presented in this thesis, regression of uraemic cardiomyopathy in 
ESRD  should  be  directed  at  reducing  cardiac  preload  and  afterload.    The  most 
amenable factors are: 
 
·  Blood pressure control 
·  Minimisation of fluid retention  
·  Aggressive management of bone mineral disorders and vascular calcification  
 
Blood pressure control should be achieved in haemodialysis patients by maintenance 
of euvolaemia and anti-hypertensive medication.  A number of promising studies 
have illustrated a reduction of LV mass using these interventions: 
 
·  In  an  early  study,  Wu  et  al  investigated  39  patients  on  long  term  haemodialysis 
before and after treatment of blood pressure with regimens of ACE inhibitors, β- 
blockers, or calcium channel blocker.  This significantly reduced the prevalence of 
LVH and LVSD.  Responders, defined by a drop in mean arterial blood pressure ≥10 
mmHg, had most regression of LVH (196). 
·  Studies that demonstrate improved BP control due to more frequent dialysis also 
demonstrate regression of LV mass.  Fagugli et al (197) compared the effect of short 
daily dialysis or standard thrice weekly dialysis on blood pressure management and 
LVMI in 12 patients over a year.  Blood pressures, LVMI and extracellular fluid 
were  significantly  lower  in  daily  dialysis  patients.    LVMI  was  measured  by 
echocardiography.  More  recently,  a  randomised  controlled  study  using  CMR  to 
determine  changes  in  LVMI  was  performed  by  Culleton  et  al  (20)  comparing 
standard  haemodialysis  regimen  (n=25)  and  frequent  (5-6times/week)  nocturnal 151 
 
haemodialysis (n=26).  Results demonstrated a significant reduction in need for BP 
medication and LVMI.  However, in both of these studies, investigators were unable 
to  determine  whether  regression  of  LV  mass  was  independent  of  blood  pressure 
control. 
 
Unfortunately  there  is  a  lack  of  studies  that  show  a  convincing  improvement  in 
myocardial function or LV dilatation in haemodialysis patients: 
 
·  In  a  small  study  (n=30)  assessing  cardiac  chamber  sizes  before  and  after  renal 
transplantation  using  echocardiography,  Peteiro  et  al  showed  a  trend  towards 
euvolaemia as demonstrated by reduction of LV ESV and EDV but no improvement 
in LV systolic function (198).  
 
Pharmacological  intervention  in  dialysis  patients  may  provide  further  survival 
benefit: 
 
·  ACE I/ ARB.  Suzuki et al demonstrated a significant reduction in fatal and non fatal 
cardiovascular events in 360 hypertensive dialysis patients treated with ARBs (125).   
·  Beta Blockers. In 114 dialysis patients with dilated cardiomyopathy, treatment with 
carvedilol  significantly  reduced  cardiovascular  deaths  and  hospital  admissions 
compared to placebo (120). In addition, a retrospective cohort study showed that beta 
blockers reduced the risk of new onset heart failure in ESRD patients (199). 
 
Alterations in haemodialysis conditions may also improve myocardial function: 
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·  Intradialytic  hypotension  and  subsequent  myocardial  ischaemia,  characterised  by 
regional wall motion abnormalities (RWMA) on echocardiography, are recognised 
complications of haemodialysis therapy and are associated with LVSD and poorer 
survival  (70).    However,  biofeedback  dialysis  (whereby  significant  reductions  in 
blood pressure are counteracted by reducing ultrafiltration rates) and cooled dialysis 
(35°C  rather  than  37°C)  are  associated  with  a  significant  reduction  of  new 
intradialytic  RWMA.    The  long  term  effect  on  prognosis  of  both  of  these 
interventions is awaited (72;73). 
 
Despite  these  studies,  pharmacological  treatment  of  heart  failure  remains 
underutilised in ESRD patients. Data from the USRDS estimated that less than 25% 
of  patients  with  ESRD  and  heart  failure  are  treated  with  beta  blockers  or 
ACEI/ARBs  (200).    The  use  of  beta  blockers  was  higher  in  this  cohort  and  is 
presumably  a  reflection  of  the  extensive  cardiovascular  history  and  greater 
awareness of appropriate drug prescribing in these patients.   However, as more well 
controlled and randomised studies are performed, medical management may change 
in the future.  
 
3.4.6  Limitations of current study  
The current study has some limitations. Data from haemodialysis patients only has 
been  presented.    This  was  due  to  the  large  amount  of  blood  and  dialysis  data 
available for these patients from our electronic patient record.  One would hope that 
the data presented here could be extrapolated to peritoneal and pre-dialysis patients.  
In  addition,  these  patients  were  referred,  by  a  nephrologist,  for  cardiovascular 
assessment  and  may  not  represent  a  cross  section  of  all  dialysis  patients  due  to 153 
 
referral bias. Finally no record of vascular access for haemodialysis was presented. 
Arterio- venous fistulae has previously been associated with development of LVH 
due to increased cardiac preload. 
 
3.5  CONCLUSIONS 
In conclusion, pathophysiological changes associated with advancing kidney disease 
(hypertension, vascular calcification, expanded intravascular volume) are implicated 
in the development of the early features of uraemic cardiomyopathy.  These initially 
adaptive  but  subsequently  pathological  processes  perpetuate  the  development  of 
other cardiac abnormalities.  In this study the strongest predictor of each abnormality 
was another cardiac measurement. Prevention  may have to be achieved by more 
aggressive management of the aetiological factors in earlier stages of chronic kidney 
disease since LV abnormalities are very common in predialysis patients.  Hopefully 
new guidelines that identify and allow treatment of cardiovascular risk factors in 
early chronic kidney disease (e.g. by aggressive blood pressure control) may reduce 
the development of uraemic cardiomyopathy.  154 
 
 
Chapter 4 
 
A study identifying predictors of cardiovascular death in ESRD patients 
undergoing screening for renal transplantation 155 
 
4.1  INTRODUCTION 
 
As  discussed  in  the  introduction,  cardiovascular  (CV)  disease  is  the  commonest 
cause of death in ESRD patients, including those on the renal transplant waiting list 
and those who have received a renal transplant.  Premature CV death may be the 
result  of  high  prevalence  of  conventional  risk  factors  (such  as  hypertension, 
smoking, dyslipidaemia  and diabetes mellitus) but the relationship between these 
risk factors and CVD is much less clear than in the general population (1;5). For 
example, lower blood pressure and cholesterol  are related to adverse outcome in 
patients  on  haemodialysis.  In  addition,  a  number  of  non-traditional  and  uraemia 
specific  risk  factors  (such  as  endothelial  dysfunction,  oxidative  stress,  volume 
overload, hyperparathyroidism) have been associated with adverse CV outcome.   
 
Previous studies have assessed the effect of abnormal structure and function assessed 
by echocardiography on patient survival (47).  However, there have been no studies 
using  CMR  to  identify  these  abnormalities,  which  provides  a  more  accurate, 
reproducible,  volume  independent  method  of  measuring  cardiac  function  and 
dimensions. In addition, as has been shown previously in this thesis, these CMR 
measured cardiac abnormalities commonly occur in combination.   The Transplant 
Unit at the Western Infirmary, Glasgow has employed CMR for pre-transplant CV 
assessment since 2001.   
 
The aims of this study were to determine whether: 156 
 
·  The  features  of  uraemic  cardiomyopathy  defined  by  CMR,  namely  left 
ventricular  hypertrophy  (LVH),  left  ventricular  systolic  dysfunction  (LVSD), 
and left ventricular dilatation (LV dilatation), predicted CV death.   
·  The accumulation of such cardiac abnormalities predicted CV death. 
·  These features act independently of other established CV risk factors such as 
past clinical history. 
 
4.2   METHODS 
 
4.2.1  Patient recruitment 
Patients  were  recruited  consecutively  from  the  Western  Infirmary,  Glasgow  as 
described in Chapter 2.  To achieve greater statistical power, 123 patients assessed 
by  Dr  Patrick  Mark  were  added  to  those  assessed  to  provide  a  larger  cohort  of 
patients.  However analyses were performed with blinding to patient outcome. 
 
4.2.2  Cardiovascular assessment 
All patients were recruited after referral from the transplant assessment team using 
criteria described in Chapter 2.  As part of the screening visit, ECG was recorded and 
classified as “abnormal” by the investigator if one of following criteria were present 
in standard limb leads or pre-cordial leads, except AVR or V1: 
 
·  ST depression≥ 1mm or ST elevation≥ 1mm 
·  T wave inversion 
·  Left bundle branch block 
·  LVH by Sokolow-Lyon criteria or Cornell index 157 
 
·  Pathological Q waves. 
  
CMR scans were acquired for assessment of LV mass and function and analysed as 
previously  described.    Patients  were  classified  as  having  LVH,  LVSD  or  LV 
dilatation based on previously described normal values.  In addition the number of 
abnormalities  was  also  recorded.    Serum  haemoglobin,  corrected  calcium  and 
phosphate were measured on the day of screening.   
 
4.2.3  Follow up 
Data on patient outcome, including cause of death, were obtained from the date of 
CMR to 30
th September 2009 using the EPR of the Western Infirmary, Glasgow and 
Glasgow Royal infirmary Renal Units.  Deaths were categorised as “cardiovascular”, 
“malignancy”, “infective” and “unknown/other”.  Cause of death was reported by the 
attending nephrologist and recorded in the EPR.   
 
Deaths were classified as CV if primary cause on the EPR was reported as: 
·  Myocardial ischaemia/infarction 
·  Cardiac arrhythmia 
·  Cardiac arrest (cause uncertain) 
·  Cardiac failure 
·  Sudden death at home- presumed cardiac 
·  Cerebrovascular accident  158 
 
4.2.4  Statistical methods 
Data are described as mean (±standard deviation) for normally distributed data or 
median (interquartile range) for non-normal data. Comparisons between patients who 
died and those that did not were performed by Student’s t test (for normal data), 
Mann-Whitney U test (for non-normal data), Chi squared test or Fisher’s exact test 
as appropriate.  
 
Survival  data  including  survival  time  (mean±  standard  deviation)  are  shown  as 
Kaplan-Meier curves (with statistical comparison using the log rank test). These data 
were also analysed by Cox multivariate survival analysis to assess the influence of 
multiple  clinical  and  cardiac  variables  on  death.  A  transplant  censored  survival 
analyses was performed to remove the beneficial effect of renal transplantation on 
outcome (201;202). Variables identified as significantly influential on outcome by 
Cox univariate analysis were entered into a backward stepwise regression model. 
Left ventricular abnormalities (LVH, LVSD and LV dilatation) or the “number of 
abnormalities present” were entered individually into the model due to significant 
interdependence between these variables. All analyses were performed using SPSS 
v15.0 (SPSS Inc, Illinois, USA).  159 
 
4.3  RESULTS 
 
4.3.1  Patients demographics 
Patient demographics are shown in Table 4.1.  Between 1
st January 2002 and 31
st 
August 2009, 446 were recruited into the study.  Mean age was 53.0±11.8years.  
Two  hundred  and  thirty  nine  (53.6%)  were  receiving  thrice  weekly  maintenance 
haemodialysis,  62  (13.9%)  were  on  peritoneal  dialysis,  134  (30.0%)  were  pre-
dialysis (i.e. within 6 months of requiring renal replacement therapy), and 11 (2.5%) 
had failing renal transplants.  The total follow up time was 7.6 years (median 4.0 
years IQR 1.5, 5.7).   
 
One  hundred  and  fifty  six  patients  (35.0%)  had  normal  cardiac  structure  and 
function.  Two hundred and seventy six patients (61.9%) had LVH, 85 (19.0%) had 
LVSD and 62 (13.9%) had LV Dilatation on CMR (Figure 4.1).  The accumulation 
of  these  abnormalities  was  examined,  194  (43.5%)  had  one  abnormality  and  96 
(21.5%) had 2 or 3 abnormalities.  LVH only was the commonest single abnormality 
present (n=183, 41% of all patients) with only  11 (2.5%) patients having  LVSD 
alone.  Fifty nine (13.2%) patients had two abnormalities and 37 (8.3%) had all 
three. 160 
 
Variable 
 
Total 
N=446 
% or ±SD 
Deaths  95  (21.3) 
Transplants  114  (25.6) 
Age (years)  53.0  (±11.8) 
Male (%)  297  (66.6) 
Body Mass Index (kg/m
2)  26.1  (±5.1) 
       
Primary  Renal   Diabetic Nephropathy  98  (22.0) 
Diagnosis  ADPCKD  50  (11.2) 
  Glomerulonephritis  88  (19.7) 
  Pyelonephritis  41  (9.2) 
   Renovascular disease  29  (6.5) 
  Unknown/Other  140  (31.4) 
Systolic BP (mmHg)  140.3  (±24.6) 
Diastolic BP (mmHg)  81.8  (±13.2) 
RRT time (years)  1.0  (2.1) 
RRT  Haemodialysis  239  (53.6) 
  Peritoneal dialysis  62  (13.9) 
  Pre-dialysis  134  (30.0) 
  Failing Renal Transplant  11  (2.5) 
Diabetes mellitus  147  (32.9) 
Ischaemic Heart Disease  90  (20.2) 
Hypertension  412  (92.3) 
Cerebrovascular disease  41  (9.2) 
Peripheral vascular disease  42  (9.4) 
Smoking  Never  219  (49.1) 
  Current  125  (28.0) 
  Ex  102  (22.9) 
Dylipidaemia  195  (43.7) 
Ischaemic ECG  151  (33.9) 
Ejection Fraction (%)  64.9  (±13.3) 
Myocardial mass/BSA   96.0  (±33.4) 
EDV/BSA (ml/ m
2)  74.5  (±31.1) 
ESV/BSA (ml/ m
2)  28.2  (23.0) 
LVSD (EF<55%)  85  (19.0) 
LVH   276  (61.9) 
LV dilatation  62   (13.9) 
Number of abnormalities  0  156  (35.0) 
  1  194  (43.5) 
  2 or 3  96  (21.5) 
       
Haemoglobin (g/dL)  11.5  (±1.7) 
Adjusted Calcium (mmmol/l)  2.38  (±0.3) 
Serum Phosphate (mmmol/l)  1.64  (±0.5) 
Calcium Phosphate Product (mmol
2/l
2)  3.88  (±1.2) 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1  Clinical, blood and cardiac information for patients.   
Data are number with percentage in parentheses or mean ± standard deviation except 
renal replacement time and CRP where median and interquartile range are used.   161 
 
 
Figure 4.1   Distribution of abnormalities in patient cohort 
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4.3.2  Patient survival- all cause mortality 
There  were  95  (21.3%)  deaths  during  the  follow  up  period.    Eighteen  deaths 
occurred after transplantation.  Figure 4.2 shows the causes of death.  CV causes 
accounted for 53 (55.8%) deaths, with infective and malignant causes recorded for 
29 (30.5%) and 5 (5.3%) respectively.  The cause of death was unknown or due to 
other causes in 8 (8.4%) of cases. 
 
Comparisons between patients who were alive and dead at the end of the study are 
shown in Table 4.2.  Patients who died during the study were significantly older, and 
more  likely  to  have  a  past  medical  history  of  diabetes  mellitus,  ischaemic  heart 
disease and cerebrovascular disease.  In addition, patients who died had significantly 
poorer LV systolic function and more likely to have LV dilatation on CMR and an 
abnormal screening ECG. There were fewer transplants and a lower mean diastolic 
blood pressure in the group that died, but this did not reach statistical significance.  
Patients with 2 or more abnormalities were more likely to die during follow up. 
 
Transplant  censored  survival  analyses  were  performed  by  removing  transplant 
recipients from the study at the time of operation.  This was performed to account for 
the beneficial effect of renal transplantation on outcome. Patient survival was not 
significantly affected by the presence of LVH on CMR (Figure 4.3a).  However, 
presence  of  LVSD  and  LV  dilatation  were  significantly  associated  with  reduced 
mean patient survival (Figure 4.3b and 4.3c respectively).  Furthermore, presence of 
2 or more cardiac abnormalities was significantly associated with poorer survival 
compared to patients with normal hearts or 1 abnormality (figure 4.3d). Survival was 163 
 
poorer  in  patients  with  3  abnormalities  compared  to  2  (mean  survival  times  2 
abnormalities 6.4±2.0y vs. 3 abnormalities 4.8±3.1y; p=0.01, graph not shown). 164 
 
 
 
Figure 4.2  Pie Chart showing causes of death.  Cardiovascular death is the 
commonest cause of death in this cohort. 
Cardiovascular
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Variable 
 
Alive 
N=351 
Dead 
N=95 
p 
Transplants  96 (27.4)  18 (18.9)  0.09 
Age (years)  52.1 (±11.9)  56.3 (±10.8)  <0.01 
Male (%)  238 (67.7)  59(62.1)  0.30 
BMI (kg/m
2)  26.1 (±4.9)  25.7 (±4.7)  0.25 
Primary Renal Diagnosis       
    Diabetic Nephropathy  73 (20.8)  25 (26.3)  0.36 
  ADPCKD  37 (10.5)  13 (13.7)   
  Glomerulonephritis  72 (20.5)  16 (16.8)   
  Pyelonephritis  37 (10.5)  4 (4.2)   
  Renovascular disease  23 (6.6)  6 (6.3)   
  Unknown/Other  109 (31.1)  31 (32.6)   
Systolic BP (mmHg)  141.1 (±24.8)  137.4 (24.1)  0.22 
Diastolic BP (mmHg)  82.5 (13.2)  80.8 (12.6)  0.09 
RRT Time (HD and PD only)  1.5 (4.3)  1.9 (4.4)  0.51 
RRT  HD  190 (54.1)  49 (51.6)   
  PD  44 (12.5)  18 (18.9)  0.37 
  Predialysis  107 (30.5)  27 (28.4)   
  Failing Trans.  10 (2.8)  1 (1.1)   
Diabetes mellitus  105 (29.9)  42 (44.2)  0.03 
Ischaemic Heart Disease  61 (17.4)  29 (30.5)  0.01 
Hypertension  321 (91.5)  91 (95.8)  0.16 
Cerebrovascular disease  27 (7.7)  14 (14.7)  0.04 
Peripheral vascular disease  34 (9.7)  8 (8.4)  0.71 
Smoking  Never  172 (49.0)  47 (49.5)   
  Current  99 (28.2)  26 (27.4)  0.99 
  Ex  80 (22.8)  22 (23.2)   
Dyslipidaemia  151 (43.0)  43 (45.3)  0.70 
Abnormal ECG  108 (30.8)  43 (45.3)  <0.01 
CMR  Ejection Fraction (%)  65.6(±12.5)  62.3(±15.3)  0.02 
Findings  Myocardial mass/BSA  95.2 (±33.5)  97.2 (±33.1)  0.67 
  EDV/BSA (ml/ m
2)  73.5 (±30.5)  78.4 (±33.5)  0.18 
  ESV/BSA (ml/ m
2)  27.0(±21.2)  32.8(±28.5)  0.07 
  LVSD(EF<55%)  60 (17.1)  25 (26.3)  0.04 
  LVH  211 (60.1)  65 (68.4)  0.14 
  LV dilatation  43 (12.3)  19 (20)  0.05 
Number of abnormalities  0  127 (35.2)  29 (30.5)   
  1  155 (44.1)  39 (41.1)  0.02 
  2 or 3  69(19.7)  27(28.4)   
Haemoglobin (g/dL)  11.5 (±1.7)  11.3(±1.5)  0.24 
Adjusted Calcium (mmmol/l)  2.38 (±0.3)  2.37(±0.2)  0.87 
Serum Phosphate (mmmol/l)  1.66 (±0.5)  1.70(±0.5)  0.61 
Calcium Phosphate Product (mmol
2/l
2)  3.94 (±1.2)  1.70 (±0.5)  0.53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Table 4.2  Comparison  between  patients  alive  or  dead  at  the  end  of  the 
study.  
Data are number with percentage in parentheses or mean ± standard deviation except 
for RRT time where median and interquartile range and shown. Tests of significance 
are  t-test  and  Chi-square  except  RRT  time  where  Mann-Whitney  U  Test  is 
performed. 166 
 
Figure 4.3a  Mean survival: No LVH (n=170) 6.5 ±2.5y vs. LVH (n=276) 6.3 
±2.7y; p=0.56.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure demonstrating no significant difference in survival between patients with and 
without LVH 
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Figure 4.3b  Mean survival: No LVSD (n=361) 6.5 ±2.5y vs. LVSD (n=85) 5.6 
±3.2y; p=0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure demonstrating association of LVSD with reduced patient survival. 
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Figure 4.3c  Mean  survival:  No  LV  Dilatation  (n=384)  6.5  ±2.5y  vs.  LV 
Dilatation (n=62) 5.7 ±2.9y; p=0.04.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure demonstrating association of LV dilatation with reduced patient survival. 
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Figure 4.3d  Mean survival for number of abnormalities:  None (n=156) 6.6 
±2.2y, 1 abnormality (n=94) 6.6 ±2.5y, 2or 3 abnormalities (n==97) 5.6 ±3.0y  
 
 
Figure  demonstrating  reduction  in  survival  of  patients  with  higher  frequency  of 
cardiac abnormalities 
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A Cox backward stepwise regression model was performed to indentify the most 
robust model for transplant censored patient survival (Table 4.3).  Increasing age, 
past  history  of  ischaemic  heart  disease  and  presence  of  LVSD  on  CMR  were 
significant  independent  predictors  of  death.    In  Chapter  3,  it  was  shown  that 
combinations of myocardial abnormalities are often present.  To this end, the number 
of  abnormalities  was  entered  into  the  multivariate  model,  as  opposed  to  the 
abnormality present.  Similarly, older age, clinical history of ischaemic heart disease 
and presence of 2 or 3 abnormalities independently predicted poorer survival. 
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Table  4.3  Results  of  univariate  and  multivariate  Cox  regression  survival 
analyses of all patients screened; all-cause mortality is the dependable variable 
Hazard  ratios  (95%  confidence  intervals)  are  shown.    Alternative  model  with 
individual LV abnormalities entered is also shown. 
 
† Multivariate model when number of abnormalities replaced by LVSD and LV Dilatation 
Variable  HR  95% CI  p 
Age (per year)  1.05  1.13,3.27  <0.01 
Ischaemic Heart Disease  1.59  0.95,2.69  0.07 
LVSD (EF<55%)  2.10  1.23,3.43  <0.01 
LV dilatation      NS 
 
  Univariate Analyses  Multivariate Analyses 
Variable  HR  95% CI  p  HR  95% CI  p 
Age (per year)  1.05  1.02, 1.07  <0.01  1.05  0.97, 1.07  <0.01 
Ischaemic Heart Disease  2.18  1.35,3.51  <0.01  1.63  1.07, 2.72  0.05 
No. of   0  1.00      1.00     
abnormalities  1  0.75  0.52, 1.50  0.75  1.01  0.57, 1.76  0.88 
  2 or 3  1.97  1.12,3.43  0.01  1.98  1.09, 3.58  0.02 
LVSD (EF<55%)  2.02  1.23,3.32  <0.01  †     
LV dilation  1.72  1.01, 2.96  0.05  †     
Abnormal ECG  1.99  1.27,3.11  <0.01       
BMI (per kg/m
2)  0.98  0.94,1.02  0.99       
Systolic BP (per mmHg)  0.82  0.99,1.01  0.82       
Diastolic BP (per mmHg)  0.99  0.97,1.01  0.10       
RRT Time (per year)  1.03  0.91,1.18  0.62       
RRT  HD  1.00           
  PD  1.83  1.02,3.30  0.06       
  Predialysis  1.17  0.67,1.97  0.55       
  Failing Trans.  0.46  0.06,3.36  0.44       
Diabetes mellitus  1.29  0.78,2.10  0.30       
Hypertension  1.27  0.47,3.50  0.64       
Cerebrovascular disease  1.72  0.80,3.67  0.16       
Peripheral vascular disease  0.75  0.29,1.92  0.55       
Smoking  Never (ref)  1.00           
  Current  1.05  0.60,1.83  0.86       
  Ex  0.93  0.48,1.77  0.82       
Dyslipidaemia  1.33  0.88,2.09  0.21       
Ejection fraction (per %)  0.98  0.96, 1.03  0.87       
LVMI (per g/m
2)  1.00  0.98,1.01  0.40       
EDV/BSA (per ml/ m
2)  0.99  0.99, 1.06  0.27       
ESV/BSA (per ml/ m
2)  1.03  0.99,1.05  0.12       
LVH   1.23  0.79, 2.05  0.32       
Haemoglobin (per g/dL)  0.94  0.78, 1.14  0.56       
Adjusted Calcium (per mmmol/l)  1.04  0.01, 4.50  0.99       
Serum Phosphate (per mmmol/l)  0.87  0.01, 7.04  0.89       
CaPO4 Product (per mmol
2/l
2)  1.04  0.40, 12.6  0.96       172 
 
4.3.3  Patient Survival- cardiovascular mortality 
Similar survival analyses were performed to better define variables associated with 
transplant censored CV mortality only.  There were 53 CV deaths during the follow 
up period.  Six of these deaths occurred after renal transplantation and thus were 
censored at the time of transplantation. 
 
Table 4.4 shows comparison of patients who experienced CV death compared to 
those who died due to other causes or were alive at the end of the study.  As before, 
CV death was significantly more common in older patients and those with a history 
of ischaemic heart disease and diabetes mellitus.  In addition, patients who died from 
CV causes were more likely to have an abnormal screening ECG, and were more 
likely to demonstrate poorer LV function, LVH and LV dilatation on CMR.  CV 
death was significantly associated with 2 or more cardiac abnormalities.  There were 
no  significant  differences  in  the  presence  of  other  CV  risk  factors  assessed 
(hypertension, cerebrovascular and peripheral vascular disease, dyslipidaemia and 
smoking history).  
 
Transplant censored survival analyses demonstrated significantly poorer CV survival 
when  LVH,  LVSD  and  LV  dilatation  were  present  on  CMR  at  the  time  of 
recruitment into the study (Figure 4.4 a, b, c respectively).  Similarly, survival was 
significantly reduced when 2 or all 3 abnormalities were present.  Presence of a 
single abnormality did not significantly affect CV death (Figure 4.4d).  CV survival 
was poorer in patients with 3 abnormalities compared to 2 but this did not reach 
statistical  significance  (mean  survival  times  2  abnormalities  6.8±2.1y  vs.  3 
abnormalities 5.8±2.8y; p=0.07, graph not shown). 173 
 
Variable 
 
Alive/Non CV 
Death 
N=393 
CV Death 
N=53 
p 
Transplants  106 (27.0)  8 (15.1)  0.06 
Age (years)  52.5 (±11.9)  56.6 (±10.2)  0.02 
Male (%)  256 (65.1)  41(77.4)  0.08 
BMI (kg/m
2)  25.9 (±4.9)  25.9 (±4.8)  0.92 
Primary Renal Diagnosis       
    Diabetic Nephropathy  84 (21.4)  14 (26.4)  0.12 
  ADPCKD  43 (10.9)  7 (13.2)   
  Glomerulonephritis  77 (19.6)  11 (20.8)   
  Pyelonephritis  41 (10.4)  0   
  Renovascular disease  26 (6.6)  3 (5.7)   
  Unknown/Other  122 (31.0)  18 (34.0)   
Systolic BP (mmHg)  140.8(±24.7)  137.0 (±24.3)  0.32 
Diastolic BP (mmHg)  82.1(±13.1)  79.6(±13.7)  0.21 
RRT Time (HD and PD only)  1.6(4.3)  1.4(4.5)  0.51 
RRT  HD  211 (53.7)  38 (52.8)   
  PD  53 (13.5)  9 (17.0)  0.59 
  Predialysis  118 (30.0)  16 (32.0)   
  Failing Trans.  11 (2.8)  0   
Diabetes mellitus  117 (29.8)  30 (56.6)  0.04 
Ischaemic Heart Disease  70 (17.8)  20 (37.7)  <0.01 
Hypertension  361 (91.9)  51 (96.2)  0.26 
Cerebrovascular disease  35 (8.9)  6 (11.3)  0.57 
Peripheral vascular disease  36 (9.2)  6 (11.3)  0.61 
Smoking  Never  194 (49.4)  25 (47.2)  0.58 
  Current  112 (28.5)  13 (24.5)   
  Ex  87 (22.1)  15 (28.3)   
Dyslipidaemia  169 (43.0)  25 (47.2)  0.57 
Abnormal  ECG  124 (31.6)  27 (50.9)  <0.01 
Ejection Fraction (%)  65.7 (±12.6)  58.7 (±16.4)  <0.01 
Myocardial mass/BSA   95.3(±33.2)  101.5 (±4.7)  0.20 
EDV/BSA (ml/ m
2)  73.4 (±30.4)  83.0(±32.7)  0.04 
ESV/BSA (ml/ m
2)  26.9 (±21.1)  38.3 (±32.7)  0.02 
LVSD (EF<55%)  69 (17.6)  16 (30.2)  <0.01 
LVH   236 (60.1)  40(75.5)  <0.01 
LV dilatation  48 (12.2)  14 (26.4)  <0.01 
Number of abnormalities  0  144 (36.6)  12 (22.6)  <0.01 
  1  171 (43.5)  23 (43.4)   
  2 or 3  78 (19.8)  18 (33.9)   
Haemoglobin (g/dL)  11.5 (±1.7)  11.3(±1.6)  0.33 
Adjusted Calcium (mmmol/l)  2.37 (±0.2)  2.37 (±0.2)  0.78 
Serum Phosphate (mmmol/l)  1.67 (±0.5)  1.65 (±0.4)  0.80 
Calcium Phosphate Product (mmol
2/l
2)  3.97 (±1.2)  3.93(±1.1)  0.88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4  Comparison  between  patients  who  experienced  CV  death  and 
those who did not at the end of the study. 
Data are number with percentage in parentheses or mean ± standard deviation except for RRT time 
where median and interquartile range and shown. 174 
 
Figure 4.4a  Mean survival: No LVH 7.2±1.3y vs. LVH 6.8±2.1y; p=0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure demonstrating reduction in CV survival of patients with LVH 
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Figure 4.4b  Mean survival: No LVSD 7.2 ±1.3y vs. LVSD 6.1±2.8y; p<0.001 
 
Figure demonstrating reduction in CV survival of patients with LVSD 
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Figure 4.4c  Mean  survival:  No  LV  Dilatation  7.1±1.6y  vs.  LV  Dilatation 
6.2±2.6y; p=0.003 
 
 
Figure demonstrating reduction in CV survival of patients with LV dilatation 
LV dilatation 
No LV dilatation 177 
 
Figure 4.4d  Mean survival for number of abnormalities:  None= 7.3±1.3y, 1 
abnormality = 7.1±1.7y, 2 or 3 abnormalities= 6.4±2.5y; p=0.002. 
 
 
Figure demonstrating reduction in CV survival of patients with higher frequency of 
cardiac abnormalities 178 
 
As before, a Cox backward stepwise regression model was performed to identify 
factors associated with transplant censored CV survival (Table 4.4).  Increasing age, 
past history of ischaemic heart disease and presence of LV dilatation on CMR were 
significant  independent  predictors  of  CV  death.    When  entering  number  of 
abnormalities  into  the  multivariate  model,  older  age  and  presence  of  2  or  3 
abnormalities independently predicted CV death. 179 
 
Table 4.4   Results  of  univariate  and  multivariate  Cox  regression  survival 
analyses of all patients screened; CV mortality is the dependable variable. 
 
Hazard ratios (95% confidence intervals) are shown.  Alternative model with individual 
LV abnormalities (**) entered are also shown 
 
 
  Univariate Analyses  Multivariate Analyses 
Variable  HR  95% CI  p  HR  95% CI  p 
Age (per year)  1.05  1.02,1.08  <0.01  1.06  1.03,1.09  <0.01 
No. of   0  1.00      1.00     
abnormalities  1  1.43  0.64,3.18  0.387  1.46  0.65, 3.26  0.36 
  2 or 3  3.39  1.53,7.51  <0.01  3.80  1.71, 8.41  <0.01 
Ischaemic Heart Disease  2.18  1.19,3.99  0.01       
LVSD (EF<55%)  2.77  1.51,5.10  <0.01  **     
LV dilatation  2.51  1.32,4.78  <0.01  **     
Ejection Fraction (per %)  0.96  0.95, 0.98  <0.01       
Abnormal ECG  2.00  1.12,3.56  0.02       
ESV/BSA (per ml/ m
2)  1.04  1.01, 1.06  <0.01       
LVH   2.00  0.99,4.03  0.05       
BMI (per kg/m
2)  1.02  0.96, 1.08  0.53       
Systolic BP (per mmHg)  1.00  0.98, 1.02  0.72       
Diastolic BP (per mmHg)  0.99  0.96, 1.02  0.57       
RRT Time (per year)  0.99  0.92,1.05  0.66       
RRT  HD  1.00           
  PD  1.26  0.57, 2.81  0.56       
  Predialysis  1.07  0.55, 2.09  0.85       
  Failing Trans.  0.98  0.46, 2.07  0.97       
Diabetes mellitus  0.94  0.52, 1.71  0.84       
Hypertension  1.39  0.34, 5.76  0.65       
Cerebrovascular disease  1.36  0.54, 3.45  0.51       
Peripheral vascular disease  1.70  0.67, 4.31  0.27       
Smoking  Never (ref)  1.00           
  Current  1.06  0.53, 2.15  0.87       
  Ex  1.07  0.53, 2.16  0.86       
Dyslipidaemia  1.40  0.78, 2.51  0.26       
LVMI (per g/m
2)  1.01  0.97, 1.02  0.34       
EDV/BSA (per ml/ m
2)  1.98  0.96, 2.08  0.71       
LV dilatation             
Haemoglobin (per g/dL)  0.77  0.56, 1.07  0.11       
Adjusted Calcium (per mmmol/l)  0.45  0.08, 2.67  0.38       
Serum Phosphate (per mmmol/l)  0.69  0.30,1.59  0.38       
CaPO4 Product (per mmol
2/l
2)  0.89  0.62, 1.27  0.51       
 
 
   
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**  Multivariate model when number of abnormalities replaced by LVSD and LV Dilatation 
 
 
 
Variable  HR  95% CI  p 
Age (per year)  1.05  1.02, 1.08  0.001 
Ischaemic Heart Disease  1.89  1.01, 3.46  0.04 
LVSD (EF<55%)      NS 
LV dilatation  2.46  1.27, 4.78  0.008 180 
 
4.5  DISCUSSION 
 
The determinants of uraemic cardiomyopathy  were described in Chapter 3.  The 
development  of  LV  abnormalities  was  described  as  a  process  initiated  and 
perpetuated by elevated cardiac preload and afterload which are very common in 
ESRD  patients  due  to  fluid  overload,  vascular  calcification  and  systemic 
hypertension.    Furthermore,  due  to  these  persistent  cardiac  stressors  it  was  very 
common  for  ESRD  patients  to  have  more  than  one  LV  abnormality  presumably 
representing different stages in the patho-physiological process.   The rationale of 
therapeutic  intervention  would  be  to  disrupt  this  process  thus  halting  and/or 
reversing abnormalities and improving CV outcome in ESRD patients. 
 
The  aim  of  this  study  was  to  investigate  the  effect  of  myocardial  abnormalities 
detected by CMR on CV survival in ESRD patients.  Although, similar studies have 
demonstrated  reduced  survival  in  ESRD  patients  with  LVH,  LVSD  and  LV 
dilatation  detected  by  echocardiography,  no  such  long  term  outcome  data  are 
available for measurements recorded by CMR.   181 
 
4.5.1  Uraemic cardiomyopathy and outcome 
Examining the cohort as a whole, there were only 95 deaths (21.3%) deaths over a 
median  follow  up  time  of  4.0  (IQR  4.2)  years.    This  mortality  rate  was  lower 
compared to other studies investigating outcome in all ESRD patients where rates 
between 30-50% have been observed over a similar follow up time.  However, the 
patients of this cohort were referred for CV assessment as part of their preparation 
for  renal  transplantation  and  thus  were  deemed  fit  enough  by  their  referring 
nephrologist to undergo renal transplantation.  Other studies in the pre-transplant 
group have demonstrated similar rates of death on follow up (203).  As in other 
studies, transplant censored survival was assessed for all cause and CV mortality to 
remove  the  beneficial  bias  conferred  by  renal  transplantation  from  the  analyses 
(134;167).   
 
4.5.2  LVH and outcome 
These  data  demonstrate  that  presence  of  LVH  and  elevated  LVMI  were  not 
significantly associated with higher all cause mortality. In addition, presence of LVH 
was not associated with reduced survival times and did not independently predict all 
cause mortality on Cox proportional survival analyses.  Although, presence of LVH 
was significantly associated with a higher CV mortality and significant reduction in 
CV  survival,  multivariate  Cox  survival  analyses  did  not  demonstrate  LVH  as 
independent predictors of CV death.  
 
This result was unexpected given previous published data demonstrating elevated 
LV  mass  and  presence  of  LVH  as  significant  predictors  of  all  cause  and  CV 182 
 
mortality  in  ESRD  patients  (47;48).      There  are  a  number  of  reasons  for  these 
discrepancies of results. 
 
Previous  studies  have  used  M  Mode  echocardiography  to  assess  LV  mass  and 
chamber size.  LVH has been reported to be present in 50-80% of patients with 
ESRD.    The  methodological  inconsistencies  of  echocardiography,  particularly  at 
higher  LVMI  (>120g/m
2)  have  been  highlighted  previously.    Parfrey  et  al  (47) 
performed a large prospective trial in 432 patients initiating dialysis therapy and their 
echocardiography results compared to these data are shown in Table 4.5. 
 
  Parfrey et al (%) 
Echocardiography 
These Data (%) 
CMR 
Normal  16  35 
LVH  41 (concentric)  61.9 
LVSD  15  19 
LV Dilatation  28 
(preserved LV function) 
13.9 
7.6%  with  preserved  LV 
function 
 
Table 4.5   Comparison between Parfrey et al and these data. 
 
These differences highlight the importance of hydration status on timing of cardiac 
scanning.  When echocardiography is used, identification of chamber borders can be 
inaccurate  especially  in  fluid  overloaded  patients,  and  errors  in  calculation  of 
chamber  size  and  LV  mass  magnified  due  to  the  computations  performed.  As  a 
result, there is a greater likelihood for patients to be incorrectly classified as having 
LVH  (when  LV  mass  is  overestimated)  or  LV  dilatation  (when  end  diastolic 
chamber size is overestimated). CMR data presented here demonstrate a much larger 
proportion  of  patients  with  normal  cardiac  structure  and  fewer  patients  with  LV 183 
 
dilatation compared to echocardiography data.   It should be noted that no formal 
distinction between eccentric and concentric LVH was made.  
 
Serial  echocardiography  has  provided  some  insight  into  the  effect  of  worsening 
cardiac changes and patient outcome.  Paoletti et al demonstrated that progression of 
LVH is a much stronger predictor of sudden cardiac death than the absolute value of 
LVMI at inception echocardiogram (89).  It is most likely that these studies included 
ESRD subjects with chronic fluid overload and in the future, repeat CMR of patients 
in this cohort may help to support this hypothesis. 
 
In summary, although presence of LVH has a statistically significant effect on CV 
survival  in  this  study,  it  did  not  have  as  great  an  effect  as  has  previously  been 
demonstrated in echocardiography studies. 
 
4.5.3  LVSD and outcome   
From previous late gadolinium enhanced CMR studies of ESRD patients, LVSD has 
been  significantly  associated  with  (usually  silent)  ischaemic  heart  disease.  As 
described in Chapter 3, micro- and macrovascular coronary disease, which are very 
common  in  ESRD  patients,  are  significant  causes  of  myocardial  ischaemia  and 
subsequent LVSD.   
 
These data confirm previous echocardiography studies demonstrating a significantly 
poorer survival (all cause and cardiovascular) in patients with impaired LV function.  
The  determinants  of  LVSD  have  previously  been  described  in  Chapter  3.  
Interestingly  presence  of  LVSD  was  a  significant  predictor  of  all  cause,  but  not 184 
 
cardiovascular, mortality independent of a past clinical history of ischaemic heart 
disease (Tables 4.3 and 4.4) and is most likely due to: 
·  Presence of LVSD also being associated with higher risk of non cardiac causes of 
death.    This  has  been  demonstrated  before  (188;204),  and  is  due  to  the  close 
association  of  LVSD  with  other  co-morbidities  including  peripheral  and 
cerebrovascular disease and diabetes mellitus in the absence of clinically apparent 
ischaemic heart disease (139). 
·  A close association between clinical history of ischaemic heart disease and LVSD in 
patients  who  died  from  CV  causes  thus  removing  independent  associations  on 
multivariate Cox survival modelling.  
 
Nonetheless, these data demonstrate a significantly poorer survival, including CV 
survival, in patients with LVSD on CMR. 
 
4.5.4  LV dilatation and outcome 
From these data, presence of LV dilatation was associated with significantly reduced 
all cause and CV survival.  Presence of LV dilatation also independently predicted 
CV death adjusted for age and past history of ischaemic heart disease. As has been 
discussed previously in this thesis, LV dilatation is independently associated with 
LVSD  and  chronic  fluid  overload  (represented  by  elevated  mean  doses  of 
ultrafiltration in haemodialysis patients) in the absence of an adequate compensatory 
increase in LV mass.  LV dilatation has previously been independently associated 
with  poorer  prognosis  in  ESRD  patients  (134).    In  particular,  in  patients  with 
established LV dilatation and preserved systolic function, survival has been shown to 
be worse in patients with higher LV cavity volumes and inadequate compensatory 185 
 
increase in LV mass.    Moreover, isolated LV dilatation was not recorded in any 
patients from this cohort, and it is likely that LV dilatation is a marker of significant 
global LV disease thus explaining poor CV outcome in patients who develop this 
abnormality. 
 
4.5.5  Accumulation of myocardial abnormalities and outcome 
Unsurprisingly, patients who had two or more cardiac abnormalities had poorer all 
cause  and  CV  survival.  In  addition,  number  of  cardiac  features  independently 
predicted all cause and CV mortality in ESRD patients.  The presence and number of 
cardiac abnormalities were not entered simultaneously into the Cox survival model 
due to their close association.  Survival (from all and CV causes) was also worst in 
patients with all 3 abnormalities compared to those with a combination of two (LVH 
and LVSD, LVH and LV dilatation or LVSD and LV dilatation).   
 
Presence of one abnormality did not have a significant effect on Kaplan Meier or 
Cox multivariate survival analyses.  LVH accounted for 94% of patients with one 
abnormality and this reflects our earlier finding that LVH did not have as significant 
an influence on survival of ESRD patients as previously demonstrated.  It would be 
interesting  in  the  future  to  repeat  this  analysis  using  more  patients  with  isolated 
LVSD.  
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4.5.6  Potential targets for intervention  
The  main  aim  of  this  study  was  to  determine  whether  features  of  uraemic 
cardiomyopathy  measured  by  CMR  had  an  effect  on  patient  CV  outcome.    In 
addition,  by  identifying  poor  prognostic  features  it  allows  targeting  of  potential 
therapeutic interventions. 
 
As discussed in Chapter 3, it is likely that the development of cardiac abnormalities 
is progressive and accounts for the common finding of more than one abnormality in 
ESRD  patients.  Thus  to  reverse  these  abnormalities  and  improve  CV  prognosis, 
interventions  should  be  aimed  at  reducing  cardiac  preload  and  afterload  (i.e. 
hypertension,  fluid  overload,  vascular  calcification)  that  propel  the 
pathophysiological  process.      Early  studies,  investigating  the  effect  of 
pharmacological  and  dialysis  interventions  on  myocardial  structure  and  function 
have been described in Chapter 3. 
 
Myocardial structure has been shown to change even in milder stages of CKD and 
continue  to  progress  as  renal  function  deteriorates  (170;  173).  Given  that  the 
prognosis in this study was not significantly different between patients with normal 
hearts  and  one  abnormality,  aggressively  targeting  patients  at  an  early  stage  to 
prevent progression to  more than one structural change may be beneficial.   It is 
essential that measures employed to prevent development or reverse LVH, LVSD 
and LV dilatation in ESRD patients be employed early.   Furthermore, slowing or 
regressing these abnormalities has not been convincingly achieved using adequately 
powered,  randomised  controlled  studies  and  it  is  still  not  known  whether 187 
 
intervention will improve CV outcome.  This study will hopefully provide data to 
power such studies in the future. 
 
4.5.7  Limitations of current study 
There were differences, particularly in mortality rates between these and previously 
published data.  As stated previously, this is most likely due to recruitment from the 
pre-transplant population.  However, it is likely  that these  results are  relevant to 
other CKD 5 patients with more significant co-morbidities. 
 
4.6  CONCLUSIONS 
In conclusion, LVSD and LV dilatation detected by CMR are associated with higher 
all cause and CV mortality in ESRD patients.  Although LVH significantly reduces 
cardiovascular  survival,  this  is  not  to  the  extent  suggested  by  echocardiography 
studies in this patient group.  Although presence of one cardiac abnormality did not 
significantly affect survival, accumulation of two or more cardiac abnormalities was 
associated  with  a  significantly  poorer  prognosis.    These  findings  suggest  that 
measures  should  be  assessed  to  aggressively  reverse  these  changes  and  improve 
cardiovascular outcome in ESRD patients. 188 
 
 
Chapter 5 
 
A study of determinants of mortality in ESRD patients with LVH: the role of 
left atrial volume. 189 
 
5.1  INTRODUCTION 
 
As previously mentioned, echocardiography studies have identified abnormalities in 
left  ventricular  structure  and  function,  termed  “uraemic  cardiomyopathy”,  that 
independently confer a poorer prognosis in ESRD patients (47).  
 
Of these, left ventricular hypertrophy is present in approximately 67% of patients 
with  ESRD  and  the  most  common  manifestation  of  uraemic  cardiomyopathy. 
Moreover, it is an independent risk factor for sudden cardiac death, heart failure, and 
cardiac  arrhythmias  in  both  the  general  population  and  patients  receiving 
haemodialysis. The presence of LVH alone has a variable prognosis. Furthermore, 
reversal of LVH in ESRD patients has proven difficult and attempts have been made 
to identify additional cardiac abnormalities that predict death and are amenable to 
intervention (53;205;206).  
 
The strengths of CMR over echocardiography to assess LV mass in ESRD have been 
described in Chapter 1.  In addition, elevated left atrial (LA) volume (corrected for 
body surface area (BSA) or height) is an independent predictor of mortality in the 
general  population,  and  in  hypertensive  and  ESRD  patients,  when  measured  by 
echocardiography (207;208). Causes of increased left atrial volume (LAV) in ESRD, 
include mitral valve disease, fluid overload and impaired left ventricular diastolic 
relaxation and filling (called LV diastolic dysfunction) (209).  LAV can be reliably 
and reproducibly measured on echocardiography and CMR using the biplane area-
length method described in Chapter 2 (155;156).   
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The  aim  of  this  prospective  study  was  to  accurately  identify  a  cohort  of  ESRD 
patients with LVH on CMR and to identify additional features that would confer 
poorer survival.  Given the findings from previous studies, LAV was included in the 
analyses.  
 
5.2  METHODS 
 
5.2.1  Patients 
ESRD patients were recruited from the renal transplant assessment clinic from the 
Western Infirmary as described in Chapter 2.  Haemodialysis data, including doses 
of ultrafiltration, were recorded at 30 day intervals up to 180 days prior to CMR.  
Only patients with evidence of LVH on CMR were entered into the study.  All 
patients were in sinus cardiac rhythm at the time of scanning. 
 
To ensure that only non valvular causes of LA dilatation were assessed, patients with 
grade II to IV mitral valve regurgitation (i.e. greater than mild) on colour Doppler 
echocardiography  were  excluded  from  the  study.    Severity  of  mitral  valve 
incompetence was assessed using American Heart Association/ American College of 
Cardiology criteria of (210): 
· Colour Doppler jet area. 
· Vena contracta diameter (defined as point in a fluid stream where the diameter of the 
stream is the least). 
 
To obtain a large cohort of patients and achieve greater statistical power, previous 
CMR scans (n=46) performed by Dr Patrick Mark were added to current studies.  191 
 
These scans, however, were analysed separately by the investigator (RKP) who was 
blinded to patients’ characteristics and outcome.   
 
5.2.2  CMR acquisition and analyses 
CMR  scans  were  acquired  as  part  of  assessment  of  LV  mass  and  function  and 
analysed as previously described.  In addition, LAV was measured using the bi-plane 
area length method for ellipsoid bodies which was previously described in Chapter 2. 
 
5.2.3  Mitral valve inflow Doppler velocity measurement 
Echocardiography  was  performed  by  an  experienced  echocardiographer  (Tony 
Cunningham, Clinical Research Iniative, Western Infirmary, Glasgow).  Diastolic 
function  was  assessed  using  pulsed-wave  Doppler  (211;212)  from  apical  four 
chamber views to measure the ratio of early (E) to late (A) mitral inflow peak flow 
velocity (E/A ratio). 
 
5.2.4  Follow up 
Patient  follow  up  data  were  collected  from  the  date  of  CMR  scan  to  the  30
th 
September  2009  from  the  electronic  patient  records  of  the  Western  Infirmary, 
Glasgow and Glasgow Royal Infirmary Renal units.  Death from all causes was the 
study end point. 
 
5.2.5  Statistical methods 
Data are described as mean and standard deviation (for normally distributed data) or 
median (interquartile range) for non-normal data. Comparisons were made between 
those patients with high or low LAV by student’s t test (for normal data), Mann-192 
 
Whitney U test (for non-normal data) and Chi squared test or Fisher’s exact test.  
Survival  data  including  survival  time  (mean±  standard  deviation)  are  shown  as 
Kaplan-Meier graphs (with statistical comparison using the log rank test). These data 
were also analysed by Cox multivariate survival analysis to assess the influence of 
multiple clinical and cardiac variables on outcome. This study included transplant 
censored  survival  analyses.  Variables  identified  as  significantly  influential  on 
outcome by univariate analysis were entered into a backward stepwise regression 
model. All analyses were performed using SPSS v15.0 (SPSS Inc, Illinois, USA).  
 
5.3  RESULTS 
 
5.3.1  Patient demographics 
From 312 ESRD patients assessed for renal transplantation with CMR, 201 patients 
with LVH were identified. Median follow up and transplant censored follow up were 
3.62 years (IQR 1.2- 5.2 years) and 1.69 years (IQR 1.0-3.9 years) respectively. The 
mean  age  of  patients  was  51.6  (±  11.8)  years;  72.1  %  were  male.  Seventy  one 
patients received a renal transplant during the period of study.  Table 5.1 shows the 
mode of renal replacement therapy, past medical history and cardiac drug history.   
 
5.3.2  Cardiac parameters 
Examining the whole cohort (Table 5.1), the mean heart rate during MRI was 77 
beats  per  minute  (±26).  Mean  ejection  fraction  was  63.1%  (±14.4),  LVMI  was 
117.3g/m
2  (±31.1),  EDV/BSA  was  86.3  ml/m
2  (±31.4)  and  ESV/BSA  was  34.1 
ml/m
2 (±25.3). Fifty (24.9%) patients had LVSD and 49 (24.4%) had LV dilatation. 
Doppler mitral valve inflow velocity measurement showed a mean peak E wave 193 
 
velocity of 0.74 cm/s (±0.2), mean peak A wave of 0.75 cm/s (±0.2) and E:A ratio of 
1.04 (±0.5). Median LAV/BSA was 30.4 ml/m 
2 (IQR 26.2, 34.1) and distribution of 
corrected LAV measurements is shown in Figure 5.1.   
 
5.3.3  Left atrial volume 
 
5.3.3 (a)  Correlates 
There  were  no  significant  correlations  between  LAV  and  patient  age,  dialysis 
vintage, LV ejection fraction, LVMI, EDV>BSA, mean dose of ultrafiltration during 
haemodialysis, or E:A ratio. 
 
5.3.3 (b)  Comparison dependent on median LAV 
To further identify determinants and consequences of elevated LAV, patients were 
divided  into  high  LAV  (≥  median  LAV/BSA;  n=100)  or  low  LAV  (LAV\BSA 
<median; n=101) groups (Table 5.2). There was a significantly higher mortality in 
the high LAV group (low LAV 18 deaths vs.  high LAV 36  deaths; p<0.01). High 
LAV was significantly associated with treatment with higher doses of ultrafiltration 
during haemodialysis.  Low LAV was significantly associated with male sex.  There 
were no significant differences in age, number of patients transplanted, BSA and 
type of renal replacement therapy or duration between high and low LAV groups. 
Furthermore,  there  were  no  significant  differences  in  number  of  patients  with 
diabetes  mellitus,  smoking  history  and  cardiovascular  (namely  ischaemic  heart 
disease, cerebrovascular and peripheral vascular diseases and chronic heart failure) 
history.  On  comparison  of  cardiac  medications,  there  were  no  other  significant 194 
 
differences between the low and high LAV groups except for statin usage which was 
higher in the high LAV group. 
 
5.3.3 (c)  Predictors of LAV≥ median 
To further identify predictors of elevated  LAV, logistic regression analyses were 
performed with LAV/BSA≥ median as the outcome variable.  Female sex and mean 
dose of ultrafiltration during haemodialysis were significant, independent predictors 
(R
2=0.27) of high LAV on CMR after logistic regression analyses.  195 
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Figure 5.1  Distribution of LAV/BSA in patient cohort 
 
 
 
 
 
 
 
 196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1   Clinical and cardiac information for patients.   
Data are number with percentage in parentheses or mean ± standard deviation. 
Variable 
 
Total 
N=201 
 
Deaths  54  (26.9) 
Transplants  71  (35.3) 
Age (years)  51.6  (±11.8) 
Male (%)  145  (72.1) 
Body Surface Area (m
2)  1.76  (±0.2) 
Left Atrial volume (ml)  56.3  (±9.7) 
Systolic BP (mmHg)  136.9  (±24.6) 
Diastolic BP (mmHg)  80.9  (±12.9) 
RRT  Haemodialysis  108  (53.7) 
  Peritoneal dialysis  52  (25.9) 
  Predialysis  41  (20.4) 
Mean Ultrafiltration (HD only)  2.3  (±0.9) 
Diabetes mellitus  121  (60.2) 
Ischaemic Heart Disease  54  (26.9) 
Heart failure  12  (6.0) 
Cerebrovascular disease  12  (6.0) 
Peripheral vascular disease  16  (8.0) 
Smoking  Never  107  (53.2) 
  Current  54  (26.9) 
  Ex  40  (19.9) 
Epo receptor Agonist  151  (75.1) 
β Adrenoceptor Blocker  87  (43.3) 
Aspirin  83  (41.3) 
Warfarin  7  (3.5) 
ACEI/ARB  54  (26.9) 
Diuretic  60  (29.6) 
Calcium Channel Blocker  58  (28.9) 
α Adrenoceptor Blocker  21  (10.4) 
Statin  83  (41.3) 
Heart Rate   76.8  (±26.1) 
Ejection Fraction (%)  63.1  (±14.4) 
Myocardial mass/BSA   117.3  (±31.1) 
EDV/BSA (ml/ m
2)  86.3  (±31.4) 
ESV/BSA (ml/ m
2)  34.1  (±25.3) 
LVSD on MRI (EF<55%)  50  (24.9) 
LV dilatation  49  (24.4) 
Peak E wave (cm/s)  0.74  (±0.2) 
Peak A wave (cm/s)  0.75  (±0.2) 
E:A ratio  1.04  (±0.4) 
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Variable 
 
Low LAV 
N=101 
High LAV 
N=100 
p 
Deaths  18(17.1)  36 (36)  <0.01 
Transplants  40(39.6)  31(31)  0.20 
Age (years)  50.4(±12.6)  52.8(±10.9)  0.14 
Male (%)  82(81.2)  63(63)  <0.01 
LA volume (ml)  50.4(±6.8)  62.3(±8.4)  <0.01 
Systolic BP (mmHg)  135.6 (±26.2)  138.4 (±22.8)  0.51 
Diastolic BP (mmHg)  82.2 (±13.5)  79.3 (±12.1)  0.20 
RRT  HD  56(55.4)  52(52)   
  PD  23 (22.8)  29(29)  0.58 
  CKD 5  22(21.8)  19(19)   
Mean Ultrafiltration (HD only)  2.2(±0.9)  2.8 (±1.2)  0.01 
Diabetes mellitus  61(60.4)  60 (60)   0.95 
Ischemic Heart Disease  24(23.8)  30(30)   0.41 
Heart failure  6 (5.9)  6(6)   0.96 
Cerebrovascular disease  6(5.9)  6(6)   0.96 
Peripheral vascular disease  6(5.9)  10(10)   0.27 
Smoking  Never  56(55.4)  51 (51)   
  Current  23 (22.8)  31 (31)  0.40 
  Ex  22 (21.8)  18 (18)   
Epo receptor Agonist  72 (71.2)  79 (79)  0.10 
β Adrenoceptor Blocker  45 (44.6)  42 (42)  0.81 
Aspirin  38 (37.6)  45(45)  0.23 
Warfarin  4 (4.0)  3 (3)  0.67 
ACEI/ARB  28 (27.7)  26 (26)  0.85 
Diuretic  31(30.7)  29 (29)  0.87 
Calcium Channel Blocker  33 (32.7)  25(25)  0.26 
α Adrenoceptor Blocker  13(12.9)  8 (8)  0.28 
Statin  35 (34.7)  48 (48)  0.05 
Heart Rate   76.3(±26.1)  77.4(±26.1)   0.31  
Ejection Fraction (%)  63.4(±13.9)   62.8(±15.0)   0.77 
Myocardial mass/BSA   115.7 (±29.8)   119.0 (±32.5)   0.44 
EDV/BSA (ml/ m
2)  86.9 (±30.5)  85.8 (±32.4)  0.81 
ESV/BSA (ml/ m
2)  33.7(±25.0)  34.5 (±25.7)  0.82 
LVSD on MRI (EF<55%)  23 (22.8)  27(27)   0.50  
LV dilatation  23 (22.8)   26(26)   0.59  
Peak E wave (cm/s)  0.77 (±0.2)  0.71 (±0.2)  0.29 
Peak A wave (cm/s)  0.76 (±0.3)  0.72 (±0.2)  0.32 
E:A ratio  1.06 (±0.4)  1.02± (0.4)  0.72 
 
Table 5.2  Comparison between patients according to median LAV/BSA (low < 
median, high ≥ median).  
Data are number with percentage in parentheses or mean ± standard deviation. Tests of 
significance are t-test and Chi-square. 198 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3  Simple  (left)  followed  by  backward  stepwise  (conditional) 
multiple  logistic  regression  analyses  (R
2=0.27)  demonstrating  independent 
predictors of presence LAV≥ median.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate model.   
 
   
  Univariate Analyses  Multivariate analyses 
 
Variable  OR   95% CI  p  OR   95% CI  P 
Mean ultrafiltration(per L)  1.64  1.09,2.46  0.02  1.68  1.09,2.57  0.02 
Male Sex  0.40  0.21,0.75  0.01  0.35  0.19,0.76  0.04 
Age (per year)  1.01  0.99, 1.04  0.14       
Duration on RRT (per year)  1.12  0.88, 1.42  0.34       
RRT  Predialysis  1.00           
  Haemodialysis  1.46  0.64, 3.32  0.37       
  Peritoneal Dialysis  1.08  0.52,3.32  0.84       
LV ejection fraction (per %)  0.98  0.98, 1.02  0.77       
LVMI (per g/m
2)  1.00  0.99, 1.01  0.44       
EDV/BSA (per ml/m
2)  0.99  0.99, 1.01  0.82       
ESV/BSA (per ml/m
2)  1.00  0.99,1.01  0.82       
LVSD  1.25  0.66, 2.38  0.48       
LV Dilation  1.19  0.63, 2.27  0.59       
Diabetes Mellitus  1.16  0.55, 2.45  0.70       
Ischaemic Heart Disease  2.49  0.90, 6.91  0.08       
Chronic Heart Failure  0.94  0.22, 5.15  0.94       
Peripheral Vascular Disease  2.19  0.50, 9.71  0.30       
Hypercholesterolaemia  1.66  0.81,3.41  0.17       
Smoking  Never  1.00           
  Current  2.24  0.99, 5.05  0.05       
  Ex smoker  0.99  0.41,2.41  0.99       
Ischaemic ECG  1.04  0.51,2.14  0.91       
E:A ratio  0.81  0.25, 2.59  0.72       
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5.3.4  Survival Analyses 
There were 54 (26.9%) deaths over a 6.65 year follow up period. Eleven of these 
deaths occurred after renal transplantation.  
 
5.3.4 (a)  Factors associated with death 
Clinical and cardiac factors were compared between patients who were alive and 
dead at the end of the study (Table 5.4).  Renal transplantation and male sex were 
significantly associated with lower mortality.  In addition, LA volumes (corrected 
for BSA) were significantly higher in the group that died compared to those that 
survived.  Similarly, LVSD on CMR and past history of ischaemic heart disease 
were  significantly  associated  with  a  higher  number  of  deaths.      Patients  who 
survived were more likely to have never smoked but less likely to have stopped 
smoking compared to those that died.  When drug usage was compared, patients 
that died were more likely to be receiving aspirin therapy.  
 
5.3.4 (b)  Clinical indicators of outcome 
The  effect  of  left  atrial  and  ventricular  abnormalities  on  patient  survival  was 
investigated  (Figure  5.2).  Left  atrial  volume  above  the  median  was  significantly 
associated with a poorer prognosis (Figure 5.2a, low LAV 5.6±2.1years vs.  high 
LAV  4.7±2.6  years;  p=0.01).  Similarly,  LVSD  (n=50)  was  associated  with  a 
significant reduction in mean survival time (Figure 5.2b, no LVSD (n=151) 5.4±1.8 
years  vs.    LVSD  (n=50)  4.4±3.9years;  p=0.01).    Left  ventricular  dilatation  was 
associated with a non-significant reduction in patient survival (Figure 5.2c, no LV 
dilatation (n=152) 5.2±1.9 years vs.  LV dilatation (n=49) 4.7±3.7 years; p=0.18).  
Past history of ischaemic heart disease conferred a significant reduction in survival 200 
 
(Figure 5.2d, no IHD (n=147) 5.3±2.3 years vs. IHD (n=54) 4.5±2.5years; p=0.02).  
Patient sex did not have a significant impact on patient survival (male 5.3±2.4 years 
vs. female 4.7±2.5 years; p= 0.11; graph not shown). 
 
Given the survival benefits of renal transplantation, a transplant censored survival 
analyses was performed (Figure 5.3). As before, left atrial volume ≥median (Figure 
5.3a)  and  LVSD  (Figure  5.3b)  were  significantly  associated  with  reduction  in 
transplant censored patient survival (low LAV 5.5±2.7years vs.  high LAV 4.5±2.9 
years; p=0.01;  no LVSD 5.3±2.7 years vs. LVSD 4.1±3.2years; p=0.02). Similarly, 
left ventricular dilatation was also associated with a non-significant effect on patient 
prognosis (Figure 5.3c, no LV dilatation 5.2±2.8 years vs.  LV Dilatation 4.3±3.0 
years;  p=0.07).    Ischaemic  heart  disease  did  not  significantly  affect  transplant 
censored survival (Figure 5.3d). 
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Variable 
 
Alive 
N=147 
Dead 
N=54 
p 
       
Transplants  60 (40.8)  11 (20.4)  0.01 
Age (years)  51.1(±11.4)  52.9(±12.8)  0.34 
Male (%)  112 (76.2)  33 (61.1)  0.04 
LA volume (ml/m
2)  29.8 (16.2, 32.5)  33.0 (26.9,42.8)  <0.01 
Systolic BP (mmHg)  137.1 (±26.7)  135.6(±17.3)  0.89 
Diastolic BP (mmHg)  81.0(±13.9)  80.4(±9.5)  0.79 
RRT  HD  79 (53.7)  29 (53.7)  0.17 
  PD  34 (23.1)  33.3 (18)   
  CKD 5  34 (23.1)  7 (13.0)   
Mean Ultrafiltration (HD only)  2.49 (±1.1)  2.6(±1.1)  0.74 
Diabetes mellitus  91 (61.9)  30 (55.6)  0.42 
Ischaemic Heart Disease  32 (21.8)  22(40.7)  0.01 
Heart failure  8 (5.6)  4 (7.4)  0.74 
Cerebrovascular disease  6(4.2)  6 (11.1)  0.07 
Peripheral vascular disease  10 (7.0)  6 (11.1)  0.35 
Smoking  Never  83 (56.5)  24 (44.4)  0.04 
  Current  41 (27.9)  13 (24.1)   
  Ex  23 (15.6)  17 (31.5)   
Epo receptor Agonist  110 (77.5)  41 (80.4)  0.66 
β Adrenoceptor Blocker  65 (45.8)  22 (43.1)  0.75 
Aspirin  55 (38.7)  28 (54.9)  0.05 
ACEI/ARB  39 (27.5)  15 (29.4)  0.79 
Diuretic  43 (30.3)  17 (33.3)  0.69 
Calcium Channel Blocker  44 (31.0)  14 (27.5)  0.64 
α Adrenoceptor Blocker  14 (9.9)  7 (13.7)  0.45 
Statin  58 (40.8)  25 (49.0)  0.31 
Heart Rate   75.2 (±20.1)  77.1(±22.9)  0.88 
Ejection Fraction (%)  63.3(±13.5)  61.6(±16.7)  0.39 
Myocardial mass/BSA   117.3 (±31.3)  117.2(±16.7)  0.97 
EDV/BSA (ml/ m
2)  84.2(±30.6)  92.3(±30.9)  0.11 
ESV/BSA (ml/ m
2)  32.4(±22.8)  38.8(±30.8)  0.12 
LVSD on MRI (EF<55%)  32 (21.8)  18 (33.3)  0.05 
LV dilatation  32 (21.8)  17 (31.5)  0.16 
Peak E wave (cm/s)  0.74 (±0.36)  0.74 (±0.2)  0.97 
Peak A wave (cm/s)  0.74 (±0.2)  0.75 (±0.42)  0.97 
E:A ratio  1.03 (±0.3)  1.06 (±0.4)  0.34 
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Figure 5.2  Kaplan Meier survival  curves according to (a) LAV median, (b) 
LVSD  
(a) 
  
(b) 
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Figure 5.2  Kaplan Meier survival  curves according to, (c) LV dilatation and 
(d) past history of ischaemic heart disease 
(c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(d) 
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Figure 5.3  Kaplan Meier transplant censored survival curves according  to 
(a) LAV median, (b) LVSD 
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Figure 5.3  Kaplan Meier transplant censored survival curves  according  to 
c) LV dilatation and (d) past history of ischaemic heart disease 
(c) 
  (d) 
No LV Dilatation 
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5.3.4 (c)  Predictors of death 
 Table  5.5  shows  univariate  and  multivariate  Cox  survival  analyses  for  patient 
clinical and cardiac characteristics. As before, we initially performed non-transplant 
censored  analyses.  Univariate  analyses  showed  that  LVSD,  LAV/BSA  (absolute 
value or categorised according to the median) and past history of ischaemic heart 
disease were significantly associated with death. Advancing age increased risk of 
death but this did not reach statistical significance. Multivariate analysis (Table 5.5) 
was  performed  only  entering  one  measurement  of  LAV  (LAV  ≥median  or 
LAV/BSA).  Independent  predictors  of  mortality  were  LVSD,  LAV/BSA  or  LAV 
≥median and past history of ischaemic heart disease.  
 
Transplant  censored  Cox  survival  analyses  was  also  performed  (Table  5.6).  The 
factors  significantly  associated  with  death  were  LVSD  and  left  atrial  volume 
(corrected for BSA or categorised according to median LAV).   Older age was also 
associated with death, but did not reach statistical significance (p=0.06).  Independent 
predictors of death were LVSD and LAV/BSA. 207 
 
 
 
 
 
 
 
 
 
 
 
**  Entering LAV/BSA instead of LAV/BSA≥ median 
LV Systolic Dysfunction     HR 1.81   95% CI 1.02-3.23    p=0.04 
LAV/BSA (per ml/m
2)    HR 1.07   95% CI 1.03-1.12    p<0.01 
Ischaemic Heart Disease    HR 2.23   95% CI 1.27-3.92   p<0.01 
 
Table 5.5  Results  of  univariate  and  multivariate  Cox  regression  survival 
analyses of all patients with LVH  
All-cause  mortality  is  the  dependable  variable.  Hazard  ratios  (95%  confidence 
intervals) are shown. 
 
  Univariate Analyses  Multivariate Analyses 
Variable  HR  95% CI  p  HR  95% CI  p 
LV Systolic Dysfunction  1.98  1.12-3.50  0.02  1.86  1.05-3.28  0.03 
LAV/BSA greater/=median  2.09  1.18-3.67  0.01  2.04  1.16-3.62  0.01 
Ischaemic Heart Disease  1.88  1.09-3.23  0.02  2.02  1.13-3.52  0.01 
Mean Dose of Ultrafiltration  1.01  0.63-1.63  0.96       
LAV/BSA (per ml/m
2)**  1.07  1.03-1.12  <0.01  **     
Ejection Fraction (per %)  0.98  0.97-1.00  0.10       
LVMI (per g/m
2)  1.00  0.99-1.01  0.59       
LV Dilatation  1.48  0.83-2.63  0.18       
Systolic BP (per mmHg)  1.00  0.98-1.02  0.94       
Diastolic BP (per mmHg)  0.99  0.95-1.03  0.76       
Age (per year)  1.02  0.99-1.05  0.08       
BSA (m
2)  0.28  0.08-1.10  0.10       
Male Sex  0.64  0.37-1.10  0.11       
Diabetes Mellitus  0.83  0.48-1.41  0.48       
Heart Failure  1.08  0.39-2.98  0.88       
Cerebrovascular Disease  1.97  0.84-4.62  0.12       
Peripheral Vascular Disease  1.22  0.52-2.84  0.65       
Smoking  Never (ref)  1.00           
  Current  1.26  0.64-2.48  0.49       
  Ex smoker  1.91  0.89-3.55  0.08       208 
 
 
 
 
 
 
 
 
 
 
 
**  Entering LAV/BSA instead of LAV/BSA≥ median 
 
LV Systolic Dysfunction     HR 2.00 95% CI 1.06-3.76 p=0.03 
LAV/BSA (per ml/m
2)    HR 1.08 95% CI 1.03-1.18 p<0.01 
 
Table 5.6  Results of univariate and multivariate Cox regression transplant 
censored patient survival analyses of all patients with LVH.  
Results of univariate and multivariate Cox regression survival analyses of all patients 
with  LVH;  all-cause  mortality  is  the  dependable  variable.  Hazard  ratios  (95% 
confidence intervals) are shown 
 
  Univariate Analyses  Multivariate Analyses 
Variable  HR  95% CI  p  HR  95% CI  p 
LV Systolic Dysfunction  2.12  1.13-3.97  0.02  1.90  1.01-3.58  0.05 
LAV/BSA  greater /= median  2.24  1.16-4.30  0.01  2.21  1.15-4.27  0.02 
LAV/BSA (per ml/m
2)**  1.08  1.03-1.13  <0.01  **     
Mean Dose of Ultrafiltration  1.27  0.72-2.23  0.41       
Ejection Fraction (per %)  0.98  0.96-1.00  0.11       
Systolic BP (per mmHg)  1.01  0.99-1.04  0.28       
Diastolic BP (per mmHg)  0.98  0.93-1.02  0.27       
LVMI (per g/m
2)  1.00  0.99-1.01  0.63       
LV Dilatation  1.77  0.95-3.32  0.08       
Age (per year)  1.02  0.99-1.05  0.06       
BSA (m
2)  0.25  0.06-1.21  0.12       
Male Sex  1.30  0.67-2.44  0.46       
Diabetes Mellitus  0.91  0.50-1.70  0.77       
Ischaemic Heart Disease  1.51  0.77-2.97  0.23       
Heart Failure  1.50  0.54-4.27  0.43       
Cerebrovascular Disease  2.29  0.90-5.86  0.12       
Peripheral Vascular Disease  2.04  0.86-4.84  0.11       
Smoking  Never (ref)  1.00           
  Current  1.49  0.72-3.08  0.28       
  Ex smoker  1.84  0.89-3.79  0.09       209 
 
5.4  DISCUSSION 
As has been stated before, LVH develops early in chronic kidney disease, with a 
roughly reciprocal relationship existing between renal function and LV mass (173).  
Most  echocardiography  studies  indicate  LVH  as  the  commonest  abnormality  of 
uraemic  cardiomyopathy,  being  prevalent  in  70-80%  of  patients  who  commence 
dialysis. This figure may  be an overestimate due to inaccurate measurement and 
calculation  of  LV  mass  using  echocardiography.  Nevertheless,  CMR  has  also 
estimated LVH to be present in approximately 60-67% of ESRD patients confirming 
these early echocardiography findings (142).  In addition, presence and progression 
of LVH are associated with poorer outcome and is an independent risk factor for 
cardiac  tachyarrhythmias,  sudden  cardiac  death  and  symptomatic  heart  failure  in 
ESRD patients (89).   
 
Whether regression of LVH in ESRD is possible, as has been demonstrated in the 
general  population,  remains  controversial  (213).    By  the  identification  and 
intervention  of  specific  variables  (such  as  intravascular  volume,  hypertension, 
calcium  and/or  phosphate),  a  number  of  small  studies  have  demonstrated  a 
significant  reduction  in  LVMI.    However,  application  of  these  data  into  clinical 
practice is limited due to lack of adequate controls and randomisation, small sample 
sizes  and  use  of  echocardiography.    A  greater  body  of  evidence  demonstrates 
persistence or  worsening of  LVH despite more intensive dialysis or better blood 
pressure and fluid control (214). 
 
Thus, to improve cardiovascular survival in ESRD patients with LVH, alternative 
targets have been sought which may be amenable to intervention.  In this way, well 210 
 
controlled, adequately powered and randomised studies could be performed to better 
tailor therapeutic strategies. 
 
Bearing  this  in  mind,  the  following  study  was  performed  using  CMR  to  assess 
cardiac morphology and performance.  To identify independent prognostic factors of 
ESRD  patients  with  LVH,  clinical  history  and  other  cardiac  abnormalities  were 
included in the survival analyses.  Ultimately, the strength of this study lies with the 
use  of  CMR  to  most  accurately  identify  a  cohort  of  patients  with  LVH  for 
subsequent  analyses.    Left  atrial  volume  was  also  measured  and  included  in  the 
prognostic modelling.   
 
5.4.1  Left atrial volume   
The left atrium performs three functions during the cardiac cycle (209) and its size 
changes accordingly: 
1.  Isovolumetric contraction and LV systole: receive and store blood from the 
pulmonary circulation. 
2.  Early Diastole: transfer blood into the left ventricle after mitral valve opening 
via a pressure gradient (this is represented by the “E wave” on mitral valve 
colour Doppler. 
3.  Late Diastole: atrial contraction augments LV stroke volume by 20% (this is 
represented by the “A wave” in mitral valve colour Doppler. 
 
5.4.1(a)  Measurement of LA volume 
In practice and in this study, maximum LAV (just before mitral valve opening) is 
routinely measured.  This can accurately and reproducibly be performed using 2D 211 
 
echocardiography and accordingly, the American Society of Echocardiography has 
recommended  quantification  of  LA  volume  using  biplane  2D  echocardiography 
using the area-length method.  Similarly, CMR accurately estimates of LA volume 
using similar cine images from vertical and horizontal log axis views (156;210). 
 
5.4.1(b)  Determinants of LA size 
Body size is a major determinant of LA volume, but a correction can be performed 
using body surface area.  Gender differences in LA volume are usually accounted for 
by variation in body size. Furthermore, age related LA enlargement and impaired 
diastolic conduit function have been reported (209).  As in ventricular remodelling, 
the atria enlarge in response to excessive pressure and volume: 
 
·  Pressure overload: LA enlargement has been demonstrated in patients with mitral 
valve stenosis and LV dysfunction (i.e. increased LA afterload).   
·  Volume overload: conditions with chronic volume overload, (valvular regurgitation, 
arterio-venous fistulae) and high cardiac output states (anaemia) are also associated 
with LA enlargement. 
 
However, in the absence of an atrial or valvular disorder, LA volume usually reflects 
ventricular filling pressures.  As ventricular relaxation and compliance are reduced 
during diastole,  LA pressure rises to maintain LV filling and is accompanied by 
increased atrial  wall tension, chamber dilatation and myocyte stretch.   Thus,  LA 
volume may be representative of the magnitude of LV diastolic dysfunction (see 
below).    The  value  of  LAV  has  been  shown  to  represent  the  average  effects  of 212 
 
chronic LV diastolic dysfunction (and hence haemodynamic control) rather than the 
immediate effect at the time of the study (215). 
 
In this study, elevated left atrial volume (above median) was less common in male 
patients.  Furthermore, female sex was an independent predictor of high LAV (≥ 
median) on CMR however neither sex nor BSA had any effect on survival in these 
analyses.  Previous studies have shown removal of sex related difference in LAV 
when  corrected  for  body  size  (see  above).  These  previous  studies  had  a  higher 
proportion of females in the study cohort (between 50-67%) compared to this study 
(27.9%) which may have affected this analysis.  
 
There was no significant difference in cardiovascular disease history between both 
groups (above or below median LAV) and heart rate, LV ejection fraction, LVMI 
and  LV  chamber  size  (at  end  diastole  and  systole)  were  similar  in  both  groups.  
Similarly, E:A ratio was not significantly different between groups. This suggests 
that  LA  size  was  not  a  marker  of  delayed  diastolic  filling  time  or  impaired  LV 
systolic  emptying.    However,  mean  dose  of  ultrafiltration  was  significantly 
associated  with  high  LAV  and  a  significant  predictor  of  LAV  in  haemodialysis 
patients. As discussed before, mean dose of ultrafiltration is a crude marker of fluid 
overload and patients with large interdialytic fluid gains most likely receive higher 
doses.  Unfortunately,  no  other  assessments  of  fluid  status,  such  as  radionuclide 
tagging or bio-impedance analyses, were available for this cohort especially those 
patients  not  receiving  haemodialysis.    However,  these  findings  confirm  previous 
studies, in the general population, that demonstrate a significant relationship between 
elevated LAV and chronic fluid overload. 213 
 
5.4.2  Left ventricular diastolic dysfunction in ESRD patients 
LV diastolic dysfunction can be defined as an abnormality of diastolic relaxation, 
filling or compliance that impairs ventricular diastolic filling.   Diastolic function can 
be assessed using Doppler echocardiography to measure rate of LV pressure decline 
(isovolumetric relaxation time: IVRT) or rate and extent of LV filling (commonly 
using mitral inflow early (E) and late (A) ratios or more recently tissue Doppler 
myocardial velocity, strain and strain rate.).  More invasive studies using cardiac 
catheterisation and angiography can be used to obtain cardiac cycle pressure-volume 
loops. 
 
Expanded intravascular volume and LV hypertrophy/interstitial fibrosis are common 
in ESRD patients and predispose to development of LV diastolic dysfunction.  Most 
studies  have  used  Doppler  echocardiography  to  quantify  diastolic  dysfunction  in 
ESRD patients: 
 
·  Josephs  et  al  demonstrated  significantly  impaired  early  diastolic  filling  in  100 
haemodialysis patients using Doppler E:A ratio as a marker of diastolic function.  In 
particular, older (>60 years) haemodialysis patients were at higher risk of diastolic 
dysfunction  and  diastolic  function  was  significantly  correlated  with  dialysis 
adequacy and higher blood pressure (216). 
 
·  Similarly in 25 CAPD patients, Huting et al demonstrated impaired LV diastolic 
dysfunction especially in patients with more severe LVH, using trans-mitral inflow 
velocities and colour tissue Doppler measurements (217). 214 
 
·  Using more invasive cardiac pressure measurements, Wizeman et al demonstrated 
elevated LV end diastolic pressure in 29 haemodialysis patient compared to healthy 
controls.  Most patients had preserved systolic function and the authors concluded 
that reduced LV compliance and subsequent impaired diastolic filling predisposed 
patients to symptoms of congestive cardiac disease (218). 
 
The data presented in this chapter do not support a role of diastolic dysfunction in 
LA enlargement within this patient group since there were no significant difference 
in E:A ratios between high and low LAV groups.   
 
5.4.3  Left atrial volume and outcome 
A number of studies in the general population have demonstrated the predictive role 
of elevated LA volume for adverse cardiovascular outcome.  Of these, two of the 
largest are described below: 
·  Data from the Cardiovascular Health Study looking at M-Mode echocardiographic 
measurements and outcome in 5888 patients demonstrated higher left atrial size as an 
independent  predictor  of  all  cause  mortality,  stroke  and  coronary  artery  disease 
(219).   
·  In  a  sub  analyses  from  the  Framingham  Heart  Study  (n=3099),  Gajewski  et  al 
demonstrated that LA enlargement predicted higher rates of stroke and death in men, 
however the effect was attenuated when corrected for LV mass (220) .   
 
In ESRD patients, two studies have demonstrated a prognostic role of LAV: 
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·  Tripepi et al used echocardiography to measure cardiac parameters and related them 
to  patient  outcome.    LAV  was  predicted  by  LVMI,  LVEF,  E:A  ratio  and 
antihypertensive  therapy.    In  addition,  elevated  LAV  corrected  for  height 
independently  predicted  death  in  this  patient  population  (207).    There  was  no 
difference in the results presented in this chapter when LAV was corrected for height 
as opposed to BSA. 
·  In  a  subsequent  study  from  the  same  group,  patients  underwent  repeat 
echocardiography.  Rise in LAV/height between scans was predictive of fatal and 
non-fatal cardiac events compared to patients whose LAV/height remained the same.  
Similarly, a 1ml/m
2 increase in LAV/height was associated with a 12% increase in 
relative risk of a cardiovascular event (221). 
 
5.4.4  Prognostic findings 
From  these  data  female  sex,  higher  LAV  corrected  for  BSA,  past  history  of 
ischaemic heart disease, and LVSD on CMR were significantly associated with death 
during the follow up period.  Aspirin use was higher in those patients who died, 
presumably due to the higher proportion of patients with a cardiac history in this 
patient group.   
 
In the survival analysis, elevated LAV and LVSD were significantly associated with 
poorer  survival  (transplant  and  non  transplant  censored;  Figure  5.2  and  5.3).  
Multivariate analysis showed that elevated LAV/BSA (represented as an absolute 
value or divided according to the median) and LVSD independently predicted death 
(even when censored for renal transplantation) in ESRD patients with LVH. Past 
history of ischaemic heart disease was a significant, independent predictor of non 216 
 
transplant  censored  mortality  and  significantly  reduced  non  transplant  censored 
survival. Presence of LV dilatation did not have a statistically significant effect on 
survival.  These data confirm the findings of previous studies investigating LAV and 
survival.  However this study differs in two aspects: 
 
·  Previously, all ESRD patients were included in analyses.  This study only includes 
patients with pre-existing features of LVH.   
·  This cohort has been examined using CMR to provide an accurate assessment of LV 
mass whereas the previous studies have used echocardiography.  One should note, 
however, that there is no difference in assessment of LAV between both methods. 
 
5.4.4 (a)  Left atrial volume and survival 
In the present study, LAV was not significantly correlated with LV mass, suggesting 
that elevated LA volume is not solely due to impaired atrial emptying into a large, 
poorly compliant LV.  LAV was not associated with diastolic dysfunction in our 
population as measured by E:A ratio, however, measurement of other markers of LV 
diastolic dysfunction, such as pulmonary venous flow velocity or LV tissue Doppler 
would have been useful to confirm these mitral valve studies.  In addition, E:A ratio 
is a limited marker for diastolic function at greater LA pressures due to a tendency 
back to normal values (also known as “pseudonormalisation”). 
 
Thus, based on these results in ESRD patients with LVH, left atrial enlargement is 
largely  caused  by  chronic  fluid  overload,  and  the  associated  expansion  in 
intravascular  volume.    This  hypothesis  is  supported  by  the  finding  that  dose  of 
ultrafiltration (acting as a crude marker of fluid retention) independently predicted 217 
 
LAV  in  haemodialysis  patients.    Reduction  of  LA  volume  has  been  achieved  in 
patients with mitral valve disease and atrial fibrillation (222;223); however its effect 
on overall prognosis remains unknown. Whether tight control of fluid-volume status 
in patients with ESRD patients similarly reduces LA volume and mortality requires 
controlled clinical trials in the future. 
 
5.4.4.(b)  Left ventricular systolic dysfunction and survival   
Left ventricular systolic dysfunction has been associated with (often asymptomatic) 
ischaemic heart disease and, in turn, with poorer survival (139). This is presumably 
due to occlusive large vessel disease and inadequate growth of penetrating epicardial 
vessels  in  response  to  cardiac  myocyte  hypertrophy.  Ventricular  action  potential 
propagation and recovery are impaired in the presence of LVH and LVSD increasing 
the risk of ventricular re-entrant tachyarrhythmias (51;224). The potential benefits of 
improving  systolic  function  on  prognosis  of  patients  with  ESRD,  has  been 
demonstrated  in  a  number  of  small  studies  using  pharmacological  approaches  or 
modification of dialysis regimens (20;124).  However, these interventions are not 
commonly used in ESRD patients due to poor tolerance of patients or the opinions of 
the treating nephrologist.  Hopefully, as more robust data becomes available medical 
practice may change in ESRD patients with myocardial dysfunction. 
 
5.4.4 (c)  Ischaemic heart disease and survival 
As has been shown before, a clinical history of CV disease also reduced survival, 
since  non-transplant  censored  multivariate  Cox  survival  analyses  identified  past 
history of ischaemic heart disease as a significant, independent predictor of death.  
Clinical  history  of  ischaemic  heart  disease  did  not,  however,  significantly,  affect 218 
 
transplant  censored  survival.    These  differences  between  transplant  and  non- 
transplant censored survival can be explained by the disproportionately high number 
of  patients  with  ischaemic  heart  disease  who  subsequently  underwent  renal 
transplantation  (IHD  53.7%  vs.  No  IHD  28.6%)  in  this  cohort.    As  a  result  of 
transplant censoring, there was not a statistically significant difference in survival 
despite Kaplan-Meier analyses demonstrated separating survival curves (Figure 5.2).  
This is presumably due to fewer patients in the IHD group.  
 
5.4.5  Limitations 
As  before,  patients  recruited  to  this  study  were  being  assessed  for  renal 
transplantation and may not be representative of all ESRD subjects.  However, since 
these patients are considered healthy enough to be considered for transplantation, it 
is likely that these results would be relevant to other patients with more significant 
co-morbidities.  In addition, limited information was obtained regarding ventricular 
diastolic function in this cohort and hopefully, as more detailed methods (e.g. tissue 
Doppler) are utilised, these data will become available. 
 
5.5  CONCLUSIONS 
In conclusion, in ESRD patients with LVH, elevated LAV and presence of LVSD 
are  independent  predictors  of  death  and  may  provide  novel  factors  that  may  be 
amenable to modification to improve cardiovascular prognosis.  Elevated LAV is 
due, in part, to fluid overload which may be a useful target in the future. 
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Chapter 6 
 
A study of Microvolt T Wave Alternans in ESRD patients 220 
 
6.1  INTRODUCTION 
As has been discussed in Chapter 1, patients with end stage renal disease (ESRD), 
including those receiving or close to requiring dialysis, have a significantly increased 
risk of premature cardiovascular death.  In contrast to the general population, where 
myocardial ischaemia and infarction (MI) are the leading cause of cardiovascular 
death, ESRD patients are significantly more likely to develop cardiac (commonly 
ventricular) tachyarrhythmias and sudden cardiac death (SCD).  Factors associated 
with SCD include myocardial structural abnormalities of uraemic cardiomyopathy 
and accelerated coronary artery disease.  In addition, factors such as large electrolyte 
fluctuations,  bone  mineral  disease,  uraemia,  autonomic  dysfunction  and 
inflammation  have  also  been  implicated  in  the  development  of  SCD.  However, 
despite elucidation of potential risk factors for ventricular tachyarrhythmias (VTA), 
identification of high risk ESRD patients and primary prevention of SCD has proven 
difficult.  Furthermore,  treatment  of  traditional  cardiovascular  risk  factors  (eg 
dyslipidemia) has shown little survival benefit (26;81). 
 
A similar problem exists in patients with symptomatic heart failure and impaired LV 
systolic  function.    Results  from  MADIT  II  and  SCD-  Heart  Failure  Trial  show 
significant survival benefit using implantable cardioverter defibrillators (ICD) for 
primary  prevention  of  SCD  in  patients  with  ischaemic  and  non-ischaemic 
cardiomyopathy (82; 83). However many of these ICDs remain unused and current 
estimates  suggest  that  to  prevent  one  SCD,  18  devices  require  to  be  inserted.  
Additional electrophysiological tests have been evaluated to better identify higher 
risk patients who would benefit from ICD insertion. 
 221 
 
Microvolt  T  Wave  Alternans  (MTWA;  HearTwave  II  system,  Cambridge  Heart, 
Bedford, Massachusetts) is a novel, non-invasive technique of assessing VTA risk in 
patients.  The  principles  of  MTWA  have  been  discussed  in  Chapter  1.    MTWA 
measures  beat-to-beat  variations  in  standard  12-lead  ECG  T-wave  morphology, 
indicating unstable ventricular repolarisation. Several large prospective trials have 
demonstrated that MTWA analysis is superior or comparable to other more invasive 
electrophysiological methods of independently predicting (negatively and positively) 
patients at risk of VTA or SCD.  These studies included patients with ischaemic 
heart disease, biventricular cardiac failure and implantable cardiac defibrillators.  In 
patients with symptomatic ischaemic cardiomyopathy, the prevalence of abnormal 
MTWA result varies between 64 and 72% (105;161;225).  Furthermore, in diabetic 
patients with no symptoms of cardiovascular disease, abnormal result has been found 
in 25.4% of patients which is significantly higher when compared to normal healthy 
controls (5.7% ) (111;226).   No such studies have been performed in ESRD patients. 
 
In  this  study,  two  hundred  patients  with  ESRD  and  30  control  patients  with 
hypertensive LVH were assessed using MTWA.  The aims of this study were to: 
·  Determine prevalence of abnormal MTWA in ESRD patients compared to patients 
with hypertensive LVH and normal renal function. 
·  Determine associations between features of uraemic cardiomyopathy and MTWA 
result. 222 
 
6.2  METHODS 
 
6.2.1  Patients 
ESRD  patients  already  established  on  or  within  6  months  of  requiring  renal 
replacement therapy (RRT) were consecutively assessed.  In addition, hypertensive 
patients  with  evidence  of  LVH  on  echocardiography  or  ECG  and  normal  renal 
function (measured within 6 months of recruitment) were also entered into the study 
as controls (termed LVH patients). 
 
 All  patients  underwent  cardiovascular  risk  factor  assessment  including  history, 
clinical examination, ECG as well as routine haematological, biochemical and lipid 
profile.  CMR was performed to measure left ventricular (LV) mass and function 
followed by MTWA testing.  Patients with contraindication to CMR (e.g. presence 
of  permanent  pacemaker  or  ferromagnetic  implants,  severe  claustrophobia, 
pregnancy)  were  not  entered  into  the  study.    Furthermore,  patients  with  atrial 
fibrillation were excluded as irregular R-R intervals confound frequency  analysis 
during MTWA testing. 
 
6.2.2  CMR acquisition and analyses 
CMR scans were acquired for assessment of LV mass and function and analysed as 
described  in  Chapter  2.    Patients  were  classified  as  having  LVH,  LVSD  or  LV 
dilatation based on previously described normal values. 
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6.2.3  MTWA testing 
Preparation,  acquisition,  analyses  and  classification  of  MTWA  testing  have  been 
described in detail in Chapter 2.  Based on previously published studies, we further 
classified  results  as  “abnormal”  for  positive  and  indeterminate  test  results  and 
negative  tests  as  “negative”.    If  initially  an  indeterminate  result  was  obtained, 
immediate  retesting  was  attempted.  The  reason  for  indeterminate  test  was  also 
provided by the analysis software (227).  
 
6.2.4  Statistical analyses 
Statistical  analyses  were  performed  using  SPSS  version  15.0  (SPSS  Inc.  Illinois, 
USA). Data are described as mean±standard deviation.  Data were compared by chi-
squared or Fisher’s test for categorical data and paired t-test for continuous data. 
Simple  followed  by  multivariate  logistic  regression  analyses  were  performed  to 
identify  individual  predictors  of  abnormal  MTWA  result.    BNP  underwent 
logarithmic transformation to allow parametric statistical comparison. Survival data 
including  survival  time  (mean±  standard  deviation)  are  shown  as  Kaplan-Meier 
graphs (with statistical comparison using the log rank test). 
 
6.3  RESULTS 
 
6.3.1  Patient demographics 
Two hundred ESRD patients and 30 LVH patients were assessed.   Table 6.1 shows 
the clinical and cardiac data for ESRD and LVH patients.   
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6.3.2  Comparison between ESRD and LVH patients 
There  were  no  statistically  significant  differences  between  age,  sex,  BMI,  and 
systolic blood pressures between each group.  Interestingly, diastolic blood pressure 
was  significantly  higher  in  the  LVH  group  compared  the  ESRD  group.    As  one 
would  expect,  there  was  a  significantly  higher  frequency  of  traditional 
cardiovascular risk factors in ESRD patients compared to patients with LVH.  This 
difference is also reflected in the medications these patients were taking.   
 
LV systolic function was preserved in both groups.  Cardiac data demonstrated a 
lower ejection fraction and higher LVMI and LV chamber size in the ESRD group 
compared  to  LVH  patients,  although  these  did  not  reach  statistical  significance.  
Presence of LVH was high in both groups and despite LVH patients being recruited 
based on previous echocardiography and ECG, only 18 (60%) had LVH on CMR.  
LVSD and LV dilatation was also more common in ESRD patients, but similarly this 
did not reach statistical significance. 
 
Microvolt  T  wave  alternans  result  was  negative  for  85  (42.5%),  positive  for  44 
(22%) and indeterminate in 71 (35.5%) in ESRD patients.  In the LVH group of 
patients, MTWA was negative in 22 (73.3%), positive in 3 (10%) and indeterminate 
in 5 (16.7%) of patients (Figure 6.1).  On comparison, abnormal MTWA result was 
significantly more common in ESRD compared to LVH patients (ESRD 57.5% vs. 
LVH 26.7%; p=0.002; Table 6.1). 
 
Reasons for indeterminate tests in ESRD patients (Figure 6.2) were failure to achieve 
heart rate between 105 and 110bpm for ≥1min (50.7% of all indeterminate results), 225 
 
excessive ventricular ectopy during exercise (23.9%), a noisy recording (21.1%) and 
rapid rise through target heart rate of 105-110bpm or unsustained MTWA (≤1 min; 
4.2%).  In LVH patients, 5 indeterminate tests were due to failure to achieve heart 
rate rise (2 patients) and to noisy recording (3 patients). 
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Table 6.1  Clinical, drug and cardiac data for patients.   
Comparisons  between  ESRD  and  LVH  patients  are  shown..  Data  are  number  with 
percentage in parentheses or mean ± standard deviation except for RRT time where median 
and interquartile range are shown .   
 
Variable 
 
ESRD 
N=200 
LVH Only 
N=30 
 
p 
MTWA abnormal   115(57.5)  8 (26.7)  <0.01 
Age (years)  56.3(±12.7)  53.1 (±10.7)  0.21 
Male (%)  142 (71)  25 (83.3)  0.16 
BMI (kg/m
2)  26.5(4.7)  27.1(4.9)  0.19 
Systolic BP (mmHg)  146 (±24.1)  152 (±22.5)  0.17 
Diastolic BP (mmHg)  82 (±14.2)  89(±11.1)  0.01 
Renal Replacement Therapy       
  HD  118 (59.0)  -   
  PD  17 (8.5)  -   
  CKD 5  65 (32.5)  -   
RRT Time  1.14 (2.1)  -   
Primary Renal Disease       
Diabetic Nephropathy  46 (23.0)  -   
APCKD  20 (10.0)  -   
Glomerulonephritis  42 (21.0)  -   
Renovascular Disease  16 (8.0)  -   
Chronic Pyelonephritis  20(10.0)  -   
Other  26 (13.0)  -   
Unknown  30 (15.0)  -   
Clinical History       
Diabetes mellitus  54 (27.0)  0  <0.01 
Ischemic Heart Disease  49 (24.5)  2(9.5)  <0.01 
Heart failure  15 (7.5)  1 (3.3)  0.70 
Cerebrovascular disease  26 (13)  1(3.3)  0.22 
Peripheral vascular disease  35 (17.5)  0  0.01 
Dyslipidaemia  117 (58.5)  10 (33.3)  0.01 
Smoking  Never  89 (44.5)  19 (61.9)  0.08 
  Current  54 (27.0)  3 (10)   
  Ex  57 (28.5)  8 (26.7)   
       
Drug History       
Epo receptor Agonist  162 (81.0)  0  <0.01 
β Adrenoceptor Blocker  92 (46.0)  10 (33.3)  0.15 
Aspirin  102 (51.0)  3 (10)  0.01 
Warfarin  13 (6.5)  0  0.23 
Clopidogrel  17 (8.5)  0  0.16 
ACEI/ARB  91 (45.5)  12 (40.0)  0.51 
Diuretic  58 (29)  6 (20.0)  0.54 
Nitrate  15 (7.5)  8(26.7)  <0.01 
Calcium Channel Blocker  76 (38.0)  8(26.7)  0.19 
α Adrenoceptor Blocker  24 (12.0)  1 (3.3)  0.09 
Statin  125 (62.5)  9(30.0)  <0.01 
CMR Results       
Ejection Fraction (%)  61.9 (±15.3)  65.8(±11.5)  0.19 
Myocardial mass/BSA  93.3 (±38.2)  82.0(±32.9)  0.13 
EDV/BSA (ml/ m
2)  68.9(±35.6)  67.1(±13.7)  0.79 
ESV/BSA (ml/ m
2)  28.7(±26.2)  23.5(±12.4)  0.08 
LVH on MRI  124 (62.0)  18 (60.0)  0.87 
LVSD on MRI (EF<55%)  45 (22.5)  4 (13.8)  0.34 
LV dilation  19 (9.5)  2 (6.9)  0.65 
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Figure 6.1  Comparison of MTWA result of ESRD and LVH patients. Data 
labels are percentage in each patient group. 228 
 
 
 
 
Figure 6.2  Cause  of  Indeterminate  MTWA  result  in  ESRD  patients  only.  
HR= heart rate, VE= ventricular ectopics 
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6.3.3  Factors associated with abnormal MTWA result 
In the ESRD group, abnormal MTWA (Table 6.2) result was significantly associated 
with older age and receiving haemodialysis as RRT.  Furthermore, those patients 
with current or past cardiovascular morbidity were more likely to have an abnormal 
MTWA result. There was a significant association between an abnormal result and 
diabetic nephropathy or renovascular disease as primary renal disorder, past medical 
history of diabetes mellitus, ischaemic heart, cerebrovascular or peripheral vascular 
disease, and dyslipidaemia. In addition, abnormal result was significantly associated 
with statin therapy. 
 
To  assess  the  effect  of  blood  parameters  on  MTWA  result,  venepuncture  was 
performed  10-  15  minutes  before  testing  (Table  6.2).    There  was  no  significant 
difference  between  measured  serum  cations  (namely  potassium  and  calcium), 
haemoglobin,  fibrinogen,  inorganic  phosphate,  PTH,  inflammatory  markers,  and 
troponin  I  between  both  groups.  Random  plasma  glucose  and  glycosylated 
haemoglobin were significantly higher in patients with an abnormal MTWA result, 
presumably as a result of higher proportion of diabetic patients in this group.   Brain 
natriuretic  peptide  was  also  significantly  higher  in  the  abnormal  MTWA  group.  
Total  plasma  cholesterol  was  significantly  lower  in  patients  with  an  abnormal 
MTWA result.   
 
The associations between LV structural abnormalities of uraemic cardiomyopathy 
and  MTWA  result  were  assessed  (Table  6.3).    Abnormal  MTWA  result  was 
significantly associated with abnormalities of uraemic cardiomyopathy: higher LV 
mass,  lower  ejection  fraction  and  higher  EDV/BSA  and  ESV/BSA.    In  addition, 230 
 
there were significantly higher proportions of patients with LVH and LV dilatation 
in the abnormal MTWA group.   More patients had LVSD in the abnormal MTWA 
group but this did not achieve sufficient statistical significance (p=0.08). 
 
6.3.4  Variables associated with abnormal MTWA result in ESRD patients 
Logistic regression analyses were performed to determine variables independently 
associated with abnormal MTWA result in ESRD patients only (Table 6.4).  In our 
model  (R
2=0.40),  entering  only  factors  found  to  be  significant  after  univariate 
analyses, increasing age and past clinical history of coronary, peripheral vascular and 
cerebrovascular  diseases  were  independently  associated  with  abnormal  MTWA 
result.    In  addition,  increasing  LVMI  (or  presence  of  LVH)  was  independently 
associated with abnormal MTWA result.  Presence of LV dilatation was associated 
with abnormal result but did not achieve statistical significance. 
 
6.3.5  Effect of abnormal MTWA result on patient outcome 
There were 16 deaths during a median follow up of 1.9 years (IQR 1.5, 2.6 years).  
Abnormal  MTWA  was  associated  with  a  higher  number  of  deaths  compared  to 
negative MTWA result (12 deaths vs. 4 deaths; p=0.15) although this did not reach 
statistical significance.  Furthermore, abnormal MTWA result was associated with a 
trend toward reduced survival compared to negative MTWA (Figure 6.3). 231 
 
 
 
 
Table 6.2 Comparisons of clinical and blood results between patients are shown 
based on MTWA result.  
Data are number with percentage in parentheses and  mean ± standard deviation except for ESR, CRP, 
PTH and BNP where median and interquartile range are shown 
Variable 
 
MTWA  
Negative 
N=85 (42.5) 
MTWA 
Abnormal 
N=115 (57.5) 
p 
Age (years)  52.4(12.8)  59.1(12.0)  <0.01 
Male (%)  59 (69.4)  83(72.2)  0.67 
BMI (kg/m
2)  26.9 (4.8)  26.2(4.6)  0.29 
BSA (m
2)  1.89(0.2)  1.87 (0.2)  0.45 
Systolic BP (mmHg)  144 (23.2)  147 (24.8)  0.29 
Diastolic BP (mmHg)  83(12.9)  82 (15.2)  0.52 
Renal Replacement Therapy  1.17 (1.7)  1.1 (2.4)  0.67 
  HD  41 (48.2)  77( 67.0)  <0.01 
  PD  11 (12.9)  6 (5.2)  0.09 
  Predialysis  33 (38.8)  32 (27.8)  0.10 
RRT Time (years)  1.2 (0.6,2,4)  1.2 (0.6, 2.4)  0.97 
Primary Renal Disease       
Diabetic Nephropathy  13 (15.3)  33 (28.7)  0.02 
APCKD  12 (14.1)  8(7.0)  0.10 
Glomerulonephritis  23 (27.1)  19 (16.5)  0.07 
Renovascular Disease  3(3.5)  13 (11.3)  0.05 
Chronic Pyelonephritis  11 (12.9)  9 (7.8)  0.23 
Other  9 (10.6)  17 (14.8)  0.38 
Unknown  14 (16.5)  16 (13.9)  0.62 
Diabetes mellitus  16 (18.8)  38 (33.0)  0.03 
Ischaemic Heart Disease  8 (9.4)  41 (35.7)  <0.01 
Hypertension  73 (85.9)  105 (91.3)  0.23 
Heart failure  4 (4.7)  11 (9.6)   
Cerebrovascular disease  3 (3.5)  23 (20)  <0.01 
Peripheral vascular disease  4 (4.7)  31 (27)  <0.01 
Dyslipidaemia  42 (49.4)  75(65.2)  0.03 
Smoking  Never  45 (52.9)  44 (38.3)  0.12 
  Current  20 (23.5)  34 (29.6)   
  Ex  20 (23.5)  37 (32.2)   
Epo receptor Agonist  64 (75.3)  98 (85.2)  0.08 
β Adrenoceptor Blocker  26 (30.6)  46(40)  0.10 
Aspirin  41 (48.2)  61 (53.0)  0.50 
ACEI/ARB  41 (47.1)  51 (44.3)  0.25 
Diuretic  29 (34.1)  29 (25.2)  0.17 
Nitrate  3 (3.5)  12 (10.4)  0.07 
Calcium Channel Blocker  28 (32.9)  48 (41.7)  0.21 
α Adrenoceptor Blocker  12 (14.1)  12 (10.4)  0.43 
Statin  46 (54.1)  79 (68.7)  0.04 
Haemoglobin (g/dL)  11.4 (1.8)  11.4 (1.8)  0.96 
Fibrinogen (g/L)  4.34 (1.1)  4.25 (1.0)  0.58 
ESR (mm/h)  28 (9.5,49.0)  31(14.5, 44.0)  0.74 
CRP (mg/L)  4.9(2.0, 9.9)  5.3 (3, 14)  0.08 
Adjusted Ca
2+(mmol/L)  2.39 (0.4)  2.40 (0.2)  0.87 
PO4 (mmol/L)  1.69 (0.5)  1.56 (0.5)  0.08 
PTH (pmol/L)  27.1(14.7, 50.7)  28.6(15.2,46.4)  0.99 
Glucose (mmol/L)  5.3 (2.4)  5.9 (2.7)  0.02 
HbA1c (%)  5.2 (1.0)  5.4 (1.5)  0.03 
Potassium (mmol/L)  4.7(0.7)  4.7 (0.8)  0.76 
BNP (ng/L)  174(45, 340)  335 (129,1340)  <0.01 
LogBNP  2.21(±0.6)  2.61(0.7)  <0.01 
Cholesterol (mmol/L)  4.61 (1.3)  4.23 (1.1)  0.04 
Triglyceride (mmol/L)  1.7 (0.9)  1.6 (0.9)  0.46 
HDL- Chol (mmol/L)  1.4 (0.8)  1.4(0.8)  0.28 
LDL- Chol (mmol/L)  2.4(1.3)  2.2 (1.3)  0.14 
Troponin I ( g/L)  0.01 (0.05)  0.03( 0.07)  0.23 
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Variable 
 
MTWA  
Negative 
N=85 (42.5) 
 
MTWA 
Abnormal 
N=115 (57.5) 
 
p 
Ejection Fraction (%)  65.1 (11.4)  59.5 (17.3)  0.01 
Myocardial mass/BSA  84.9 (33.1)  99.7 (40.6)  <0.01 
EDV/BSA (ml/ m
2)  60.6 (22.6)  75.2 (41.8)  <0.01 
ESV/BSA (ml/ m
2)  22.4 (14.2)  33.5 (31.7)  <0.01 
SV/BSA (ml/m
2)  38.2 (13.5)  41.6 (21.9)  0.21 
LVH on MRI  46 (54.1)  78 (67.8)  0.05 
LVSD on MRI (EF<55%)  14 (16.5)  31 (27.0)  0.08 
LV dilation  2 (2.4)  17 (14.8)  <0.01 
 
Table 6.3 Comparisons of CMR data between patients are shown based on 
MTWA result.  
Data are number with percentage in parentheses or mean ± standard deviation. 
Tests of significance are t-test and Chi-square. 233 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.4  Simple  (left)  followed  by  backward  stepwise  (conditional) 
multiple  logistic  regression  analyses  (R
2=0.40)  demonstrating  independent 
predictors of abnormal MTWA result.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate model.  †LVMI or LVH were entered individually in the model. 
  Univariate Analyses  Multivariate analyses 
 
Variable  OR   95% CI  p  OR   95% CI  P 
             
Age (per year)  1.04  1.02,1.07  <0.01  1.04  1.01,1.07  0.01 
Ischaemic Heart Disease  6.19  2.74,13.94  <0.01  3.24  1.31,8.02  0.01 
Cerebrovascular Disease  6.83  1.98,23.60  <0.01  5.81  1.56,12.87  <0.01 
Peripheral Vascular Disease  7.47  2.53,22.11  <0.01  5.34  1.68,16.96  <0.01 
LVH  1.79  1.01,3.18  0.05  †2.01  1.01,4.03  0.05 
LV Dilation  7.20  1.62,32.07  0.01  4.34  0.98,21.90  0.06 
Log BNP  2.66  1.45,4.87  <0.01       
Glucose (per mmol/L)  1.10  1.02,1.19  0.01       
Ejection fraction (per %)  0.98  0.95,0.98  0.01       
LVMI (per g/m
2)  1.01  1.00,1.02  0.01  † 1.02  1.01,1.02  0.02 
LVSD  1.87  0.93,3.79  0.08       
Diabetes Mellitus  2.12  1.09,4.15  0.03       
Hypercholesterolemia  1.92  1.08,3.40  0.03       
Renal Replacement Therapy             
  Predialysis  1.00           
  PD  0.57  0.19,1.70  0.31       
  HD  1.93  1.05,3.59  0.04       
RRT Time (per year)  1.10  0.91,1.33  0.30       
Sex (Male vs. Female)  1.06  0.59,1.90  0.84       
BMI (per kg/m
2)  0.97  0.92,1.03  0.36       
Systolic BP (per mmHg)  1.01  0.99, 1.02  0.07       
Diastolic BP (mmHg)  0.97  0.95, 1.00  0.06       
Pulse Pressure  1.02  0.99,1.03  0.07       
Chronic Heart Failure  2.14  0.65,6.97  0.21       
Smoking  Never  1.00           
  Current  1.73  0.88,3.47  0.12       
  Ex  0.70  0.95,3.75  0.09       
Haemoglobin (per g/dL)  1.02  0.86,1.18  0.96       
Fibrinogen (per g/L)  0.92  0.70,1.23  0.58       
ESR (per mm/h)  0.99  0.98,1.01  0.83       
CRP (per mg/L)  1.01  0.99,1.02  0.62       
Adjusted Ca
2+( per mmol/L)  1.08  0.41,2.85  0.86       
PO4 (per mmol/L)  0.60  0.34,1.07  0.08       
PTH (per pmol/L)  0.99  0.98,1.01  0.42       
HbA1c (per %)  0.99  0.98,1.01  0.48       
Potassium (per mmol/L)  0.94  0.63,1.40  0.76       
BNP (per ng/L)  1.02  1.01,1.04  <0.01       
Cholesterol (per mmol/L)  0.60  0.32,1.17  0.13       
Triglyceride (per mmol/L)  1.12  0.69,1.81  0.67       
HDL- Chol (per mmol/L)  1.34  0.70,2.57  0.38       
LDL- Chol (per mmol/L)  1.17  0.63,2.16  0.62       
Troponin I (per  g/L)  12.15  0.02,32.8  0.26       
EDV/BSA (ml/ m
2)  1.00  0.98,1.02  0.64       
ESV/BSA (ml/ m
2)  1.02  0.98,1.04  0.21       
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Figure 6.3  Kaplan Meier survival curve of ESRD patients based on MTWA 
result based on (a) abnormal/negative classification and (b) automated result 
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6.4  DISCUSSION 
 
As  has  been  discussed  in  Chapter  1,  premature  cardiovascular  death  is  the 
commonest cause of death in patients with ESRD including those receiving or within 
6 months of requiring renal replacement therapy. According to the USRDS (4; 228), 
the commonest causes of death in ESRD and dialysis patients are cardiac arrhythmia 
and  cardiac  arrest  accounting  for  between  60-65%  of  cardiac  and  20-25%  of  all 
deaths.   
 
Findings from the “Deutsche Diabetes Dialyse Studies (4D)”   and  “A Study to 
Evaluate  the  Use  of  Rosuvastatin  in  Subjects  on  Regular  Hemodialysis:  An 
Assessment  of  Survival  and  Cardiovascular  Events  (AURORA)”  trial    have 
highlighted  significant  differences  in  cardiovascular  disease  between  dialysis 
patients and the general population (25;26). 
 
·  The 4D study was a prospective randomised controlled trail investigating the effect 
of  atorvastatin  therapy  on  cardiovascular  outcome  in  1225  type  2  diabetic 
haemodialysis  patients.    Although  LDL  cholesterol  was  reduced,  there  was  no 
statistical significant reduction of the composite primary endpoint (death from all 
cardiac causes, fatal stroke, non fatal MI, or non fatal stroke).  Post hoc analyses, 
however,  revealed  that  adjudicated  deaths  due  to  coronary  artery  disease  only 
accounted  for  9%  of  deaths  and  sudden  death  accounted  for  26%  of  all  cause 
mortality (25).  
·  In the AURORA trial, a prospective randomised  study investigating therapy with 
rosuvastatin in 2776 haemodialysis patients, LDL cholesterol was reduced by 43% in 236 
 
the therapy arm but there was no significant effect on primary outcome (adjudicated 
death from cardiovascular causes, non fatal MI, non fatal stroke).  In the rosuvastatin 
treated group, death from cardiovascular cause occurred at a rate of 7.2 events/100 
patient-years  compared  to  7.3  events/100  patient–years  in  the  placebo  group 
(p=0.97)  and  death  from  definite  coronary  heart  disease  was  not  significantly 
different (26).  
 
Both of these studies, in combination with previous interventional studies, suggest 
that  in  non-ESRD  population,  coronary  atherosclerosis  causes  myocardial 
ischaemia/infarction which may lead to sudden cardiac death.  However in ESRD 
patients, sudden cardiac death is not as greatly influenced by coronary artery disease 
compared  to  the  general  population.    Alternatively,  these  data  may  suggest  that 
CAD in ESRD patients does not respond to statin treatment. 
 
 
6.4.1   Factors associated with sudden cardiac death in ESRD 
The presence of stable VTAs on ambulatory ECG monitoring has been shown to 
increases risk of SCD in the general population (99).  Ventricular tachyarrhythmia 
development is commonly due to the interaction of abnormal myocardial substrate 
and  aetiological  triggers  which  interfere  with  normal,  uniform  cardiac  action 
potential  propagation  and  myocardial  repolarisation.    In  the  general  population, 
transient myocardial ischaemia or areas of post MI scarring commonly produce areas 
of  slowed  ventricular  action  potential  conduction,  non-uniform 
depolarisation/repolarisation, and increase risk of re-entry and VTA.  In patients with 
preserved LV function, these arrhythmias have only a small haemodynamic effect.  237 
 
However, if patients have compromised myocardial function, haemodynamic effects 
may  be  great  and  may  lead  to  degeneration  of  depolarisation  wavefront  and 
ventricular  fibrillation.    ESRD  patients  are  at  risk  of  unique  factors  that  affect 
substrate  (myocardium)  and  triggers  that  have  been  discussed  in  more  detail  in 
Chapter 1.  Briefly these features include: 
 
1.  Changes in myocardial structure and function (substrate):  
Including  features  of  uraemic  cardiomyopathy,  accelerated  coronary  artery 
disease and fluid overload induced myocardial stretching. 
 
2.  Changes in myocardial environment (trigger): 
Including  fluctuations/imbalances  in  extracellular  electrolyte  concentrations, 
uraemia, anaemia, inflammation and autonomic imbalance. 
 
6.4.2  Reducing risk of sudden cardiac death in ESRD patients 
Ideally, reduction of sudden cardiac death in ESRD patients should be achieved by 
identification of individuals at high risk and implementation of therapy shown to 
reduce cardiac events with randomised prospective trials.  Unfortunately, studies in 
this area have provided limited data due to under powering, absence of sufficient 
controls,  or  the  retrospective  nature  of  their  design.    However,  a  number  of 
promising studies have identified therapeutic agents that may reduce VTA and SCD 
in ESRD patients. 
·  Beta adrenergic  receptor blockers   
In a small prospective study, Cici et al randomised 144 haemodialysis patients with 
dilated  cardiomyopathy  to  receive  carvedilol  or  placebo.    Prevalence  of 238 
 
cardiovascular death after 2 years was 29.3% in the carvedilol group compared to 
67.9%  in  the  placebo  group.    In  addition,  there  was  a  trend  to  reduced  SCD 
(carvedilol 3.4% vs placebo 10.6%) but did not achieve statistical significance due to 
inadequate  numbers  (120).    Further  studies  are  required  to  determine  whether  β 
blockers  similarly  reduce  SCD  in  ESRD  patients  with  normal  LV  function  and 
structure. 
 
In  post  MI  studies  (CAPRICORN  and  COPERNICUS),  patients  with  mild  to 
moderate CKD also showed marked reduction in cardiovascular death when treated 
with  carvedilol  compared  to  placebo  suggesting  that  blockade  of  sympathetic 
nervous system at early stages of CKD may provide some benefit (229;230). 
 
·  Renin angiotensin system blockers 
There  are  no  studies  to  prospectively  evaluate  the  role  of  ACE  inhibitors  or 
angiotensin  receptor  blockers  (ARBs)  in  ESRD  patients  with  SCD  as  a  primary 
outcome.    In  addition,  no  interventional  studies  have  been  performed  in  ESRD 
patients with reduced LV function.  Small observational studies have demonstrated a 
significant reduction in mortality, independent of blood pressure reduction in dialysis 
patients  treated  with  ACE  inhibitors  (231).    However,  a  prospective  trial  with 
fosinopril found no difference in fatal and non fatal cardiovascular events between 
treatment and placebo group.  A small prospective study of candersartan showed a 
reduction in cardiac arrhythmias and cardiovascular events in haemodialysis patients.  
However,  this  result  was  not  statistically  significant  due  to  small  event  numbers 
(123;125). 
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Nonetheless, ACEI/ARBs are attractive therapies, if tolerated, due to their multiple 
effects  demonstrated  in  non  renal  populations  (i.e.  effects  on  neurohumoral 
activation, vascular haemodynamics, myocardial architecture, vascular inflammation 
and oxidative stress).   
 
· Aldosterone receptor blockers 
In patients with severe symptomatic heart failure, spiranolactone has been shown to 
significantly  reduce  cardiovascular  death  and  SCD  (RALES  study)  (232).    In 
addition, aldosterone may contribute to myocyte hypertrophy and fibrosis in ESRD 
patients and earlier stages of CKD (233) and is an attractive target for intervention.  
Most clinicians will not prescribe these agents  to dialysis patients due to risk of 
hyperkalaemia.  In a recent prospective study of spiranolactone in 30 haemodialysis 
patients, no patients developed serum K
+> 6.0mmol/l and only two patients required 
alteration  in  dialysate  suggesting  that  this  recognised  side  effect  can  be 
accommodated  if  necessary.  Unfortunately  this  study  demonstrated  no  effect  on 
LVMI measured by CMR after 9 months of spiranolactone therapy (234). 
 
· Implantable cardioverter defibrillators (ICD).  
In  patients  with  reduced  LV  ejection  fraction,  secondary  prevention  with  ICD 
insertion  has  been  associated  with  reduced  mortality  (82).  Studies  which  have 
investigated  beneficial  effects  of  ICD  in  dialysis  patients  have  already  been 
discussed in Chapter 1. 
 
In addition, some investigators believe that the survival benefit afforded by primary 
ICD  insertion  patients  may  be  negated  in  patients  with  significant  co-morbid 240 
 
conditions such as ESRD.  For example, in a retrospective study of 585 patients 
(235)  who  received  ICDs,  survival  in  dialysis  patients  was  significantly  reduced 
compared to patients with normal renal function patients, despite receiving dialysis 
being a significant predictor of ICD discharge (HR 2.30 95% CI 1.20-4.50).  
 
In  secondary  prevention  of  VTA,  data  from  the  USRDS  have  demonstrated  a 
significant (42%) reduction in mortality in dialysis patients who receive ICDs (128).  
Unfortunately, this study also reported that only 8% of dialysis patients who met 
criteria  for  ICD  insertion  as  secondary  prevention  of  SCD  had  a  device  fitted. 
Underutilisation of ICDs may be due to recent data reporting higher complication 
rates (bleeding, infection) in dialysis patients and problems when dialysis access and 
insertion site are ipselateral (such as subclavian vein stenosis and occlusion) (130). 
 
Intervention in ESRD patients, particularly for primary prevention of SCD, remains 
controversial  necessitating  more  studies.  Similar  to  the  therapeutic  approach  of 
patients with heart failure, intervention should be directed and intensified to well 
characterised groups of ESRD patients that have been identified as higher risk of 
VTA and SCD.   
 
6.4.3  ESRD patients at high risk of sudden cardiac death- role of MTWA 
A large number of studies have demonstrated strong negative and positive predictive 
power (similar to invasive electrophysiological testing) of MTWA test results for all 
cause mortality in ischaemic and non-ischaemic cardiomyopathy (105;106).  Based 
on  these  initial  findings,  MTWA  was  considered  an  ideal  method  of  identifying 
those patients with reduced LV function (ejection fraction<30-35%) who would have 241 
 
survival  benefit  from  primary  ICD  implantation.    Two  more  recent  prospective 
studies (MASTER and TWA SCD-HeFT) have suggested reduced specificity and 
sensitivity  of  MTWA  for  risk  stratifying  heart  failure  patients  (109;110).    These 
studies  used  cardiac  arrhythmia,  ICD  discharge  or  sudden  cardiac  death  as  a 
composite  end  point  compared  to  all  cause  or  cardiovascular  mortality  used  in 
previous  studies.    Further  investigations  are  currently  underway  to  elucidate  the 
setting in which MTWA would be useful for predicting VTA in heart failure patients 
and other patients at risk of SCD.  
 
To this end, this study was performed in ESRD patients using MTWA testing to 
assess  the  prevalence  of  and  significant  associations  with  an  abnormal  MTWA 
result.  CMR measurements were obtained in subjects to assess relationship with 
features of uraemic cardiomyopathy. 
 
These data show that abnormal MTWA test results are common (57.5%) in ESRD 
patients  and  this  prevalence  is  similar  to  previous  heart  failure  studies  (236). 
However, the patients in our cohort had preserved LV function (ejection fraction 
61.9±15.3%) suggesting that the aetiology of cardiac arrhythmias differs between 
ESRD patients and patients with ischaemic and non ischaemic cardiomyopathy. On 
comparison of these results with diabetics and healthy athletes, abnormal MTWA 
result was more common in ESRD patients (111).   
 
6.4.4  Comparison between ESRD and hypertensive LVH 
Patients with hypertensive LVH and normal renal function were used as controls in 
this study. Hypertensive LVH differs from uraemic cardiomyopathy both in extent 242 
 
and pattern of sarcomere expansion and interstitial fibrosis (49;51).  This control 
group was used to provide an indication of the additional risk afforded by uraemic 
cardiomyopathy and the abnormal myocardial environment in ESRD patients.  These 
data show that prevalence of abnormal MTWA was significantly higher in ESRD 
patients compared to hypertensive LVH patients despite similar LV size and function 
between both groups. 
 
An  earlier  study  comparing  MTWA  results  between  patients  with  hypertrophic 
cardiomyopathy and hypertensive LVH patients found a much higher prevalence of 
positive test result (31%) in LVH patients compared to data presented in this chapter.  
However  different  MTWA  exercise  protocols  (only  HR  up  to  110  bpm  were 
performed) and older classification criteria (indeterminate tests were not reported) 
were employed in this study (237). 
 
Abnormal MTWA result has been associated with repolarisation alternans, which is 
defined as discordant and alternating action potential duration between neighbouring 
cardiomyocytes.  Biopsy  proven  cellular  changes  (myocyte  hypertrophy)  and 
arrangement (disarray) in conjunction with myocardial fibrosis have been associated 
with abnormal MTWA result and may contribute with repolarisation alternans (103).  
Endomyocardial  biopsies  have  demonstrated  increasing  myocardial  fibrosis  and 
more heterogeneous histology with worsening CKD (51).  One would expect with 
higher inter-myocyte deposition of collagen (usually type 1), and greater changes in 
tissue  arrangement,  there  would  be  greater  fluctuations  in  AP 
depolarisation/repolarisation, leading to non- uniform depolarisation and increasing 
risk of abnormal MTWA result and SCD.  243 
 
However,  there  are  some  limitations  in  this  comparison.    Prior  to  recruitment, 
hypertensive  patients  were  eligible  for  inclusion  based  on  prior  ECG  or 
echocardiographical  evidence  of  LVH.    Unfortunately,  CMR  results  showed  that 
only 18 (60%) of patients had LVH using previously defined cut offs for LVMI 
(154).  Furthermore  there  were  no  significant  differences  between  myocardial 
abnormalities  of  both  groups  since  this  study  was  powered  only  to  determine  a 
difference in MTWA result. On examination of the data, however, ESRD patients 
had  more  extreme  cardiac  abnormalities  (represented  by  higher  LVMI,  greater 
variability in LV chamber size, and reduced ejection fraction) and a greater number 
of cardiovascular risk factors compared to LVH patients.  
 
6.4.5  Implications for an indeterminate MTWA test 
The rate of indeterminate tests was high (35.5%) and a large proportion (51%) of 
these patients were unable to achieve adequate HR elevation reflecting poor exercise 
tolerance of ESRD patients.  A proportion of these patients were able to attempt a 
repeat test but this did not affect final MTWA result.  Poor exercise tolerance in 
ESRD patients has been demonstrated by other studies and is due to high levels of 
co-morbidity including peripheral vascular disease, diabetic peripheral neuropathy 
and pulmonary oedema (238).   In heart failure patients, pharmacological attempts to 
elevate heart rate have been used, however ethical approval for this approach was not 
obtained.    Nonetheless,  an  indeterminate  result  has  been  demonstrated  as  a 
significant independent predictor of death (both arrhythmic and non-arrhythmic) in 
heart failure patients in a small prospective trial (227) and the relevance in ESRD 
patients remains to be assessed.  
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6.4.6  MTWA and uraemic cardiomyopathy 
This study also demonstrates a strong association between the features of uraemic 
cardiomyopathy (LVH, LVSD and LV dilatation) and abnormal MTWA result (table 
6.3).    In  patients  with  other  cardiomyopathies  (such  as  dilated  or  hypertrophic), 
abnormal  MTWA  result  rate  is  high  (between  65-78%)  and  it  follows  that  non 
uniform repolarisation is associated with atypical myocardial cytoarchitecture (e.g. 
LVH,  myocardial  fibrosis)  (105).    Unfortunately,  due  to  the  association  between 
gadolinium based contrast agents and nephrogenic systemic fibrosis (NSF), further 
assessment of myocardial fibrosis could not be performed (239).   
 
6.4.7  Factors associated with abnormal MTWA 
ESRD patients with an abnormal test were significantly older, which is similar to 
findings  of  previous  studies  in  patients  with  ischaemic  and  non  ischaemic 
cardiomyopathy (225).  Diabetic patients with ESRD had a significantly higher rate 
of abnormal test result and this most likely represents the additional, and initially 
silent, cardiovascular morbidity that diabetics have compared to non-diabetic ESRD 
patients. In addition, presence of abnormal MTWA result was significantly higher in 
ESRD  patients  with  history  of  macrovascular  atheromatous  disease,  namely 
coronary, peripheral and cerebrovascular, which is reflected in their medical therapy- 
abnormal result was associated with greater statin usage.  Interestingly, there was no 
difference  in  aspirin,  beta  adrenergic  blocker  and  ACE  inhibitor  or  angiotensin 
receptor blocker therapy between both  groups supporting the evidence  that these 
drugs may be under utilised in high cardiovascular risk patients.  To further identify 
factors independently associated with abnormal test, multivariate logistic regression 
analysis was performed using abnormal MTWA result at the outcome variable.  This 245 
 
confirmed older age, past clinical history of macrovascular diseases, and features of 
uraemic  cardiomyopathy  (higher  LVMI  and  presence  of  LV  dilatation)  as 
independent predictors of abnormal MTWA result.  Interestingly, abnormal MTWA 
was independently predicted by clinical history of peripheral and cerebrovascular 
atheromatous disease.  These results suggest that in the absence of CMR evidence of 
uraemic cardiomyopathy or ischaemic heart disease, interference of cardiomyocyte 
repolarisation  occurs  in  patients  with  previous  stroke  or  lower  limb  vascular 
insufficiency.   It is likely that in these patients, cardiac small vessel disease and 
clinically silent myocardial ischaemia are present. 
  
At  this  stage  of  the  study,  a  trend  toward  reduced  survival  in  the  patients  with 
abnormal  MTWA  result  was  demonstrated  (Figure  6.3).  These  results  are 
unsurprising given that major predictors of CV death in ESRD patients include past 
medical history of CV disease and myocardial structural changes (Chapter 4).  Given 
that abnormal MTWA result was more  common in patients with  established CV 
disease, additional information for predicting SCD seems unlikely.  However,  as 
more data on patient outcome for this cohort becomes available, the predictive value 
of MTWA for SCD in ESRD patients can hopefully be fully established.  
 
6.4.8  Limitations of current study 
As  before  this  study  was  limited  by  the  recruitment  of  patients  undergoing  pre-
transplant  CV  assessment.    Furthermore,  although  control  patients  had 
echocardiographical or ECG evidence of LVH, only 60% had CMR proven LVH.  
This study was powered to compare differences between MTWA results only based 246 
 
on pilot data and previously published studies.  As a result there was a discrepancy 
between the numbers of patients in each group. 
 
6.5  CONCLUSIONS 
In conclusion, this study demonstrates a strong association between the myocardial 
abnormalities of uraemic cardiomyopathy and abnormal MTWA result, implicating 
abnormal  ventricular  repolarisation  with  high  risk  of  SCD  in  ESRD  patients.  
Similarly, a history of macrovascular atheromatous disease is significantly associated 
with  an  abnormal  MTWA  result.    The  potential  role  that  MWTA  may  have  to 
independently predict development of cardiac arrhythmia and SCD remains to be 
assessed.  
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Chapter 7 
 
A study of 
31P Magnetic resonance spectroscopy in uraemic and hypertensive 
cardiomyopathy 248 
 
7.1  INTRODUCTION 
As  discussed  in  Chapter  1,  uraemic  cardiomyopathy  is  characterised  by 
abnormalities of myocardial structure, namely LVH, LVSD and LV dilatation, which 
are associated with elevated risk of CV morbidity and mortality.  In patients with 
heart  failure,  abnormal  cardiac  structure  is  associated  with  alteration  in 
cardiomyocyte metabolism (147).  Changes occur in metabolic substrate transport 
and usage, oxidative phosphorylation, and high energy phosphate metabolism.  The 
latter  is  particularly  important  since  reduced  creatine  kinase  activity  results  in 
decreased free ATP concentration, reduced transfer of energy (in the form of high 
energy  phosphate  bonds)  from  cardiomyocyte  mitochondria  to  myofibrils,  and 
elevation  of  cytoplasmic  ADP  concentration.   
31P-MRS  allows  non-invasive 
measurement  of  relative  concentrations  of  phosphorus  containing  compounds 
including ATP, PCr and 2, 3-DPG and thus the assessment of high energy phosphate 
(HEP) metabolism. Previously, only small studies have been performed in ESRD 
patients and patients with hypertensive LVH.  In addition, the relationships between 
HEP  metabolism  and  features  of  uraemic  cardiomyopathy  have  not  been 
investigated. 
 
The aims of this study were to: 
·  Compare  HEP  metabolism  in  a  cohort  of  ESRD  patients  and  hypertensive  LVH 
patients with normal renal function to determine the additional detrimental effects of 
uraemia. 
·  Determine associations between uraemic cardiomyopathy and HEP metabolism. 
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7.2  METHODS 
 
7.2.1  Patients 
As  before,  ESRD  patients  were  recruited  from  subjects  being  assessed  for  renal 
transplantation as discussed in Chapter 2.  In addition, 30 hypertensive patients with 
ECG or echocardiographic evidence of LVH and normal renal function (within 6 
months of recruitment) were assessed (termed LVH patients).  Each patient provided 
cardiovascular  history,  examination,  ECG,  and  blood  for  biochemical  and 
haematological profile.  Patients with contraindication to MRI (see Chapter 2) were 
excluded.  Since only the effect of uraemia was to be assessed, patients with past or 
current history of ischaemic heart disease or heart failure were excluded from the 
study.   
 
7.2.2  CMR acquisition and analyses 
CMR scans were acquired for assessment of LV mass and function and analysed as 
described  in  Chapter  2.    Patients  were  classified  as  having  LVH,  LVSD  or  LV 
dilatation based on previously described normal values. 
 
7.2.3 
31P MRS acquisition 
Resting 
31P MRS was performed in all patients as described in Chapter 2.  Care was 
taken to ensure spectra were acquired from areas of uniform LV contraction (ie not 
from regions of poor wall motion).  Areas under the curve for 2,3-DPG, PCr, and β-
ATP were measured, and a blood corrected PCr: βATP ratio (PCr: ATP) calculated 
(156). 
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7.2.4  Statistical analyses 
Statistical  analyses  were  performed  using  SPSS  version  15.0  (SPSS  Inc.  Illinois, 
USA). Data are described as mean± standard deviation.  Data were compared by chi 
squared or Fisher’s test for categorical data and paired t-test for continuous data.  
Correlations  between  PCr:  ATP  and  cardiac  measurements  were  evaluated  by 
Pearson’s and Spearman’s correlation coefficient as appropriate.  
 
Twenty anonymised spectra were used for reproducibility studies.  Intra-observer 
variability of PCr: ATP was determined by a single observer (RKP) assessing each 
scan twice (at least 7 days apart) followed by calculation of the differences between 
each scan.  Inter-observer variability was determined by two independent observers 
(RKP and T Steedman, Clinical Research Initiative, Western Infirmary, Glasgow) 
analysing the same scans.  The level of difference for PCr: ATP was measured for all 
scans  and  the  consistency  of  ratios  assessed  using  the  intra-class  correlation 
coefficient (ICC) 
 
7.3  RESULTS 
 
7.3.1  Patient demographics 
Clinical, drug and blood data for ESRD (n=53) and LVH (n=30) patients are shown 
in Table 7.1. Despite excluding patients with symptomatic ischaemic heart disease, 
there was higher burden of CV disease in ESRD compared to LVH patients; there 
was  a  higher  number  of  ESRD  patients  with  a  past  history  of  diabetes  mellitus, 
peripheral  and  cerebrovascular  disease,  dyslipidaemia,  and  current  or  previous 
history of smoking compared to patients with LVH.  Furthermore, use of aspirin, β 251 
 
blockers, statins and calcium channel blockers was more common in ESRD patients.  
Diastolic blood pressure was higher in LVH patients compared to ESRD patients 
probably reflecting wider pulse pressure and increased vascular stiffness in ESRD.   
There were no significant differences in age, sex, systolic blood pressure and use of 
warfarin  or  diuretic  therapy  between  both  patient  groups.  Comparison  of  blood 
results between ESRD and a population with normal renal function was as expected 
(in ESRD patients haemoglobin was lower, inflammatory markers were elevated, 
biochemical  features  of  secondary  hyperparathyroidism  were  present  and  serum 
potassium was higher.)  Glucose was also higher in the ESRD compared to LVH 
patients  due  to  the  higher  proportion  of  diabetic  patients  in  this  cohort.    Serum 
cholesterol was significantly higher in the LVH group, however the use of statins 
was lower in these patients compared to ESRD subjects.  Brain natriuretic peptide 
levels were significantly higher in the ESRD group compared to the LVH group, 
most likely due to chronic fluid overload, myocardial dysfunction and subsequent 
elevated ventricular wall tension. 
 
7.3.2  Cardiac data 
Table  7.2  shows  CMR  results  for  ESRD  and  LVH  patients.        There  were  no 
significant differences in LV systolic function (which was preserved), LV mass or 
chamber size.  Despite echocardiography or ECG evidence of LVH, only 18 (60%) 
of  hypertensive  patients  had  LVH  on  CMR  assessment,  based  on  previously 
published values.  LV systolic dysfunction and dilatation were more common in the 
ESRD group compared to the LVH group, however, LVSD did not reach statistical 
significance due to small sample size. 
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7.3.3  Reproducibility  of  measurement  of  cardiac 
31P  magnetic  resonance 
spectroscopy 
To assess reproducibility, twenty anonymised spectra were re-analysed.  The intra-
observer variability of measurements of PCr: ATP, assessed by absolute difference 
of ratios was 0.17±0.24, and there was no significance between analyses (p=0.78).  
The inter-observer variation was determined by comparing mean corrected PCr: ATP 
for all scans measured by each observer: RKP= 1.28±0.43, TS= 1.21±0.41; p=0.56.  
Intra-class correlation coefficient was 0.89. 
 
7.3.4  Comparison of 
31P-MRS results   
Table 7.2 shows comparison of 
31P-MRS results between ESRD and LVH patients.  
There were no significant differences between PCr, β-ATP and 2,3- DPG values.  
However,  mean  PCr:  ATP  ratios  (uncorrected  and  corrected  for  blood 
contamination) were significantly lower in ESRD patients compared to LVH patients 
(corrected PCr: ATP ESRD 1.3±0.5 vs. LVH 1.6±0.4 p=0.007, Figure 7.1).  In the 
ESRD group, there was no significant difference between diabetic and non diabetic 
patients  (PCr:  ATP  diabetic  1.4±0.7  vs  non  diabetic  1.3±0.4;  p=0.66,  data  not 
shown).      Only  18  (60%)  of  hypertensive  patients  with  echocardiographic/ECG 
evidence of LVH met CMR criteria for LVH.  PCr: ATP was significantly lower in 
ESRD  patients  compared  to  hypertensive  patients  with  CMR  evidence  of  LVH 
(ESRD n=53 corrected PCr: ATP 1.3±0.5 vs. LVH on CMR n=16 :1.7±0.3 p=0.03) 
 
7.3.5  PCr: ATP and uraemic cardiomyopathy 
In the ESRD group, PCr: ATP was significantly lower in patients with LV systolic 
dysfunction (no LVSD 2.0±0.5 vs LVSD 1.2±0.2; p=0.05) and LV dilatation (no LV 253 
 
dilatation 1.79±0.4 vs LV dilatation 0.98±0.8; p=0.01).  LVH was not associated 
with significant difference in PCr:  ATP. 
 
7.3.6  Correlations of PCr: ATP in ESRD patients 
There was a weak but significant correlation between corrected PCr: ATP and LV 
ejection fraction (Pearson’s R= 0.31; p=0.03).  BSA corrected end systolic volume 
was negatively correlated with corrected PCr: ATP (Pearson’s R= -0.27, p= 0.06), 
but  this  did  not  reach  statistical  significance  (Table  7.3).    There  were  no  other 
significant  correlations  between  PCr:  ATP  and  clinical,  blood  and  cardiac  data 
(including, LVMI, haemoglobin and bone biochemistry). 
 
7.3.7  Determinants of PCr: ATP in ESRD patients 
Multivariable  linear  regression  analysis  was  performed  to  create  the  most  robust 
predictive model for PCr: ATP (Table 7.3).  Factors considered in the model were 
those identified as significant (or close) correlates with PCr: ATP.  Using backward 
stepwise regression, the most significant model (highest R
2=0.27) demonstrated LV 
ejection fraction as the only significant variable that was independently associated 
with PCr: ATP. 
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Variable 
 
ESRD 
N=53 
LVH Only 
N=30 
p 
Age (years)  54.7(±12.6)  54.6 (±10.6)  0.98 
Male (%)  33(63.3)  24 (80.0)  0.09 
BMI (kg/m
2)  26.2(±5.2)  27.1(±3.6)  0.41 
Systolic BP (mmHg)  142 (±23)  139 (±17)  0.53 
Diastolic BP (mmHg)  81 (±14)  87 (±9)  0.03 
RRT  HD  37 (69.8)  -   
  PD  0  -   
  CKD 5  16(30.2)  -   
RRT Time(years)  1.26 (1.9)  -   
Primary Renal Disease       
Diabetic Nephropathy  22 (41.5)  -   
APCKD  5(9.4)  -   
Glomerulonephritis  6(11.3)  -   
Renovascular Disease  4(7.5)  -   
Chronic Pyelonephritis  5(9.4)  -   
Other/Uknown  11(20.8)  -   
Diabetes mellitus  14 (26.4)  0  <0.01 
Hypertension  39 (73.6)  30 (100)  0.08 
Cerebrovascular disease  11 (20.8)  1 (3.3)   
Peripheral vascular disease  12 (14.5)  0   
Dyslipidaemia  25 (47.1)  9(30)  <0.01 
Smoking  Never  22 (41.5)  19 (63.3)  0.06 
  Current  17 (32.1)  3(10)   
  Ex  14 (26.4)  8 (26.7)   
Epo receptor Agonist  46(86.8)  0   
β Adrenoceptor Blocker  25 (47.2)  10 (33.3)  <0.01 
Aspirin  35 (66.0)  3 (10)  <0.01 
Warfarin  3(5.7)  0  0.63 
Clopidogrel  3(5.7)  0   
ACEI/ARB  30 (56.6)  12 (40.0)  0.08 
Diuretic  13(24.5)  6 (20.0)  0.11 
Nitrate  0  8(26.7)   
Calcium Channel Blocker  26 (49.1)  8(26.7)  0.02 
α Adrenoceptor Blocker  6 (11.3)  1 (3.3)   
Statin  30 (56.6)  9(30.0)  0.03 
Haemoglobin (g/dL)  11.8(±2.2)  14.8(±1.4)  <0.01 
Fibrinogen (g/L)  4.1(±1.0)  3.2(±0.5)  <0.01 
ESR (mm/s)  29 (14, 56)  8(2, 10)  <0.01 
CRP (mg/L)  5.0(3.3, 13.3)  1.1 (0.7, 4.3)  <0.01 
Adjusted Ca
2+(mmol/L)  2.33(±0.2)  2.41 (±0.1)  <0.01 
PO4 (mmol/L)  1.52(±0.4)  1.05 (±0.1)  <0.01 
PTH (pmol/L)  19.3(11.6, 45.1)  5.6(4.6, 7.5)  <0.01 
Glucose (mmol/L)  9.1(±1.8)  5.2(±3.3)  <0.01 
HbA1c (%)  6.9(±2.8)  5.4(±0.9)  0.02 
Potassium (mmol/L)  4.8(±0.3)  4.1(±0.3)  <0.01 
BNP (ng/L)  228(134, 557)  27 (13, 43)  <0.01 
Cholesterol (mmol/L)  4.3(±1.2)  5.4(±1.2)  <0.01 
Triglyceride (mmol/L)  1.9(±0.8)  2.0(±1.1)  0.68 
HDL- Chol (mmol/L)  1.2(±0.6)  1.4(±0.4)  0.14 
LDL- Chol (mmol/L)  2.4(±0.4)  2.8(±0.8)  0.21 
 
Table 7.1 Comparisons of clinical and blood results between ESRD and LVH 
patients.  
Data are number with percentage in parentheses and mean ± standard deviation 
except for ESR, CRP, PTH and BNP where median and interquartiles are shown.  
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Variable 
 
ESRD 
N=53 
LVH Only 
N=30 
P 
Ejection Fraction (%)  66.4(±12.4)  65.5(±11.2)  0.75 
Myocardial mass/BSA  87.5(±30.4)  82.4(±32.6)  0.48 
EDV/BSA (ml/ m
2)  63.8(±24.9)  65.7(±14.1)  0.70 
ESV/BSA (ml/ m
2)  22.4(±15.8)  23.2(±12.1)  0.81 
LVH on MRI  33(62.2)  18 (60)  0.72 
LVSD on MRI (EF<55%)  8(22.9)  1(3.3)  0.07 
LV dilatation  22 (41.5)  1(3.3)  <0.01 
PCr   7.7(±3.8)  8.3(±3.6)  0.48 
β-ATP  6.5(±3.1)  5.3(±2.6)  0.10 
2,3-DPG  1.1(±0.8)  1.2(±0.9)  0.55 
Uncorrected PCr: βATP  1.9(±0.8)  2.4(±0.7)  <0.01 
Corrected PCr: βATP  1.3(±0.5)  1.6(±0.4)  <0.01 
 
Table 7.2 Comparisons of cardiac and 31P MRS results between ESRD and 
LVH patients.  
Data are number with percentage in parentheses and mean ± standard deviation.   
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Figure 7.1  Bar chart showing mean (± standard deviation) of corrected PCr: 
ATP for ESRD (n=53) and LVH patients (n=30) 
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Table 7.3  Correlation  between  PCr:ATP  and  clinical,  blood  and  cardiac 
parameter  (left)  and  multivariate  linear  regression  (right)  entering  only 
significant correlates into the (backward stepwise) model (adjusted R
2=0.27). 
        p  95% CI 
      Constant 
0.35 
 
0.27 
 
-0.28-0.98
  r  p  B  β    β 
LV Ejection fraction (per %)  0.31  0.03  0.10  0.27  0.04  0.21-0.42 
ESV/BSA (per ml/m
2)  -0.27  0.06         
LDL- Cholesterol (per mmol/l)  0.35  0.20         
Serum Cholesterol (per mmol/l)  0.30  0.24         
ESR (per mm/s)  0.59  0.07         
Male Sex   -0.17  0.22         
BMI (per kg/m
2)  -0.05  0.75         
Haemodialysis (ref predialysis)  0.08  0.54         
Systolic Blood Pressure (per mmHg)  0.06  0.66       
Diastolic Blood Pressure (per mmHg)  0.16  0.25       
Haemoglobin (per g/dL)  0.15  0.56       
Fibrinogen (per g/L)  -0.36  0.20       
CRP (per mg/L)  0.02  0.94       
Serum Calcium (per mmol/l)  0.21  0.88       
Serum Phosphate (per mmol/l)  -0.43  0.86       
Ca x PO4 Product(per mmol
2/l
2)  -0.12  0.93       
Parathyroid Hormone (per pmol/l)  -0.06  0.66       
Glucose (per mmol/l)  -0.21  0.17       
Serum Potassium (per mmol/l)  -0.05  0.74       
Triglyceride (per mmom/l)  0.25  0.11       
HDL-  Cholesterol (per mmol/l)  0.09  0.55       
BNP (ng/L)  -0.33  0.13       
LVMI (per g/m
2)  -0.96  0.34       
EDV/BSA (per ml/m
2)  -0.08  0.56       
Diabetes Mellitus   0.03  0.81       
Cerebrovascular Disease   -0.05  0.74       
Peripheral vascular disease  -0.03  0.82       
Smoker  0.04  0.79       
Β Blocker  0.08  0.58       
Aspirin  -0.05  0.72       
Erythropoietin   -0.27  0.16       
ACE Inhibitor/ARB  0.15  0.21       
Calcium Channel Antagonist  0.18  0.16       
Statin  -0.13  0.33       
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7.4  DISCUSSION 
 
31Phosphorus magnetic resonance spectroscopy has been used in vivo to study LV 
high energy phosphate (HEP) metabolism in human hearts (145;146).  As stated in 
Chapter  1,  inherited  and  acquired  cardiomyopathies  are  not  only  associated  with 
abnormal cardiac structure but also reduced PCr: ATP in areas of apparently normal 
LV contraction.  These results suggest that although echocardiography or CMR may 
demonstrate “normal” myocardial contraction, biochemical abnormalities are present 
which  may  precede  development  of  systolic  dysfunction  by  reducing  metabolic 
activity and/or efficiency (147).  The clinical relevance of HEP metabolism has been 
demonstrated in heart failure patients, where reduced myocardial PCr: ATP has been 
significantly  associated  with  lower  LVEF  and  NYHA  symptom  severity.  
Furthermore, in dilated cardiomyopathy patients, lower PCr: ATP is significantly 
associated with reduced survival and is a better predictor of survival than LVEF or 
NYHA class (144). 
 
As  shown  in  Chapter  4,  features  of  uraemic  cardiomyopathy  are  associated  with 
poorer survival and are independent predictors of adverse CV outcome.  In ESRD 
patients, presence of wall motion abnormalities are rare at rest (240), indicating that 
global,  uniform  LV  “disease”  is  a  more  common  cause  of  reduced  LV  ejection 
fraction. 
 
In  this  current  study,  HEP  metabolism  was  investigated  in  a  cohort  of  ESRD 
patients.  Patients with known ischaemic heart disease were excluded to assess the 
effect of uraemia and small vessel ischaemia (Table 8.1).  Acquisition voxels were 259 
 
placed on visibly functioning myocardium to ensure that PCr: ATP was measured 
from viable cardiac tissue and not scar/fibrotic tissue.  As a control group, patients 
with  LVH  due  to  hypertension  were  assessed  to  allow  the  effect  of  additional 
abnormalities (LVSD and LV dilatation) and uraemia to be determined in ESRD 
patients.   
 
7.4.1   Reduced PCr:ATP in uraemic cardiomyopathy 
The  biochemical  changes  that  accompany  reduced  PCr:ATP  are  not  completely 
understood and derived mostly from animal studies.   Lowered PCr:ATP indicates 
that in the resting state there are reduced myocardial energy reserves and in animal 
models for cardiac hypertrophy (e.g. spontaneously hypertensive rat) a reduction in 
PCr:ATP has been demonstrated  (241;242).   In clinical and experimental models of 
cardiac  failure,  reduced  PCr:ATP  ratio  have  been  attributed  to  reduced  levels  of 
creatine kinase activity.  However, in animal models of uraemic cardiomyopathy 
changes in creatine kinase activity (243) and cyptoplasmic creatine concentration 
have not been convincingly demonstrated (244). 
 
Impaired  ATP  synthesis  (e.g.  from  oxidative  phosphorylation)  or  increased 
utilisation  (excitation-  contraction  coupling)  may  reduce  PCr  by  the  buffering 
creatine kinase system.  Furthermore, the subsequent elevation in free cyptoplasmic 
ADP may affect cardiac function adversely, since high ADP concentration inhibit 
myosin  ATPase  activity  thus  exacerbating  contractile  dysfunction.    These 
experimental finding are consistent with the results of this study.  In ESRD patients, 
not  only  were  features  of  uraemic  cardiomyopathy  (LVSD  and  LV  dilatation), 260 
 
significantly associated with reduced PCr:ATP ratio but LV ejection fraction was the 
only variable that was independently associated with PCr:ATP measurements.  
 
7.4.2  Comparison of PCr: ATP result 
The values obtained for ESRD and LVH patients are comparable to previous studies 
(149;245).  These results show that despite similar LV mass, function and chamber 
size, PCr: ATP ratios were significantly lower in ESRD patients compared to LVH 
patients.  As one would expect, there were significantly more ESRD patients with 
LVSD  and  LV  dilatation  using  established  criteria.  Only  60%  of  hypertensive 
patients with LVH on echocardiography had evidence on CMR, highlighting greater 
accuracy of LV mass measurement using CMR.  PCr:ATP ratio was similarly lower 
in ESRD patients compared to hypertensive patients with LVH on CMR.  Consistent 
with a previous smaller study which compared HEP metabolism between diabetic 
and non diabetic uraemic patients (149), there was no significant difference in PCr: 
ATP between diabetic and non diabetic ESRD patients. 
 
The differences between PCr:ATP in ESRD and LVH patients are most likely due to 
alteration of: 
· Composition of myocardial interstitial tissue  
· Cardiomyocte metabolic function. 
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7.4.3  Alteration in intercellular composition- myocardial fibrosis. 
 
Left  ventricular  hypertrophy  is  characterised  by  changes  in  tissue  architecture 
including myocardial fibrosis and expansion of sacrcomere volume and density.  In 
patients with systemic hypertension and ESRD, myocardial fibrosis is a consequence 
of accumulation of collagen, mostly type 1 fibres, within the cardiac interstitium, and 
around the intermyocyte arterial tree.  This accumulation is due to a combination of 
excessive collagen production by fibroblasts accompanied with reduced or unstable 
degradation of older fibres by extracellular metalloproteinases (50; 51).   
 
Initially in patients with hypertension and CKD, factors such as pressure overload, 
oxidative  stress,  inflammation  and  production  of  pro-  fibrotic  cytokines  (namely 
TGF-β and cardiotrophin-1) stimulate collagen fibre production.  Both in vitro and in 
vivo studies using the spontaneously hypertensive rat (SHR), have demonstrated that 
chronic  pressure  overload  stimulates  procollagen  gene  expression  and  collagen 
protein  synthesis  resulting  in  deposition  of  collagen  fibres  within  the  cardiac 
interstitium (51).  Post-mortem and endomyocardial biopsy studies of hypertensive 
and  ESRD  patients  have  demonstrated  similar  patterns  of  collagen  deposition 
reflecting lines of excessive wall stress and  increasing collagen density proportional 
to wall thickness (246;247).  Angiotensin II is a potent stimulator of cardiac fibrosis 
in humans with hypertension via stimulation of the angiotensin II receptor- 1 and is 
facilitated by locally produced factors produced by cardiomyocytes (e.g. ostepontin, 
endothelin-1).  Studies assessing regression of fibrosis using ACE inhibitors or AII 
receptor blockers have demonstrated some improvement in patients with no renal 
impairment but little effect in ESRD individuals (248;249). 262 
 
Myocardial fibrosis is also stimulated by other factors in advanced stages of renal 
disease.  Parathyroid hormone stimulates rat cardiac fibroblast proliferation in vitro.  
In 5/6 nephrectomised rats (acting as an animal model of uraemic cardiomyopathy), 
interstitial fibroblasts express higher levels of proliferation markers (eg proliferating 
cell  nuclear  antigen),  platelet  derived  growth  factor,  integrin  β1  and  laminin 
compared to experimental models of genetic hypertension (61;250).   
 
In patients with hypertensive heart disease, the degree of myocardial fibrosis has 
previously  been  assessed  using  endomyocardial  biopsy,  MRI  with  gadolinium 
enhancement, and serum markers for collagen type 1 deposition (251).  In patients 
with  advancing  stages  of  CKD,  the  degree  of  LVH  and  indicators  of  diastolic 
dysfunction increase at a similar rate and this may be due, in part, to higher levels of 
myocardial  fibrosis.    Patients  with  worsening  degrees  of  CKD  have  consistently 
demonstrated higher levels of inter-myocyte fibrosis (252). Furthermore, in patients 
with dilated cardiomyopathy, dialysed patients have been shown to have more severe 
and disorganised myocardial fibrosis on endomyocardial biopsies compared to their 
non dialysed counterparts (253).  Taken together, interstitial cardiac fibrosis is likely 
to contribute to CMR and echocardiographical features of uraemic cardiomyopathy. 
 
Thus it is likely that a greater degree of inter-myocyte fibrosis within the tissue of 
interest  is  a  significant  contributing  factor  to  reduced  PCr:ATP  ratio  in  ESRD 
patients compared to LVH ones.  Reduction of measured HEP metabolism may be a 
consequence of: 
·  Impeded  nutrient/metabolic  substrate  (e.g.  glucose,  oxygen)  transfer  to  cardiac 
myocytes as a result of intervening collagen. 263 
 
·  Reduced cardiomyocyte volume per acquisition voxel due to presence of fibrosis 
which may not interfere with macroscopic contracting tissue. 
 
7.4.4  Alteration of cardiomyocyte function 
Several  animal  model  and  clinical  studies  have  demonstrated  abnormalities  of 
cardiomyocyte metabolism in uraemia. 
 
7.4.4a  Abnormal cyptoplasmic calcium cycling within cardiomyocytes. 
Since  intracellular  Ca
2+  plays  a  central  role  in  excitation-contraction  coupling  of 
cardiomyocytes, alterations of intracellular handling may contribute to contractile 
failure. In experimental rat models of uraemic cardiomyopathy (5/6 nephrectomy), 
elevating extracellular perfusing Ca
2+ did not have an effect on uraemic hearts (n=8) 
compared  to  the  positively  inotropic  response  of  sham  operated  controls  (n=8), 
despite similar changes in heart rate (244). This was also associated with a reduced 
PCr:ATP in the uraemic cardiomyopathy group compared to controls. The authors 
concluded  that  disordered  myocardial  calcium  usage  may  contribute  to  cardiac 
metabolic  derangements.    Furthermore,  the  same  group  performed  isolated 
ventricular  myocyte  studies  from  similar  rat  groups.    Using  steady  state  field 
stimulation  to  investigate  intracellular  Ca
2+  concentration  changes  during  cell 
contraction,  significant  slowing  of  return  to  diastolic  intracellular  Ca
2+  levels 
compared  to  controls  was  demonstrated  in  myocytes  from  uraemic  hearts  (254).  
This effect has been abolished by inhibiting the Na
+/Ca
2+ exchanger suggesting that 
membrane bound transporters play a pivotal role in controlling intracellular Ca
2+ 
concentrations and relaxation during diastole in myocytes from uraemic hearts (255). 264 
 
Similarly, in an isolated rat cardiac myocyte system investigating Ca
2+ cycling and 
contractile function, treatment of these cells with uraemic patient sera (n=6) resulted 
in prolongation of cell relaxation and calcium mediated recovery compared to sera 
from healthy controls (256). Thus, uraemia is associated with abnormal Ca
2+ cycling 
which may significantly affect excitation coupling and relaxation of cardiac tissue 
and utilisation of ATP during the cardiac cycle. 
 
7.4.4b Microvascular disease and myocardial ischaemia 
Development of cardiac hypertrophy is commonly due to an adaptive response to 
pressure  and  volume  overload.    However,  a  mismatch  of  energy  demand  (from 
hypertrophied  myocytes)  and  supply  (due  to  inadequate  angiogenesis)  may 
contribute to the development of cardiac failure (257).  
 
Myocardial ATP production is primarily achieved by oxidative phosphorylation and 
the creatine kinase reaction acts as a cardiac energy buffer/reserve providing ATP 
rapidly to the sites of need.  Cardiomyocyte ATP production is directly related to 
myocardial oxygen consumption, and any reduction in oxygen supply has a profound 
effect on  cardiac energetics and the PCr:ATP ratio.   In this study, there was no 
significant difference in cardiac parameters between ESRD and LVH groups even 
when patients with symptomatic CAD were excluded.  Furthermore, care was taken 
not to acquire spectra from areas of obvious wall motion abnormality.  Nonetheless, 
it is likely that microvascular disease due to inadequate angiogenesis, myocardial 
ischaemia and subsequent reduction of mitochondrial oxidative phosphorylation may 
be an important cause of reduced PCr:ATP ratio in uraemic hearts.  As stated before, 265 
 
silent myocardial ischaemia is common in ESRD patients and often associated with 
CMR features of LVSD (139).   
 
The cause of inadequate angiogenesis in ESRD is not due to hypertension alone and 
appears to be specific to the heart.  In 5/6 nephrectomised rats, the density of cardiac 
capillaries is less than sham operated controls and the SHR model for hypertension 
(258).   Similarly studies have shown lower cardiac capillary density in uraemic 
patients compared to subjects with LVH due to hypertension and healthy controls 
(257). However, this inadequate angiogenesis was not found in other muscles (e.g. 
psoas).  The cause of this uraemia specific effect is not clear but may be related to 
centrally acting sympathetic stimulation and locally derived endothelial factors since 
in experimental models, cardiac capillary density could be improved by monoxidine 
and  endothelin  receptor  blockers  (49;257;259).      These  effects  could  not  be 
reproduced with calcium channel blocking agents or ACE inhibitors. 
 
Other alterations of cardiac metabolism occur during low oxygen supply.  Changes 
in metabolic substrate usage of cardiomyocytes from fatty acids to glucose have been 
described in hypoxic conditions.  Interestingly, experimental rat models of uraemic 
cardiomyopathy have demonstrated reduction in expression of membrane glucose 
transporter,  Glut  4,  possibly  further  hindering  substrate  availability  for  oxidative 
phosphorylation (49). 
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7.4.5  Limitations of current studies 
This small study was limited by noisy signal during MRS acquisition.  This was 
minimised by ensuring the magnetic field was homogenised completely.  As before, 
only 60% of patients labelled as “LVH” had evidence on CMR.  However this did 
not alter the findings that cardiac energy metabolism was lower in ESRD patients 
and patients with LVH when CMR confirmed cases were compared.   An interesting 
additional  control  group  would  have  been  healthy  individuals,  however  ethical 
approval was not obtained for this part of the study. 
7.5  CONCLUSIONS 
This study shows that despite similar myocardial mass, ESRD patients have lower 
HEP metabolism compared to LVH patients.  This may be due to greater myocardial 
fibrosis or altered myocyte metabolic function in ESRD patients. Lower PCr: βATP 
ratio is associated with features of uraemic cardiomyopathy  267 
 
 
Chapter 8 
 
A study of changes in left ventricular mass after renal transplantation 268 
 
8.1  INTRODUCTION 
 
As discussed in Chapter 1, left ventricular hypertrophy (LVH) is the most common 
myocardial  abnormality  in  patients  with  ESRD,  a  component  of  uraemic 
cardiomyopathy,  and  an  independent  risk  factor  for  sudden  cardiac  death,  heart 
failure,  and  cardiac  arrhythmias  in  the  general  population  and  dialysis  patients 
(1;205).  Furthermore, successful renal transplantation (RT) is associated with lower 
cardiovascular  morbidity  and  mortality  compared  to  patients  who  remain  on  the 
transplant  waiting  list  (201;202)  and  has  been  associated  with  significant 
echocardiographic regression of LVH (260;261). 
 
The inaccuracies of echocardiographic estimation of left ventricular mass (LV mass) 
in patients with ESRD, as previously discussed, are due to geometric assumptions 
made during calculation of LV mass and limited visualisation of chamber borders.  
To this end, cardiac magnetic resonance (CMR) imaging has been used to provide a 
more detailed, volume independent, measurement of cardiac structure in this patient 
population. 
 
The aim of this study was to compare changes in LV structure and function between 
patients  who  undergo  RT  and  those  who  remain  on  the  transplant  waiting  list 
receiving maintenance haemodialysis (HD). 269 
 
8.2  METHODS 
 
8.2.1  Patients 
The  subjects  from  this  study  were  obtained  from  a  larger  project  investigating 
outcomes in patients undergoing cardiovascular assessment for renal transplantation.  
Patients were recruited from the renal transplant assessment clinic from the Western 
Infirmary as described in Chapter 2.  This study recruited 25 patients accepted onto 
the transplant waiting list who were later successfully transplanted (defined as serum 
creatinine <150 µmol/litre at the time of second scanning), and another 25 patients 
accepted for transplantation, who remained on the waiting list.    
 
8.2.2   CMR acquisition 
Initial CMR scans were acquired as part of assessment of LV function and analysed 
as previously described.  Patients were invited for repeat CMR scan as part of the 
study.  Definitions of  LVH,  LVSD  and  LV  dilatation  have  been  presented  in 
Chapter 2. 
 
8.2.3  Data collection 
Mean  haemoglobin  and  blood  pressures  were  calculated  from  monthly 
measurements  3  months  before  and  after  CMR  scanning.  Blood  pressure 
measurements taken immediately before the start of haemodialysis were recorded. 
 
8.2.8  Statistical analyses   
Statistical  analyses  were  performed  using  SPSS  version  15.0  (SPSS  Inc.  Illinois, 
USA).  Data are expressed as mean ± standard deviation or median and interquartile 270 
 
range.  Comparisons were made between those patients who received a transplant 
and those who remained on the waiting list by student’s t test (for normal data) or 
Mann-Whitney U test (for non-normal data).  Time between scans for both groups 
was calculated from the difference between dates of CMRs.  Due to inter-patient 
variation in time between CMR scans, changes were expressed as percentage change 
per year (%/y).  
 
8.3  RESULTS 
 
8.3.1  Patient demographics 
Fifty patients were studied.  The mean time between the CMR studies was 2.8±1.1 
years for those patients who were transplanted and 2.4 ±1.2years for those remaining 
on the waiting list.  No patients had cardiac events (myocardial infarction, acute 
coronary syndrome, cardiac arrhythmias) between scans.   
 
The demographic data are presented in Table 8.1.  This shows that patients who 
received a transplant were younger at the time of first scan (45.9± 14.4 years vs 52.7 
± 10.4 years; p=0.06) compared to those who remained on the transplant waiting list.  
However, there was no significant difference in the number of patients who were 
male,  who  had  diabetes  mellitus,  a  past  history  of  ischaemic  heart  disease, 
hypertension,  heart  failure,  or  in  the  smoking  status  (although  there  was  a  trend 
towards non-smokers in the transplanted group).   At the time of first scan, there was 
no  significant  difference  in  duration  on  renal  replacement  therapy  between  both 
groups (not transplanted 2.3±2.6 years vs. transplanted 3.0±3.0years; p=0.47).  The 
distribution of cardio active drugs was not significantly different between the groups.  271 
 
The  only  noted  change  was  that  one  patient  was  on  erythropoietin  following 
transplantation, compared to 80% of those who remained on the waiting list.  All 
transplant recipients were receiving low dose maintenance glucocorticoid therapy, a 
purine  synthesis  inhibitor,  and  a  calcineurin  inhibitor  as  part  of  their 
immunosuppressive regimen. 
 
Systolic  blood  pressure  was  higher  after  transplantation  and  during  transplant 
assessment (performed on a non-dialysis day).  However, there was no significant 
difference in systolic or diastolic blood pressure between those transplanted or those 
remaining  on  the  waiting  list;  nor  was  there  a  change  in  the  number  of  anti-
hypertensive agents taken.  Haemoglobin was well controlled on dialysis, and there 
was no significant difference between groups after transplantation. 
 
8.3.2  Cardiac structure and function 
Table  8.2  shows  cardiac  measurements  for  both  CMR  scans.    There  was  no 
difference in any of the cardiac parameters measured (Table 8.2) – ejection fraction, 
left  ventricular  mass  index  (Figure  8.1),  BSA  corrected  end-diastolic  and  end-
systolic volumes before transplantation or on follow-up scans.    
 
There was a small reduction in left ventricular mass index (-3.6% per annum) in 
dialysis  patients  and  a  small  increase  associated  with  transplantation  (+2.8%  per 
annum).    However,  none  of  the  measured  cardiac  parameters  achieved  statistical 
significance  (Figure  8.1).    The  proportion  of  patients  with  left  ventricular 
hypertrophy was 68% in both groups and did not change significantly on follow-up.   272 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Not Transplanted 
N=25 
Transplanted 
N=25 
p 
Age  52.7 (±10.4)  45.9(±14.4)  0.06 
Male  15 (62.5)  20 (80)  0.18 
Diabetes Mellitus  4 (16)  5(20)  0.11 
Past history IHD  6 (24)  4(16)  0.48 
Hypertension  24 (96)  22 (88)  0.29 
Heart Failure  3 (12)  1(4)  0.29 
Smoking status 
Never 
Yes 
Ex 
 
8 (32) 
11 (44) 
6(24) 
 
16(64) 
6(24) 
3(12) 
 
 
0.08 
Number on haemodialysis  12(48)  10 (44)  0.41 
Time on RRT prior to CMR1(y)  2.31 (±2.6)  3.01(±3.0)  0.47 
Drug History       
ESA   
                        
 
CMR 1  
CMR 2 
20(80) 
20 (80) 
18 (72) 
1 (4) 
0.51 
<0.01 
Beta Blocker    CMR1 
CMR2 
8(32) 
19(76) 
 
11(44) 
15(60) 
0.38 
 
Aspirin 
 
CMR1 
CMR2 
6(24) 
10 (40) 
 
9(36) 
9(36) 
0.36 
0.77 
ACE-I/AIIRA 
 
CMR1 
CMR2 
7 (28) 
8(32) 
 
6(26) 
9(36) 
0.75 
0.77 
Calcium channel 
antagonist 
CMR1 
CMR2 
2 (8) 
4 (16) 
 
7 (28) 
6(24) 
0.06 
0.48 
Other clinical data 
 
     
Mean SBP   CMR1  
CMR2 
139 (±17.2) 
145 (±20.5) 
 
135 (±20.1) 
147(±17.4) 
0.40 
0.31 
Mean DBP  CMR1  
CMR2 
81 (±12.3) 
77 (±13.2) 
 
78(±11.5) 
81(±13.1) 
0.41 
0.35 
Mean BMI (kg/m
2)  CMR1 
CMR2 
26.4(±4.0) 
26.8 (±4.1) 
 
26.1(±5.2) 
27.0(±5.7) 
0.79 
0.92 
Mean Hb (g/dL)  CMR1  
CMR2 
12.1 (±1.8) 
13.0 (±7.0) 
 
11.9(±1.9) 
12.8 (±2.3) 
0.61 
0.89 
Mean Haematocrit  CMR1  
CMR2 
0.38 (±0.05) 
0.37(±0.05) 
 
0.37(±0.06) 
0.39(±0.06) 
0.22 
0.26 
 
Table 8.1  Comparison of demographic, clinical and drug data for patients. 
CMR1=  first  CMR;  CMR2=  second  CMR.  Data  are  number  with  percentage  in 
parentheses or mean ± standard deviation 273 
 
 
   Not Transplanted 
N=25 
Transplanted 
N=25 
p 
Mean Time between CMRs (y)  2.4(±1.1)  2.8 (±1.2)  0.14 
Mean Time Transplant to 
CMR2 (y) 
  1.8 (±0.9)   
Ejection Fraction %  CMR1 
CMR2 
64.2 (±12.2) 
64.7 (±11.5) 
66.3(±11.5) 
67.1 (±12.2) 
0.56 
0.52 
 
LVMI (g/m
2)  CMR1 
CMR2 
90.5 (75.1, 113.5) 
87.4 (69.3, 112.1) 
94.7 (77.2, 108.7) 
99.1 (79.1, 119.9) 
0.96 
0.27 
 
EDV/BSA (ml/ m
2)  CMR1 
CMR2 
74.6(±31.4) 
59.2 (±18.9) 
69.3(±18.9) 
62.3 (±18.6) 
0.51 
0.59 
 
ESV/BSA (ml/ m
2)  CMR1 
CMR2 
28.8 (±23.3) 
21.9(±17.4) 
24.3±(±20.6) 
25.4(±20.7) 
0.55 
0.51 
 
% change ejection fraction/year  + 2.1 (±11.9)  - 0.4 (±5.3)  0.34 
% change LVMI/year  - 3.6 ( ±16.7)  + 2.8 (9.1)  0.10 
% change EDV/year  - 3.4  (±31.5)  + 0.1(±19.5)  0.64 
% change ESV/year  + 3.0 (±55.5)  + 15.2 (±65.2)  0.48 
 
LVH   CMR1 
CMR2 
17 (68) 
15 (60) 
17 (68) 
19 (76) 
1.00 
0.23 
LVSD  CMR1 
CMR2 
5 (20) 
2 (8) 
3(12) 
2 (8) 
 
LV dilatation  CMR1 
CMR2 
5(20) 
1 (4) 
4 (16) 
0 
 
 
Table 8.2  Comparisons  of  cardiac  MRI  results  for  baseline  (CMR1)  and 
second scan (CMR2).   
Data are mean ± standard deviation in parentheses except for LVMI on MRI where 
median and interquartile range is shown. 
 274 
 
no yes
Transplant
-40.00
-20.00
0.00
20.00
P
e
r
c
e
n
t
a
g
e
 
c
h
a
n
g
e
 
L
V
M
I
 
p
e
r
 
y
e
a
r
O
O
no yes
Transplant
-10.00
-5.00
0.00
5.00
M
e
a
n
 
c
h
a
n
g
e
 
e
j
e
c
t
i
o
n
 
f
r
a
c
t
i
o
n
 
p
e
r
 
y
e
a
r
O
O
 (a) 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
Figure 8.1  Bar graphs demonstrating (a) mean percentage change of ejection 
fraction per year (with 95% confidence intervals; p=0.34). (b) mean percentage 
change of LVMI per year (with 95% CI; p=0.10) 
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8.4  DISCUSSION 
 
The incidence of patients commencing renal replacement therapy is increasing (262).  
Renal transplantation remains the treatment of choice for patients with ESRD due to 
improved  morbidity  and  significant  increase  in  life  expectancy.    This  has  been 
shown in a number of studies: 
 
·  In  a  longitudinal  study  comparing  survival  between  transplanted  and  wait-listed 
patients between 1991 and 1997, Wolfe et al demonstrated an increased risk of death 
in the immediate 2 weeks following transplantation (RR 2.88).  However, there was 
a significant reduction in mortality after 18 months (RR 0.32, 95% CI 0.30-0.35, 
p<0.01)  in  transplant  recipients  compared  to  patients  that  remained  on  the  renal 
transplant waiting list (201). 
·  A study conducted in Scotland, assessed survival in first renal transplant recipients 
and demonstrated a long term reduction in the risk of death after 18 months (RR 0.18 
95% CI 0.08-0.82) compared to patients on dialysis. Projected life expectancy for 
transplant recipients was significantly higher (17.19 years transplant vs. 5.88 years 
on dialysis) (263).  
 
Improved  survival  is  believed  to  be  due  to  a  number  of  factors  including 
improvements  in  immunosuppression,  organ  procurement,  patient  selection  and 
preparation,  and  surgical  techniques.    However,  cardiovascular  death  is  very 
common  in  patients  with  functioning  renal  transplants  and  although  renal 
transplantation confers a favourable cardiovascular survival benefit this is still 50-
fold higher than the general population: 276 
 
·  In a retrospective analysis from the United States Renal Database Service, Meier- 
Kriesche et al demonstrated a significant improvement in long term cardiovascular 
survival  in  60  181  first  kidney  transplant  recipients  compared  to  patients  that 
remained on the renal transplant waiting list.  CV death rates decreased as transplant 
vintage  increased  and  this  relationship  existed  for  living  and  deceased  donor 
transplants (202). 
 
This  cardiovascular  benefit  is  unexpected  due  to  the  deleterious  effect  of  renal 
transplantation  on  established  cardiovascular  risk  factors  including 
immunosuppression  related  hypertension,  dyslipidaemia,  anaemia  and  diabetes 
mellitus (262).  Some investigators believe that renal transplantation may have an 
effect on uraemic cardiomyopathy, specifically regression of LVH. 
 
8.4.1  Renal transplantation and cardiac structure 
Given the close relationship between cardiomyopathy, long standing renal disease, 
and cardiovascular survival it has been postulated that improved renal function and 
better  fluid  volume  control  after  renal  transplantation  may  reverse  or  alleviate 
abnormalities of uraemic cardiomyopathy. 
 
Most  studies  have  been  performed  in  patients  with  pre-existing  cardiac  disease 
before transplantation: 
 
·  Melchor  et  al  prospectively  investigated  the  effect  of  renal  transplantation  in  29 
recipients with echocardiographic evidence of LV dysfunction.  They demonstrated 
significant improvement in LVEF (pre transplant EF= 38.8%, post transplant EF= 277 
 
58.2%; p<0.001) with a reduction in LVH prevalence (21% pre transplant to 18% 
post transplant) (264). 
·  Wali et al investigated 138 patients with CKD 5, LV dysfunction (EF≤ 40%) and 
symptomatic chronic heart failure.  Repeat radionuclide ventriculograms performed 
at 6 and 12 months post transplant demonstrated improved mean LVEF (32 to 52%) 
which was associated with improvement in NYHA classification and lower mortality 
and hospitalisation (265). 
·  Midvetdt et al demonstrated 15% reduction in LVMI after renal transplantation using 
echocardiography in a study comparing nifedipine and lisinopril to control blood 
pressure in hypertensive transplant recipients. (266). 
 
However in patients with LVH only, the effect of renal transplantation on cardiac 
structure remains controversial: 
 
·  Peteiro  et  al  examined  30  patients  before  and  after  (10±1.8  months)  renal 
transplantation using M-mode echocardiography.  These patients had near normal 
LV ejection fraction.  They demonstrated a significant reduction in ESV, EDV and 
LVMI (201g/m
2 pre transplant to 171g/m
2 post transplant; p<0.01) but no significant 
change on LVEF (200). 
· Ferriera et al demonstrated a significant decrease in LVMI and LV dilatation after 
renal  transplantation.    There  was  resolution  of  LVSD  (8.3%  of  patients  before 
transplantation to none after) but overall LVEF did not increase significantly (52.9% 
pre transplant to 60.0% 12 months post transplant; p=0.88) (267). 
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CMR  scanning  provides  a  more  detailed  characterisation  of  the  left  ventricular 
borders  resulting  in  consistently  reproducible  measurements  compared  to 
echocardiography (Chapter 1).  In view of this, the present study was performed 
using CMR to provide accurate, volume independent assessment of LV mass.  There 
was no significant change in left ventricular mass index between patients who were 
receiving  hospital  haemodialysis  for  a  period  of  2-3  years  and  patients  who 
underwent successful transplantation over the same time scale.  Similarly, there was 
no difference in LV chamber volumes or ejection fraction between the groups. 
 
8.4.2  Left ventricular mass after renal transplantation 
These findings cast doubt on the reversibility of left ventricular hypertrophy after 
renal transplantation.  As described in chapter 3, the main determinants of LV mass 
in  haemodialysis  patients  are  elevated  cardiac  preload  (volume  overload)  and 
afterload (systemic hypertension and markers of vascular calcification).  These data 
suggest that some of these features persist after renal transplantation perpetuating 
development and/or preventing reversal of LVH.   
 
8.4.2(a)  Hypertension 
Hypertension is the most common cardiovascular risk factor in transplant recipients 
and is significantly associated with adverse outcome: 
·  Recent  observational  studies  have  demonstrated  significant  association  between 
mortality and blood pressure in renal transplant recipients.  In the largest study to 
date,  Kasiske  et  al  demonstrated  that  a  10mm  Hg  increase  in  systolic  BP  was 
associated with an increase in death (RR 1,18 95% CI 1.12, 1.23), and total or death 
censored graft failure (268). 279 
 
The  most  potent  aetiological  factors  for  post  transplant  hypertension  are  pre 
transplant hypertension and use of calcineurin inhibitors (260;262).  In this cohort, 
there was no significant reduction in BP after renal transplantation (Table 8.1) and 
all  transplant  recipients  were  immunosuppressed  with  either  tacrolimus  or 
cyclosporine. Together, these findings suggest that hypertension may be associated 
with increase in LVMI after renal transplantation. 
 
8.4.2(b)  Bone mineral disorders 
The  relationship  in  haemodialysis  patients  between  LVMI  and  abnormal  bone 
mineral metabolism (Chapters 1 and 3) has previously been discussed.   Although 
much  has  been  published  in  dialysis  population,  there  is  a  paucity  of  studies 
investigating  the  effect  of  correcting  bone  mineral  parameters  after  renal 
transplantation. No data was obtained data regarding calcium and phosphate for this 
study. 
 
8.4.2 (c)  Fluid overload 
One of the benefits of successful renal transplantation is a return to near normal body 
electrolyte and thus fluid composition (269). Unfortunately, the transplant is unable 
to achieve the same level of body volume control achieved by two native kidneys 
due  to  glucocorticoid  therapy  interfering  with  sodium  handling,  and  calcineurin 
inhibitors altering glomerular filtration pressures and potassium handling.  The effect 
of a trend toward euvolaemia on cardiac preload and filling is controversial.  Most 
studies have used echocardiography to assess chamber dimensions: 
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·  Ferreira et al investigated 28 patients with no evidence of pre-transplant LVSD on 
echocardiography.  They showed that there was a significant reduction in LV end 
diastolic diameter (LVEDD) 12 months after transplantation (267). 
·  Dudziak et al performed a similar study in 23 transplant recipients and showed no 
significant reduction in LVEDD after 3 months from successful renal transplantation 
(260).  Similarly, Oppert et al showed no significant difference in LV chamber size 
one year after simultaneous pancreas kidney transplantation (270). 
 
The  inconsistencies  of  previous  published  work  highlight  the  weakness  of 
echocardiography studies in ESRD and transplant recipients.  On the other hand, the 
strength  of  the  present  study  lies  with  the  use  of  CMR  which  allows  precise 
visualisation of epicardial borders and volume independent measurement of the LV 
chamber and wall. 
 
Thus, based on these data, LV chamber size at end diastole and systole and LV 
ejection fraction are not affected by renal transplantation.  This presumably reflects 
action of the homeostatic mechanisms that control cardiac preload, such as venous 
tone,  which  increase  in  response  to  reduced  intravascular  volume.    In  addition, 
increases  in  LV  ejection  fraction  and  reductions  in  LV  mass  are  most  likely  an 
artefact of reduced extracellular and hence intraventricular fluid. 
 
8.4.3  Limitations 
Although the current study is limited by small sample size and variability in timing 
of  scans  it  is  the  first  study  to  serially  evaluate  the  LVs  of  patients  who  have 
undergone renal transplantation using CMR.  Greater precision and reproducibility 281 
 
of CMR permits smaller, adequately powered studies to be meaningful compared to 
echocardiography  (137).    Furthermore,  interdialytic  changes  of  haemodialysis 
patients were reduced by standardising the timing of CMR (24 hours after end of last 
haemodialysis session) for both scans.  
 
8.5  CONCLUSIONS 
Cardiovascular disease remains a major cause of morbidity and mortality after renal 
transplantation, and this study supports a possible role for LVH.  These findings cast 
doubt on the reversibility of left ventricular hypertrophy in this population and it is 
likely that prevention, for example by tight blood pressure and bone mineral control, 
in  the  earliest  phases  of  progressive  renal  disease  with  the  aim  of  preventing 
development  of  left  ventricular  hypertrophy  will  be  a  more  successful  strategy. 
Moreover, it seems likely that the previous positive results are artefactual due to 
normalisation of intravascular volume following successful transplantation. 282 
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9.1  Utilisation of cardiovascular MRI to assess uraemic cardiomyopathy 
The  principal  aims  of  these  studies  were  to  elucidate  features  of  uraemic 
cardiomyopathy using CMR which account for increased risk of CV (usually sudden 
cardiac) death in ESRD patients.  In particular, these studies addressed: 
· The prognostic effect of left atrial and ventricular abnormalities detected by CMR. 
· The  pathophysiological  features  of  uraemic  cardiomyopathy  using  novel,  non-
invasive techniques which have been evaluated in other patient populations. 
 
As  stated  in  Chapter  1,  greater  accuracy  and  precision  of  CMR  compared  to 
echocardiography for measuring LV mass and chamber dimensions allows smaller 
sample size to be studied with no loss of statistical power. 
 
9.2  Summary of findings 
The  strengths  of  these  studies  lie  with  the  use  of  CMR  to  accurately  assess  LV 
abnormalities  in  ESRD patients.    Furthermore  these  are  the  largest  observational 
studies using CMR to identify prognostic features of uraemic cardiomyopathy and 
present important, novel results.  Chapters 6 and 7 present data that are novel and 
provide valuable insight regarding the electrophysiological and metabolic changes 
associated with uraemic cardiomyopathy. 
 
9.2.1  Determinants and prognostic features of uraemic cardiomyopathy 
Figure 9.1 summarises findings from Chapters 3 to 5.  The cardiovascular changes of 
advancing  renal  disease  predispose  to  development  of  uraemic  cardiomyopathy, 
namely  intravascular  volume  expansion,  hypertension  and  reduced  vascular 284 
 
compliance.    As  with  other  disease  states  (e.g.  advancing  heart  failure)  initial 
compensatory  mechanisms,  such  as  additional  sarcomere  proliferation,  ultimately 
result in further deterioration of LV architecture.  One notable finding from Chapter 
3 was a close relationship between different LV abnormalities, which was postulated 
to  represent  differing  stages  of  development  of  uraemic  cardiomyopathy.    The 
prognostic effects of LV abnormalities on CV survival were also demonstrated in a 
large  prospective  CMR  study  of  ESRD  patients  (Chapter  4)  and  results  are  also 
summarised in Figure 9.1.  Elevated end systolic LAV has been assessed in studies 
of ESRD patients (207) using echocardiography.  However, given the paucity of 
studies demonstrating convincing reversal of LVH in ESRD patients (which is very 
common and usually severe) using interventions trialled in the general population, 
other potentially modifiable cardiac factors independent of LV mass were evaluated 
(Chapter 5).  Elevated LAV also adversely reduced survival of ESRD patients.  
 
9.2.2  Novel pathophysiological features of uraemic cardiomyopathy 
Figure  9.2  shows  some  of  the  electrophysiological  and  metabolic  abnormalities 
associated with uraemic cardiomyopathy which were presented in the later chapters 
of  this  thesis.    In  the  first  study  of  ESRD  patients,  the  effects  of  LV  structural 
changes detected by CMR were investigated using MTWA to determine abnormal 
myocyte  repolarisation.    MTWA  has  not  previously  been  used  to  assess  ESRD 
patients  and,  as  discussed  in  Chapter  6,  may  provide  additional  information  to 
identify subjects at risk of SCD.  As well as being independently associated with 
features  of  uraemic  cardiomyopathy,  MTWA  was  also  associated  with  a  clinical 
history of macrovascular atheromatous disease suggesting that even in the absence of 
LV  abnormalities,  patients  with  occlusive  vascular  disease  develop  abnormal 285 
 
ventricular repolarisation.  These early changes are most likely due to microvascular 
changes and myocardial fibrosis, which may not be evident on CMR examination 
but are nonetheless common in ESRD patients (49;257).  In Chapter 8, novel data 
were  presented  demonstrating  altered  cardiac  energetics  and  HEP  metabolism  in 
patients  with  features  of  uraemic  cardiomyopathy  compared  to  patients  with 
hypertensive  LVH.    Furthermore,  reduced  HEP  metabolism  was  independently 
associated  with  LVSD  of  uraemic  cardiomyopathy.  A  smaller  study  (149)  has 
demonstrated a difference between 
31P MRS results of diabetic patients and renal 
transplantation  recipients,  but  this  study  uniquely  demonstrates  a  significant 
association with LVSD and LV dilatation in ESRD subjects. 
 
9.2.3   Effect of successful renal transplantation on left ventricular mass 
In Chapter 9, data from a small observational study showed that successful renal 
transplantation was not associated with a significant regression of LVMI compared 
to patients who remained on the renal transplant waiting list. These data highlight 
two issues:   
·  Previous  studies  that  demonstrated  significant  reduction  in  LV  mass  using 
echocardiography, were most likely showing artefactual changes by measuring 
improvement  in  intravascular  and  hence  LV  chamber  volume  as  opposed  to 
reduction in myocardial wall thickness (260;261). 
·  It is likely that factors, such as hypertension and vascular stiffness remain after 
renal transplantation and may perpetuate increases in LVMI.   286 
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Figure 9.1 Determinants and prognostic features of uraemic cardiomyopathy  
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9.3  Limitations of current studies 
There are limitations in these studies.  In the initial study design, 24 hour ambulatory 
ECG  monitoring  was  planned  to  assess  sinus  rhythm  changes  and  provide  more 
prognostic data for this patient cohort (115).   Unfortunately, this was not completed 
as many patients did not wish to wear ambulatory monitors overnight.  However 
with  these  data,  presence  of  significant  “resting”  arrhythmias  may  have  been 
detected  and  the  additional  effect  on  MTWA  result  and/or  overall  risk  of  CV 
mortality may have been evaluated.   Twenty four hour ECG monitoring is a cheaper 
and  more  readily  available  method  of  detecting  cardiac  electrophysiology 
abnormalities  compared  to  MTWA,  however  the  sensitivity  and  specificity  for 
identifying ESRD patients at risk of SCD remains to be convincingly demonstrated.   
In  addition,  measurement  of  other  cardiac  electrophysiological  parameters  was 
proposed  for  study,  namely  QT  dispersion  and  heart  rate  variability.    However, 
detection hardware and software were not available by the time of recruitment. 
 
As stated in Chapter 2, patients recruited into these studies were those being assessed 
for  renal  transplantation.    This  cohort  has  previously  been  criticised  as  some 
investigators  believe  that  this  may  not  provide  true  cross  sectional  sampling  of 
patients with ESRD.  Historically, patients considered (by a transplant surgeon or 
nephrologist)  likely  to  survive  the  peri-operative  period  were  referred  for  pre-
transplant CV assessment.  However, since these patients were considered fit enough 
to  be  considered  for  transplantation,  it  is  likely  that  these  results  underestimate 
cardiac abnormalities of ESRD patients and would be relevant to other individuals 
with more significant co-morbidities.   
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Although  our  main  aims  and  objectives  were  achieved,  outcome  data  based  on 
MTWA and HEP metabolism were not available.  Nonetheless, the MTWA study 
finished recruiting 12 months ago and there was a trend toward reduced survival in 
the abnormal MTWA group (Chapter 6).   
 
9.4  MTWA and HEP metabolism as predictors of sudden cardiac death 
In  this  thesis,  data  are  presented  demonstrating  significant  abnormalities  of 
cardiomyocyte  action  potential  (AP)  propagation  and  recovery  in  ESRD  patients 
using MTWA.  As stated in Chapter 1, any changes of cell function resulting in 
abnormal intracellular cation cycling and subsequent non uniform membrane de- and 
repolarisation may increase risk of re-entrant tachyarrhythmias. Abnormal MTWA 
results in ESRD patients were associated with features of uraemic cardiomyopathy 
on  CMR  examination.    T  wave  alternans  develops  at  higher  heart  rates  due  to 
discordant repolarisation alternans between adjacent cardiomyocytes on an every- 
other- beat basis. This most likely develops in uraemic hearts due to pathological 
changes described including abnormal intracellular calcium handling, microvascular 
ischaemia, interstitial fibrosis and inadequate metabolic substrate availability.  
 
Abnormal MTWA was also independently predicted by clinical history of peripheral 
and  cerebrovascular  atheromatous  disease,  implying  that  other  forms  of 
macrovascular  disease  are  associated  with  abnormal  ventricular  repolarisation. 
Metabolic abnormalities can be measured non- invasively using 
31P MRS and in the 
future it will be interesting to evaluate the additional prognostic effect of these MRS 
results with MTWA on development of SCD. 
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9.5  Future studies  
A striking feature of these studies was the high proportion of ESRD patients with 
established  LV  abnormalities,  even  in  the  pre-dialysis  period  of  renal  disease, 
implying that these changes develop in the earlier stages of CKD. Regression of 
uraemic  cardiomyopathy,  especially  LVH,  has  been  difficult  to  achieve  thus 
prevention needs to be assessed.  With the use of eGFR to identify patients with 
earlier stages of CKD, future studies may allow early cardiac assessment to detect 
onset of cardiomyopathy and potentially modifiable aetiological factors 
 
Prior to the discovery of anassociation with nephrogenic systemic fibrosis (NSF) in 
patients  with  advanced  renal  disease,  gadolinium  based  contrast  CMR  provided 
useful diagnostic and prognostic information in ESRD patients.  These agents are no 
longer considered to be safe in patients with advanced renal dysfunction.  However 
macrocyclic chelating agents (such as gadoteridol) are associated with a lower risk of 
NSF  and  the  only  group  of  Food  and  Drink  Administration  approved  agents  for 
clinical investigation in patients with advanced renal disease (271).  Nonetheless, the 
use of these agents has to be weighed against the benefit of the diagnostic procedure 
and  availability  of  other  imaging  modalities.    These  agents  are  obviously  not 
appropriate in a research setting. 
  
Blood  oxygen  level-  dependent  (BOLD)  contrast  CMR  is  based  on  the  differing 
magnetic  properties  of  oxyhaemoglobin  and  deoxyhaemoglobin  which  can  be 
detected by T1 and T2* weighted scans.  As a result, areas where oxyhaemoglobin 
concentrations  are  high  (coronary  blood  perfusion  is  greater  than  myocardial 
demand)  can  be  visualised.    Conversely,  areas  of  myocardial  ischaemia  can  be 291 
 
detected without the use of gadolinium based contrast agents.  Blood oxygen level- 
dependent CMR has been used to detect myocardial ischaemia in animal models of 
coronary artery occlusion and in patients with inducible myocardial ischaemia due to 
large  and  small  vessel  coronary  artery  disease  (272-274).    The  prognostic 
implications for BOLD contrast CMR remains to be elucidated, however given the 
high prevalence of small and large vessel ischaemic heart disease in ESRD patients, 
this may be a CMR technique that could be pursued in the future.  Alternative non 
gadolinium contrast agents include superparamagnetic iron oxide particles (SIOP) 
which  has  also  been  investigated  for  their  potential  role  of  quantifying  not  only 
myocardial stress perfusion but areas of fibrosis and previous myocardial infarction 
(similar to gadolinium contrast scans) (275).  To this end, these agents may also 
provide a safe means of performing contrast enhanced scans in patients with ESRD. 
 
Data from Chapter 7 support earlier studies performed in animal models of uraemic 
cardiomyopathy demonstrating abnormal metabolic function in apparently normally 
contracting myocardium.  Given the relative small size of this study, these data could 
be used to power larger prognostic studies in patients with ESRD once outcome data 
are  available.      Furthermore,  other  nuclei  have  been  investigated  using  MRS.  
1Hydrogen  allows  quantification  of  myocardial  fat  content,  lactate,  carnitine, 
deoxyhaemoglobin and total creatine levels which are reduced in patients with heart 
failure (276).  However these studies are limited due to the high level of 
1H within 
cardiomyocytes  (mostly  in  the  form  of  water),  which  may  provide  even  greater 
technical difficulties in patients with ESRD where total body water is increased. 
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Finally, further investigation of CV changes that occur after renal transplantation 
may provide insights to potential modifiable factors in patients with ESRD.  In this 
thesis,  renal  transplantation  was  not  associated  with  significant  regression  of  LV 
mass after a mean period of 1.8 years.  It is possible that a longer follow up would be 
necessary  to  demonstrate  a  significant  reduction,  however  post  transplant 
hypertension is one of the major side effects of long term immunosuppression and 
most likely perpetuates rising LV mass.  Alternative studies could include 
31P MRS 
to determine the effect of reduced “uraemic” toxins and better intravascular fluid 
control  after  successful  renal  transplantation.    Similarly,  measurement  of  aortic 
compliance and vascular stiffness using CMR has been performed in ESRD patients 
(203), and an interesting study would be to assess the effect of renal transplantation 
on these parameters.   
 
9.6  Reducing cardiovascular disease in ESRD patients 
The main aims of the KDIGO guidelines for identifying patients with early CKD 
was  not  only  to  slow  progression  of  renal  dysfunction,  but  to  address  the 
concomitant rise in CV disease (2).  Unfortunately, this subject has a paucity of well 
controlled and adequately powered interventional studies demonstrating convincing 
evidence of benefit for  ESRD patients.  However, it is postulated that given the 
association  of  CV  death  and  uraemic  cardiomyopathy  presented  in  Chapter  4, 
slowing or preventing development of LV architectural changes may be an attractive 
target for intervention. 
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9.6.1  Preventing development of uraemic cardiomyopathy 
Preventing development of uraemic cardiomyopathy remains an attractive target in 
early stages of kidney disease. Data presented in Chapter 3 demonstrate that features 
of CKD (e.g. hypertension, vascular stiffening) are associated with the development 
of uraemic cardiomyopathy and that LV abnormalities are closely associated once 
cardiomyopathy is established.  Unfortunately, attempts to alter other established CV 
risk  factors  in  ESRD  patients,  such  as  dyslipidaemia,  have  shown  no  significant 
survival benefit (AURORA, 4D).  Although not entirely evidence based, aggressive 
management  of  other  established  cardiovascular  risk  factors  in  earlier  stages  of 
kidney disease, in particular hypertension, may slow or reduce prevalence of uraemic 
cardiomyopathy  and  subsequent  CV  morbidity  and  mortality.    In  addition,  other 
novel and renal specific risk factors need to be identified that predispose to CV 
disease and may be amenable to intervention to prevent development of uraemic 
cardiomyopathy.   
 
Chronic expansion of extravascular volume is a hallmark of advancing renal disease 
and has been shown in these and other studies to be a potential aetiological factor for 
development of LV abnormalities (169;170).  In practice, however, control of body 
fluid  volume  is  predominately  dictated  by  patient  symptoms  (peripheral  and 
pulmonary oedema) and/or “dry” or “ideal” body weight in more advanced stages of 
CKD.  Tighter control of fluid balance with oral restriction and diuretic therapy at 
earlier  stages  of  renal  dysfunction  may  reduce  development  of  uraemic 
cardiomyopathy.    Unfortunately,  patient  compliance  remains  a  major  restricting 
factor particularly when interventions have unpleasant side effects (e.g. xerostomia 
and excessive micturition).  More objective means of measuring body fluid status, 294 
 
such  as  bioimpedance  spectroscopy,  may  provide  more  convincing  evidence  to 
pursue these studies further (194). 
 
Furthermore,  bone  mineral  disorder  is  associated  with  development  of  LVH  in 
ESRD  patients  implicating  arterial  stiffness  as  an  aetiological  factor  for  uraemic 
cardiomyopathy.    Although  not  a  conventional  risk  factor  for  CV  disease, 
intervention at an early stage of bone mineral disorder, perhaps before development 
of significant secondary hyperparathyroidism would be appropriate (current Renal 
Association  guidelines  state  that  vitamin  D  analogue  therapy  should  start  when 
parathyroid hormone therapy is 2-4 times upper limit of normal range) (42).    Both 
KDIGO  and  Renal  Association  guidelines  highlight  the  need  for  prospectively 
controlled studies addressing the benefit for treatment of bone mineral disorders in 
earlier stages of renal dysfunction (277). 
 
9.6.2  Reversing uraemic cardiomyopathy 
Preventing development of uraemic cardiomyopathy  has been the most attractive 
option  in  patients  with  CKD  because  reversal,  once  established,  has  been  very 
difficult to achieve.  The absence of prospective studies has made development of 
evidence based guidelines for reversal of uraemic cardiomyopathy in patients with 
established ESRD difficult.  There are a number of factors that have been presented 
in this thesis and other studies that merit further evaluation in such studies. 
 
Tight control of intravascular and extracellular volume is an important factor.  In 
Chapter 3, extracellular volume was a significant determinant of development of 
LVH, LVSD and LV dilatation.  As with CKD patients, this can be achieved with 295 
 
rigorous adherence to fluid and salt restriction to reduce interdialytic weight gains 
for haemodialysis patients and use of diuretic therapy in patients with residual renal 
function.  Excessive intradialtytic ultrafiltration may provide some benefit, however 
this should be performed with caution given increased risk of myocardial stunning 
and  intradialytic  hypotension  (70).  A  small  (n=25)  prospective  study  in  Scottish 
haemodialysis  patients  has  been  performed  to  assess  the  effect  of  intradialytic 
bioimpedance monitoring over 6 months on a number of CV parameters including 
LV mass measured by CMR.  These data will be presented within the next 6 months. 
 
The  use  of  antihypertensive  pharmacological  agents  needs  to  be  fully  assessed.  
Blood  pressure  (including  pulse  pressure)  control  may  be  partially  achieved  by 
controlling intravascular volume adequately.  Nonetheless, from small prospective 
trials using beta blockers, angiotensin converting enzyme inhibitors and angiotensin 
II receptor blockers mentioned in Chapter 1, some benefit has been demonstrated in 
patients  with  ESRD  (120;125).    Whether  these  agents  improve  outcome 
independently of blood pressure control in ESRD patients remains to be assessed. 
Despite these findings, cardioactive medications remain grossly underused even in 
ESRD patients who have developed significant CV morbidity (36) indicating that a 
change in clinical practice needs to be implemented.   
 
More frequent and greater quality of dialysis may reverse uraemic cardiomyopathy 
in  haemodialysis  patients.    Reduction  of  LV  mass  measured  by  CMR  has  been 
demonstrated  in  small  prospective  and  observational  studies  in  haemodialysis 
patients treated with frequent and/or nocturnal regimens compared to conventional 
thrice weekly haemodialysis (20;278). The findings of the Frequent Haemodialysis 296 
 
Network randomised controlled trial investigating frequent haemodialysis (daily in-
centre and nocturnal home haemodialysis) with conventional thrice weekly regimen 
are due within the next 6 months and has CMR measured LVMI as a composite end 
point.    Furthermore,  more  efficient  removal  of  solutes  using  high  flux  dialysis 
membranes  has  been  associated  with  longer  survival  in  hypoalbuminaemic 
haemodialysis patients compared to those treated with conventional low flux ones 
(279).  Whether this type of dialysis improves LV myocardial changes remains to be 
evaluated. 
 
In  Chapter  8,  absence  of  reduction  of  LV  mass  after  renal  transplantation  was 
attributed to post transplant hypertension (possibly related to calcineurin inhibitor 
use), bone mineral disease and intravascular expansion.  Further study of transplant 
recipients with older  grafts, tighter  control of  blood pressure and fluid status, or 
usage  of  lower  dose/alternative  immunosuppressive  agents  may  also  demonstrate 
significant changes in myocardial architecture. 
 
The  effect  of  treatment  of  ESRD  related  bone  mineral  disorders  on  reversal  of 
uraemic  cardiomyopathy  has  not  been  established.    Use  of  non  calcium  based 
phosphate binders is associated with reduced coronary calcification and improved 
survival  in  haemodialysis  patients  (280).    Furthermore,  in  primary 
hyperparathyroidism patients with no renal disease parathyroidectomy is associated 
with reduction of LV mass (281).  Whether treatment of hyperparathyroidism by 
surgery or newer calcimimetic agents affect uraemic cardiomyopathy would be an 
interesting study to pursue. 
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Finally, the benefit of ICD insertion in ESRD patients needs to be established.  In a 
recent  meta-  analysis  of  dialysis  patients  with  ICDs  (n=89),  there  was  still 
significantly  elevated  CV  mortality  in  ESRD  patients  (282)  compared  to  ICD 
recipients  with  milder  renal  diseases.    A  prospective  pilot  study  assessing  ICD 
insertion in dialysis patients (ICD2) has recruited 200 patients in the Netherlands and 
plans to report outcome data in 2012 (283). 
 
As with studies in patients with heart failure, careful selection of patients is required 
to identify those who would benefit most from pharmacological or ICD intervention.  
The results of studies presented in this thesis aim to provide information for selecting 
ESRD patients at higher risk of CV or sudden cardiac death (Figure 9.3).  With these 
results in mind, further prospective studies will be able to carefully select groups of 
ESRD  patients  with  differing  left  ventricular,  left  atrial,  electrophysiological  and 
biochemical properties to demonstrate survival benefit with specific interventional 
agents.  In this way, future therapies for ESRD patients can be tailored to improve 
cardiovascular survival. 298 
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Figure 9.3  Possible features of ESRD patients who are at an increased risk of 
cardiovascular or sudden cardiac death 
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9.7  CONCLUSIONS 
·  Premature, usually sudden, cardiovascular death is the commonest cause of death in 
patients with end stage renal disease.   
·  Elevated risk of cardiovascular death is due to higher prevalence of traditional, novel 
and uraemic specific cardiovascular risk factors.   
·  Abnormalities  of  left  ventricular  structure  (LV  hypertrophy,  dysfunction  and 
dilatation), collectively termed uraemic cardiomyopathy have been implicated with 
higher cardiovascular mortality. 
·  Cardiovascular  magnetic  resonance  imaging  is  the  most  accurate  and  volume 
independent  method  of  assessing  myocardial  structure  in  ESRD  patients.  
Furthermore, 
31P magnetic spectroscopy is a method which non- invasively assesses 
cardiac metabolic activity. 
·  Hypertension, presence of bone mineral disorders and expanded extracellular volume 
are common features of advanced CKD and are major determinants of presence of 
LVH, LVSD and LV dilatation on CMR.   
·  LVSD and LV dilation detected by CMR are associated with reduced all cause and 
CV  survival  in  ESRD  patients.    LVH  is  significantly  associated  with  reduced 
cardiovascular survival. End stage renal disease patients with two or more cardiac 
abnormalities on CMR have a significantly poorer prognosis. 
·  High LAV and presence of LVSD are associated with poorer all cause survival and 
independent predictors of mortality in ESRD patients with LVH.    
·  Microvolt T Wave Alternans is a novel, non invasive electrophysiological technique 
of  measuring  variability  in  ventricular  repolarisation  and  is  associated  with 
development of life threatening tachyarrhythmias.  Abnormal MTWA result is more 
common  in  ESRD  patients  compared  to  hypertensive  LVH  patients  and  is 300 
 
significantly  associated  with  uraemic  cardiomyopathy  and  a  history  of 
macrovascular atheromatous disease in ESRD patients.   
·  End  stage  renal  disease  patients  have  lower  HEP  metabolism  compared  to 
hypertensive  LVH  patients  despite  similar  LV  mass.    Lower  PCr:  βATP  ratio  is 
associated with features of uraemic cardiomyopathy  
·  Successful renal transplantation is not associated with significant regression of LVH 
when measured by CMR. 
·  Future studies may use these pathophysiological and prognostic features of uraemic 
cardiomyopathy  to  identify  patients  suitable  for  interventions  which  improve 
cardiovascular survival in ESRD patients. 301 
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